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This thesis describes the development and characterization of a novel 
linker protein designed to target Ad vectors to cells involved in 
atherosclerosis. The introduction first gives an outline on atherosclerosis. 
Subsequently, gene therapy and one of its powerful tools, namely 
adenovirus vectors, are introduced. Next, the current state on gene 
therapeutic approaches in atherosclerosis are described indicating the 
need for targeting of vectors. Finally, an overview on targeting strategies 





Atherosclerosis is a disease characterized by localized, chronic 
inflammation of the vessel wall of the large elastic arteries and the slightly 
smaller muscular arteries. At predisposed sites, lesions (plaques) in 
different stages of severity are present. Although the disease manifests 
itself usually in the middle aged/ elderly population, early stages of the 
atherogenic process already arise in young individuals (1-3). Based on 
morphological characteristics of the plaque during development, plaques 
have been classified into six distinct stages (fig. 1, (4;5)). The first stage is 
characterized by the local infiltration of lipoproteins and the presence of 
lipid laden macrophages in the intima. From stages II to VI severity of the 
atherosclerotic lesion increases, and lesions are characterized by smooth 
muscle cell (SMC) migration from the media into the intima, lipid 
deposition and necrosis in the core of the plaque and synthesis of large 
amounts of extra cellular matrix, resulting in loss of lumen diameter. More 
complicated lesions may give rise to intra-plaque hemorrhage and 
thrombosis (6). Rupture of plaques and subsequent thrombosis caused by 
the exposure of the plaque content to the circulation may result in 
thromboembolic events and arterial occlusion exemplified by myocardial 
























Atherosclerosis has a complex multi-factorial etiology. A wide range of 
genetic and environmental factors are known to be involved including 
elevated low-density-lipoprotein (LDL) cholesterol levels, hypertension, 
smoking and diabetes mellitus. Atherosclerosis is commonly described as 
the consequence of an exaggerated response of the endothelium to injury 
(7-10). Upon injury of the endothelium (caused by a range of stimuli, such 
as oxidized LDL (11), low, turbulent shear stress (12), infectious agents (13), 
or homocysteine (14), the endothelial lining of the vessel becomes 
activated and more permeable to circulating monocytes, T lymphocytes 
and lipoproteins. The resulting vicious circle of monocyte adhesion, 
differentiation, the secretion of chemo-attractants and subsequent SMC 
proliferation results in a chronically inflamed vessel wall and plaque 
development as mentioned above. 
 
 
1.1.2.1 Shear stress 
Hematological blood flow is not uniform along the circulatory tree. At 
branching points in the arterial system, blood flow is not lamellar resulting 
in differences in shear stress (15;16); shear stress being the force of 
passing blood exerted parallel to the vessel wall. Atherosclerotic lesions 
are not evenly distributed throughout the aorta and muscular arteries but 
are found at sites where shear stress is low or oscillating, early lesions are 
almost exclusively found at these specific predisposed sites such as the 
aortic arch, the carotid and iliac bifurcations, and the branching points in 
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the coronary circulation (15;16). Gimbrone and colleagues found that 
expression of certain extra cellular molecules on the endothelium is 
regulated by differences in shear stress (17). Turbulent blood flow, found at 
atherosclerosis-prone sites, upregulates the expression of pro-atherogenic 
molecules such as vascular cell adhesion molecule 1 (VCAM-1), E-
Selectin, P-Selectin, Endothelin-1 (18-20). In contrast, laminar blood flow 
down-regulates VCAM-1 expression (21). Causal involvement of VCAM-1 
in atherosclerosis has been demonstrated by Cybulsky, showing that 
VCAM-1 deficiency fully protects against diet induced atherosclerosis 
formation in LDLr-/- mice (22). Laminar flow also stimulates the production 
of athero-protective factors such as the enzymes endothelial nitric oxide 
synthase (eNOS) and cyclooxygenase-2 (COX-2), whereas eNOS 
production is attenuated by oscillatory shear stress (23;24). Much of the 
molecular and signal transduction pathways linking shear stress to protein 
expression remain to be identified but do involve the pro-inflammatory 
transcription factor nuclear factor κ B (NF-κB). NF-κB was found to be 
upregulated in endothelial cells subject to disturbances in laminar sheer 
stress (reviewed by Lehoux (25)). Therapeutic intervention in these 
pathways may be beneficial. However, a complete absence of NF-κB has 
been shown to result in apoptosis in vitro (26;27), absence of RelA in vivo 
results in embryonic lethality and liver degeneration (28), indicating the 
importance of the NF-κB signaling pathway. This indicates that the NF-κB 
regulated response is a delicate balance between survival, activation and 





In atherosclerosis, the immune system responds to injury to the 
endothelial cells. Different proinflammatory stimuli such as tumor necrosis 
factor-α (TNF-α), interleukin-1, modified LDL, advanced glycation end 
products and bacterial lipopolysaccharides induce activation of 
intracellular transduction pathways. The nuclear factor-κB (NF-κB) is 
thought to be central to these pathways in endothelial cells (29;30). NF-κB is 
responsible for the expression of endothelial adhesion molecules such as 
E-selectin, ICAM-1, and VCAM-1 as well as for the expression of 
chemokines such as MCP-1 and IL-8 (31). Although many stimuli can 
activate the NF-κB pathway, there are multiple levels of control and 
diversification. Because NF-κB-mediated responses are both cell and 
stimulus specific, it is likely that not all activators utilize the same signaling 




The inflammatory response is aimed towards elimination of the 
initiating stimulus, damage control and subsequent repair of the site of 
injury. Leukocytes play a key role throughout the inflammatory response. 
Since intervention in the first stage of the immune response, extravasation 
of leukocytes, might be beneficial to prevent or interrupt the continuous 
circle resulting in chronically activated endothelium, this introduction only 
focuses on the extravasation. Five sequential steps characterize this 
extravasation: capture, rolling, adhesion, transmigration and chemotaxis 
(32). To facilitate the leukocyte response, the endothelium undergoes 
several changes including vasodilation, increase in vascular permeability 
and the upregulation of the expression of several adhesion molecules to 
enhance adhesiveness of the endothelium for leukocytes. Adhesion 
molecules involved in leukocyte extravasation can be divided into three 
classes: selectins, integrines and glycoproteins of the immunoglobulin 
family (33). Three different selectins are involved in endothelium – 
leukocyte adhesion. 1) L-selectin is constitutively expressed by leukocytes 
(34). 2) P-selectin is expressed by activated platelets and endothelial cells 
that are involved in the initial rolling of the leukocytes on the endothelium 
(35;36). 3) E-selectin is expressed by the activated endothelium, acts at a 
later stage in the immune response and is involved in decreasing rolling 
velocity to allow firm adhesion (37;38). Studies in mice have shown that P-
selectin is a predominant player in endothelium-leukocyte adhesion (39;40). 
Transmigration through the endothelial barrier is mediated by integrins, 
expression of VLA-4 and MAC-1 (CD11b/ CD18) by leukocytes and 
VCAM-1 and, to a lesser extent, ICAM-1 expression by endothelial cells 
(41), and reviewed by Jackson (42). Finally, chemotaxis is mediated by 
factors in the plaques i.e. invaded lipoproteins, or factors secreted by cells 
in the lesion i.e. IL-8 and MCP-1 reviewed by Charo (43).  
 
 
1.1.2.3 Plasma components 
Plasma components are in constant interaction with the endothelial cells 
lining the vessels and therefore have a major influence on the condition of 
these endothelial cells. A strong correlation exists between the incidence 
of ischemic heart disease and plasma levels of components of the 
coagulation cascade, plasma glucose and lipid levels (44). High levels of 
LDL cholesterol, lipoprotein (a) and triglycerides are associated with an 
increased risk of ischemic heart disease (45), whereas high levels of high 
density lipoprotein (HDL) cholesterol have a protective effect (46). 
 
Lipids (triglycerides and cholesterol) are insoluble in water and their 




hydrophobic core containing the a-polar cholesterol esters and 
triglycerides. The surface of lipoprotein particles is composed of polar 
phospholipids and proteins. These so-called apolipoproteins are involved 
in the production, distribution and uptake throughout the body of the 
lipoprotein particles. Lipoproteins are divided into five categories: 
Chylomicrons, very low density lipoproteins (VLDL), intermediate density 
lipoproteins (IDL), low density lipoproteins (LDL), and high density 
lipoproteins (HDL) depending on their density and their lipid and 
apolipoprotein (apo) composition (47). Lipid and cholesterol transport can 
be divided into three different pathways: the exogenous pathway, dealing 
with dietary lipids and cholesterol, the endogenous pathway dealing with 
cholesterol and lipids produced by the liver and the reverse cholesterol 
transport pathway, dealing with the cholesterol transport from the 
periphery back to the liver. 
 
In the exogenous pathway, chylomicrons play an important role. 
These particles are based on a single ApoB48 molecule, formed intra-
cellularly in the enterocyte and contain mostly triglycerides (48). In the 
bloodstream they acquire several apolipoproteins including apoC-II and 
apoE. ApoC-II is a co-activator of the enzyme lipoprotein lipase (LPL), 
present on the luminal surface of capillaries and arteries. LPL hydrolyses 
the triglycerides from the chylomicron core into free fatty acids to enable 
their uptake by the cells. After delipidation of the triglycerides and the 
phospholipids chylomicron remnants remain, which are efficiently cleared 
from the circulation by the liver through apoE-LDL receptor interaction 
(49;50).  
In the endogenous pathway, VLDL produced by the liver plays the 
predominant role. VLDL is formed in the hepatocyte by the addition of 
triglycerides to apoB100 via the enzyme MTP (51). Release of the 
triglycerides from VLDL in the periphery is mediated by LPL in the same 
way as occurs with chylomicrons. The remaining particles, called VLDL 
remnants or intermediate density lipoproteins (IDL), are cleared from the 
circulation by the liver via interaction of apoB100 and the LDL receptor. A 
fraction of VLDL is further converted to cholesterol-rich LDL, which is poor 
in triglycerides. In humans approximately 70% off all cholesterol in the 
plasma is present in LDL particles. 
In the reverse cholesterol transport pathway, HDL transports 
cholesterol from the periphery back to the liver (52). This is one of the 
potential mechanisms by which HDL confers its positive effect on the 
incidence of atherosclerosis (53). HDL particles are relatively lipid poor and 
have therefore a high density. Cholesterol efflux from the cells is mediated 
via members of the ATP binding cassette (ABC) family (54-57). Cholesterol 




Cholesterol Acyltransferase (LCAT) (58). HDL contains apoAI and apoE. 
The cholesteryl esters can be transferred to triglyceride-rich-lipoprotein 
particles via cholesteryl ester transfer protein (CETP) reviewed by Stein 
(59). HDL particles are removed from the circulation via interaction with the 
LDL receptor and scavenger receptor BI (60).  
 
LDL is the primary source for cholesterol present in the plaques (61;62). The 
LDL uptake and retention in the intima is affected by LDL concentrations 
in blood, blood pressure and endothelial permeability. Macrophage 
derived foam cells have a relatively low level of LDL receptor expression 
and they internalize modified and oxidized LDL (OxLDL) very efficiently via 
members of the scavenger receptor family (63). In the plaque, endothelial 
cells, macrophages and smooth muscle cells are able to oxidize 
lipoproteins. Thus formed oxidized fatty acids act as chemoattractant to 
monocytes present in the circulation and induce monocyte adhesion to the 
endothelial cells(64). Furthermore, oxLDL is responsible for the shift in 
gene expression profiles of endothelial cells and for instance the 
upregulation of monocyte chemoattractant protein 1 (MCP-1) and intra 
cellular adhesion molecule 1 (ICAM-1) (65-67). OxLDL is toxic and can 
trigger the release of cytosolic enzymes and cause necrosis, aggravating 
the inflammation in the vessel wall.  
 
 
1.2 Gene therapy  
Current therapies for atherosclerosis are aimed at prevention by lowering 
plasma cholesterol levels through inhibition of HMG-CoA-reductase (68;69) 
or at treatment of stenosis with coronary artery bypass grafting (CABG) or 
percutanious transluminal coronary angioplasty (PTCA) (70). However, 
both CABG and PTCA are hampered by the occurrence of neo-intima 
formation in over 25% of the treated patients (71;72). Prevention of 
atherosclerosis or neo-intima formation by subtle modulation of the 
various molecular pathways involved would be an attractive alternative. 
Modulation of rate-limiting steps in the lipoprotein metabolism could 
reduce the “triglyceride and cholesterol stress” on the vessel wall (68;69). 
Patients suffering from familial hypercholesterolemia might be helped by 
introduction of the LDL receptor in the liver. Proof of concept of this 
approach was shown by dichek and colleagues (73). Locally, the immune 
response can be modulated by intervention in the NF-κB mediated 
signaling pathway (74;75) or vasodilation can be induced through 
stimulation of the eNOS expression (76;77). 
For all of these options, functional vectors capable of modulating gene 




lies in the possibility to intervene genetically in a specific cell or tissue in a 
well-defined process at a specific time-point. Because this intervention 
alters expression of endogenous proteins, it is capable of subtle 
intervention and minimizing toxic, adverse effects.  
Below, these requirements and the current tools to achieve these 
goals are reviewed, with specific emphasis on the adenoviral vector 
system. Subsequently the approaches for gene therapy and adenoviral 
vector targeting with relevance to atherosclerosis are reviewed. 
 
 
1.2.1 Requirements and Tools 
Gene therapy can be defined as the introduction of genetic material into a 
cell to exert certain therapeutic effects. This genetic material is aimed at 
altering the expression level of endogenous genes or the introduction of 
exogenous genes. Modulating expression levels of endogenous genes 
may be beneficial in a variety of pathological processes. Introduction of 
exogenous genes encoding for the correct version of defective proteins 
has long been regarded as the solution in treating monogenetic disorders 
(Reviewed by Griesenbach (78), D’Azzo (79) and Kizana (80)). Alternatively, 
novel genes could be introduced designed to counteract or compensate 
the effect of endogenous genes. For gene therapy to be safe and effective 
Anderson has formulated three criteria (81): 
o The vector used for the introduction of the genetic material should be 
targeted to the tissue and/ or cells where the gene-product is to exert 
its effect  
o The expression of the genetic material should be at the right level 
and for the right duration 
o Since uncontrolled (germ line) transmission of genetic material is 
undesirable, therapy has to occur within acceptable safety limits. 
 
The sequence of events ultimately resulting in therapeutic gene 
expression requires several, sometimes mutually conflicting properties 
from the vectors. (I) They must contain the genetic material in such a way 
that it can be transported through the organism to the tissue/ cells of 
interest, ideally escaping the host immune system and specifically target 
the tissue/ cells of interest. (II) The amount of genetic material (promoter, 
gene, enhancer etc) that can be carried should be sufficient to enable the 
desired expression level. Expression cassette sizes differ among different 
applications: down regulation of endogenous genes requires relatively 
small expression cassettes whereas insertion of complete genes 
(including enhancers and promoter) into host cells requires the 




at the tissue of interest, the genetic material must be transported over the 
plasma membrane or facilitate the uptake of the genetic material by the 
host cell and ensure delivery to the appropriate cellular compartment to 
prevent degradation and assist expression. Expression of the inserted 
material needs to be at the right time, at the right expression level and for 
the right duration in order to be effective.  
Taken all these requirements into account, it becomes clear that a 
universal tool that meets all of them is currently not available; different 
tissues, expression levels and/ or duration will require different tools. 
Viruses are natural tools that fulfill some of these requirements. Viral 
vectors differ in their properties, so specific applications may demand 
specific vectors. Retrovirus vectors are able to integrate their genome into 
that of the host cell resulting in sustained expression. Unfortunately, they 
can only infect dividing cells. An extensive discussion on the biology and 
applications of retroviral vectors is beyond the scope of this introduction 
but complete overviews are given by Sinn and colleagues (82) and 
Anderson and colleagues (83). Related to the adenovirus vectors are the 
lenti or adeno associated viruses (AAV). AAV are non-enveloped 
icosahedral particles of approximately 22 nm containing a 4.7 kb single 
stranded DNA genome. In contrast to adenovirus vectors AAV are able to 
integrate their genetic payload in the genome of the host cell, ensuring a 
longer expression as compared to adenovirus mediated expression. As for 
the retrovirus vectors, an extensive introduction on AAV is beyond the 
scope of this introduction. Ample overviews on AAV have been written by 
Grierger and Samulski (84) and Gonçalves (85). In contrast to retroviral 
vectors, AAV and adenovirus vectors are capable of infecting both mitotic 
and quiescent cells. Adenoviral vectors do not integrate into the host 
genome and consequently the expression time is shorter but the 
expression levels are higher. Other advantages are the extensive 
knowledge of adenovirus biology, the capability of high titer production 
and the broad range of available vectors with different transgenes, 
promoters and combinations hereof.  
 
 
1.2.2 Adenovirus vectors 
1.2.2.1 Introduction 
Since their introduction in biological research in the early 80's adenovirus 
vectors (Ad) have become powerful tools to influence gene expression in 
mammalian cells. Ad vectors are non-enveloped icosahedral particles 
encapsulating a 36 kB double stranded DNA genome, leaving ample room 




distinct subgroups (A to F), containing at least 51 serotypes (86-88), on the 
basis of their genetic variability, oncogenic potential, and G+C content of 
their DNA (89-91). Ads are able to infect a wide variety of tissues. Detailed 
phylogenetic analysis of the different Ad serotypes has yielded several 
phenotypic clusters; the gastrointestinal cluster, with subgroups A and F 
(89-91) and references therein, (92), the respiratory cluster, with subgroups 
B, C and E (89-91;93). Phylogenetic relations between all different serotypes 











































Figure 2. Phylogenetic tree generated by parsimony analysis of fiber knob 
amino acid sequences of fiber derived from human adenovirus serotypes. 
The fiber's origin from the wild-type serotype is indicated by the number to 
the right. Designations A, BI, BII, C, D, E, FL (long fiber of subgroup F 
virus), and FS (short fiber of subgroup F virus) correspond to subgroup 
determination based on classical subtyping assays i.e., HA inhibition 






The majority of vectors in research use today are of serotype 5 
origin (Ad5). The capsid of the virion consists of 3 major proteins (Fig. 3): 
(i) The hexon, this structural protein is the most abundant (720 copies per 
virion) but does not play a role in the uptake of the particle. (ii) The penton, 
this protein is of vital importance as it anchors the fiber firmly into the 
virion and it plays a crucial role in the uptake of the particle and (iii) the 
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Figure 3. Schematic representation of an Adenovirus 
 
The fiber protein consists of three parts: the amino terminus, responsible 
for anchoring in the capsid, the shaft, a rod like shaped structure variable 
in length between the several serotypes (16 nm in the case of Ad3, up to 
37.3 nm in the case of Ad2 and 5) and the carboxy terminal knob. This 
knob domain is the major component in host cell binding and subsequent 
uptake of the particle. The other function of the knob is the initiation of 
trimerisation of the fiber, a key process for normal function of the fiber. X-
ray crystallography studies with E. coli produced fiber proteins have 
revealed the trimerised knob as a structure similar to a three bladed 
propeller (95). Each blade consists of two anti parallel β-sheets and several 
connecting loops (96;97). Besides these three major proteins several other 
proteins are present in the capsid including pIIIa and pIX which serve as 
glue between the hexon proteins. 
 
 
1.2.2.2 Infection pathways 
Since the vector needs to be taken up by specific cells or tissues to exert 




infection. Infection of the host cell resulting in the expression of the viral 
genome, depicted in figure 4, is initiated via the interaction between the 
viral capsid proteins and cell surface components of the host cell (fig. 4, 
step 1). 
 
Figure 4. Sequential steps resulting in viral genome expression 
 
 All serotypes except serotype B use the Coxsackie Adenovirus Receptor 
(CAR) on the host cell surface as docking protein (98;99) and references 
therein). Therefore the tropism of Ad5 vectors is determined by the tissue 
specific expression pattern of CAR. This receptor is highly, but not 
exclusively, expressed on parenchymal cells in the liver, thus explaining 
the broad tropism of the vector in vitro and the high preference for 
infection of the liver after systemic application of Ad5 vectors (100;101). 
Sequence analysis suggested that the 46 kD glycoprotein CAR is 
composed of two immunoglobulin like domains (IgV and IgC2), followed 
by a transmembrane domain and an intracellular C terminus (98). The 
physiological function of this receptor, other then docking of Ad particles, 
is not exactly known. Experiments in heterozygous knockout mice 
(homozygous knockouts are lethal (102)) however, suggest a function for 
CAR in the GAP-junctions (103) in several organs including the heart (104) 
and kidney (105). Interaction between the C-terminal part of the fiber 
protein of the virion and the Ig like domains located in the N-terminal part 





In addition to CAR, Fibronectin type III (FNIII) and MHC-I α2 are 
involved in binding of serotypes 2 and 5 to the cellular surface. When 
expressed in fusion with GST, both FNIII- and MHC-I α2-derived motifs 
showed a serotype 5 and 2 (but not 3) fiber knob-binding capacity in vitro. 
In in vivo assays, peptides representing the MHC-Iα2 segment efficiently 
neutralized serotype 5 and 2 (but not 3), whereas peptides representing 
the FNIII motif, significantly enhanced Ad5 cellular attachment. These data 
suggest that a segment of MHC-I α2, which is conserved between all HLA 
alleles, is involved in the primary binding of Ad5 to cells, and that FNIII 
modules carried by other membrane components could act as auxiliary 
receptors or binding co-factors (106).  
Next, in a process that has been shown to be independent of fiber-
cell recognition (107-109), the penton base proteins of the virus particles bind 
to αV-integrins present on the cell surface through the Arg-Gly-Asp (RGD) 
motive, a tripeptide motif that protrudes from the tertiary peptide structure 
of the penton base, resulting in rapid endocytosis of the virus particle 
through clathrin-coated vesicles (90;109-113), depicted in fig. 4, step 2.  
After internalization the viral capsid is dismantled in a stepwise 
process starting with the removal of the fiber proteins followed by the 
release of capsid proteins IIIa and VIII (fig. 4, step 3). The reactivation of 
cysteine protease p23 by penton base-integrin interactions and the 
reducing environment in endosomes or the cytosol, present in the capsid, 
facilitates the degradation of protein VI (114;115). Import of the viral DNA into 
the nucleus, a process for which the nuclear calcium levels are very 
important, requires contact between the now weakened capsid and 
elements of the nuclear pore complex (115) (fig. 4, step 5 and 6). 
Transcription of the Adenovirus genome is regulated by virus-encoded 
trans-acting regulatory factors.  
 
 
1.2.3 Gene therapeutic approaches in cardiovascular disease 
Pathological mechanisms often involve the (deregulated) expression, or 
absence of a limited set of key regulators. Restoring expression levels or 
inducing expression of novel therapeutic genes might have beneficial 
effects. The therapeutic gene might encode an intracellular protein, in 
which case the therapeutic effect is predominantly autocrine. Alternatively, 
the therapeutic protein could be secreted and exert physiological effects in 
a paracrine or endocrine fashion. This latter approach has as a major 
advantage that not all cells have to be transduced to exert an effect in a 
larger number of cells. “Gain-of-function” strategies have been used 




in animal models and in patients with vascular and myocardial disease 
(116-118). 
An alternative approach is the “loss of function“ strategy. Silencing 
of certain pathogenic genes might slow down disease progression. 
Transcriptional or translational silencing of can be achieved by treatment 
with short single-stranded antisense oligodeoxynucleotides serving as 
decoys (119;120), ribozymes, RNA interference (121;122), hybridizing to 
specific mRNA target sequences. Alternatively, silencing can be achieved 
by the expression of dominant negative proteins. Transcription factors can 
be inhibited by binding of double-stranded decoy oligonucleotides to cis-
elements in DNA consensus binding sequences (119). This latter approach 
has been validated by Wang and colleagues who disrupted NF-κB 
mediated expression of tissue factor (123) in HUVEC. Abnormal tissue 
factor (TF) expression on vascular endothelial cells may account for 
thrombotic events associated with cardiovascular disease (124;125). In 
humans, several clinical trails have shown proof of principle in gene 




1.2.3.1 Vascular tone control  
A balance between vasodilator (i.e. nitric oxide) and vasoconstrictor (i.e. 
angiotensin, adrenalin) elements controls vascular tone. Overexpression 
of vasodilator genes, including NO-synthase has proven to reduce blood 
pressure in hypertensive animals. Induction of endothelial nitric oxide 
synthase (eNOS) expression by intravenous delivery of a plasmid has 
resulted in a sustained hypotensive effect in spontaneously hypertensive 
rats (SHRs) (126). Systemic delivery of adenoviral vectors encoding atrial 
natriuretic factor (127), adrenomedullin (128) or kallikrein (129) decreased 
blood pressure and attenuated renal and myocardial damage in salt-fed 
Dahl salt-sensitive and in deoxycorticostersone acetate fed rats. 
Intervention in the vasoconstrictor side of the balance also has 
beneficial effects on blood pressure. Tang and colleagues have shown 
that delivery of angiotensinogen antisense cDNA by AAV dose-
dependently decreases arterial blood pressure in adult SHRs combined 
with reduced angiotensinogen levels (130). Inhibition of other components 
of the renin– angiotensin signaling system, including the antisense 
inhibition of angiotensinogen-converting enzyme (ACE) (131) and the 
angiotensinogen II type 1 (AT1) receptor (132), gave comparable results. 
Inhibition of the β1-adrenoceptors via antisense oligonucleotides also 
reduces blood pressure (133), suggesting that gene therapeutic intervention 






1.2.3.2 Atherosclerosis and thrombosis 
Since plaque stability is directly linked to acute coronary events, gene 
therapy aimed at increasing thromboresistance and plaque strength 
resulting in long-term plaque stabilization could potentially offer great 
benefits for the patient (134).  
For example, adenovirus mediated overexpression of 
apolipoprotein ApoA1 in mice was shown to increase serum high-density 
lipoprotein levels, and thus stimulating the transport of cholesterol back to 
the liver. (135). Inhibition of monocyte chemoattractant protein-1 (MCP-1) 
receptor results in the blockade of monocyte infiltration and activation in 
the arterial wall and was shown to retard the onset and limit the 
progression and destabilization of established atherosclerotic lesions in 
ApoE knockout mice (136). eNOS has vasoprotective functions in addition 
to controlling vascular tone, including inhibition of vascular smooth muscle 
cell proliferation and migration and inhibition of platelet activation and 
adhesion (137). Gene therapy aimed at increasing NO activity and thus 
enhancing its anti-atherogenic properties of the vessel wall could be 
beneficial (138). For example, local administration of adenovirus vectors 
encoding eNOS to the carotid arteries of cholesterol-fed rabbits reduces 
inflammatory cell infiltration and lipid deposition (139). Gene transfer of 
cytoprotective genes, such as heme oxygenase-1 (HO-1) and superoxide 
dismutase (SOD), can also result in vasoprotective effects (140). 
Adenovirus-mediated local delivery of HO-1 decreased iron depositions 
and attenuated the development of aortic lesions in ApoE-deficient mice 
(141), whereas gene therapy inducing manganese SOD expression in pre-
atherosclerotic carotid arteries improved endothelium-dependent 
vasorelaxation in hypercholesterolemic rabbits (142). De Nooijer and 
colleagues have shown that local infection of advanced atherosclerotic 
lesions with adenovirus mediated expression of TIMP-1 in mice reduced 
intra-plaque hemorrhage as compared to adenovirus mediated MMP-9 
expression (143). These data indicate that inhibition of MMP-9 might have a 
stabilizing effect on advanced lesions. 
Monogenic disorders, such as hemophilia and cystic fibrosis in humans 
were among the first diseases that could potentially be cured with gene 
therapy (Reviewed by Griesenbach (78), D’Azzo (79) and Kizana (80)). 
Because inherited lipid metabolism disorders such as familial 
hypercholesterolemia (FH) and ApoE deficiency do not or hardly respond 
to medical treatment, gene therapy aimed at lowering lipid levels is likely 
to be useful. In the case of FH, gene therapy has been applied in a small 




levels was found in 3 out of 5 patients after administration of a retroviral 
vector expressing the wild-type LDL receptor. The effect was temporary 
likely due to silencing of the exogenous gene.  
1.2.3.3 Neointima formation 
Success of percutanious transluminal coronary angioplasty (PTCA) and 
coronary artery bypass grafting (CABG) is limited by the (re)occurrence of 
intimal hyperplasia following the procedures (71;72). Hyperplasia is either 
due to migration of SMC from the media, proliferation of VSMC or a 
combination of both. Prevention of neointima formation is a likely target for 
gene therapeutic intervention since it is initiated by local damage due to 
the PTCA procedure or altered flow conditions and increases stress in the 
graft in the case of CABG and specific processes are involved. Gene 
therapeutic intervention in cell-cycle mediators of endothelial and SMC 
provides the opportunity to render these cells resistant to atherosclerosis 
and neointimal formation after PTCA or CABG (133;145). Delivering anti-
proliferative genes, such as those coding for the NOS isoforms, inhibits 
the intimal hyperplasia (138). 
Gene transfer of eNOS in balloon-injured rat carotid arteries using 
fusigenic liposomes has proven to be vasculoprotective and 
antiproliferative (146). Both endothelial and inducible NOS gene transfer 
was efficacious in reducing neointimal proliferation after PTCA (138;147). 
Direct inhibition of the cell cycle via the inhibition of key regulatory proteins 
controlling progression is another approach to intervene in neointima 
hyperplasia (148;149). Jugular veins of New Zealand rabbits were treated 
with hemagglutinating virus of Japan (HVJ)–liposome complexes 
containing antisense oligonucleotide against the cell-cycle regulators 
proliferating- cell nuclear antigen (PCNA) and cdc2 kinase in vivo before 
carotid-artery interpositional grafting (150). Adaptive remodeling and 
induction of medial hypertrophy combined with inhibition of intimal 
hyperplasia of the graft was observed after the gene therapy, resulting in 
vessels resembling normal arteries (150). Likewise, treatment of grafts prior 
to implantation with a decoy deoxyoligonucleotide containing the 
consensus binding sequence for E2F-1, a transcriptional factor involved in 
cell-cycle progression, resulted in prolonged resistance to neointima 
hyperplasia of the graft after transplantation in rats (151).  
Another interesting target for intervention is the plasminogen 
activation system, which plays a central role in cell migration (152;153). 
Lamfers and colleagues have constructed a fusion protein consisting of 
the amino-terminal fragment (ATF) of human urokinase plasminogen 
activator linked to bovine pancreas trypsin inhibitor, a very potent inhibitor 




reduces SMC migration and neointima formation in both human and 
murine blood vessels (155). 
In humans, intervention in cell cycle progression as a means to 
inhibit neointima formation and vein-graft failure has been evaluated in 
early-phase clinical trials. Mann and colleagues have undertaken the 
PREVENT-I trial, a prospective randomized doubleblind trial in which 
human saphenous vein-grafts were treated with E2F decoy 
oligonucleotides in high-risk patients suffering from peripheral arterial 
occlusion (156). This phase I trial demonstrated that E2F decoy 
oligonucleotides can be administered safely to the graft ex vivo, prior to 
implantation. In the recent follow-up phase II trial (PREVENT-IV) the study 
design was expanded with a placebo arm (157). Interim results of this study 
confirmed the results from PREVENT-I. Analysis of the secondary 
endpoints, using quantitative coronary angiography and three-dimensional 
intravascular ultrasound, demonstrated increased vessel patency, 
adaptive vessel remodeling and reduction in neointima size. Critical 
stenosis was reduced by 40% in the treated group one year after 
treatment (yet unpublished data, but commented in (158)). These results 
await conformation and validation by an appropriately powered phase III 
trial to demonstrate the feasibility of this approach. A separate phase I trial 
is evaluating the efficacy of preventing restenosis of coronary arteries after 
PTCA by catheter-based iNOS gene delivery (REGENT-I) (77). 
 
 
1.2.3.4 Inflammation and apoptosis 
Overexpression of anti-apoptotic genes and the inhibition of 
proinflammatory and cell-adhesion molecules might have therapeutic 
potential for the treatment of apoptosis and inflammation of the vessel wall 
in atherosclerosis (159;160).  
In vitro, adenovirus mediated expression of IκBα and a dominant 
negative form of IKK-2 inhibited TNFα-induced expression of E-selectin, 
VCAM-1 and ICAM-1 in human umbilical vein endothelial cells (161). In 
vivo, acute myocardial ischemia during cardiac transplantation could be 
reduced by the inhibition of proinflammatory genes. For example, treating 
the myocardium of rabbits ex vivo, before transplantation, with Ad 
expressing the immunosuppressive cytokine IL-10 prolonged cardiac 
allograft tolerance and longterm survival (162).  
Von der Thusen and colleagues showed that IL-10 is able to 
attenuate atherosclerosis after systemic or local adenovirus mediated IL-
10 expression (163), systemically because of monocyte deactivation and 




stenosis. Adenovirus mediated IκBα expression in a rabbit iliac artery 
restenosis model reduced ICAM-1 and MCP-1 expression and reduced 
the recruitment of macrophages and lumen narrowing (164).  
Overexpression of anti-apoptotic genes such as Bcl-2 and Akt 
(165;166), immunosuppressive cytokines i.e. Il-10 (162), adenosine A1 and A3 
receptors (167) and hepatocyte growth factor (HGF) (168-170) protectes the 
myocardium from reperfusion damage and ischemia. Likewise, a 
promising strategy for acute protection against these kinds of injury could 
be the inhibition of proinflammatory genes. Morishita and colleagues have 
shown that pretreatment of the myocardium with a decoy oligonucleotide 
capable of inhibiting the transactivating activity of NF-κB reduced infarct 
size after coronary artery ligation in rats (171). Hepatic Growth Factor 
(HGF), an organotrophic and angiogenic factor, has also been reported to 
exert cardio protective properties. Intracoronary delivery of HGF in rat 
hearts reduced myocardial enzyme leakage significantly and enhanced 
cardiac recovery after global ischemia in isolated hearts (169). 
Intramyocardial, adenoviral HGF delivery in mice attenuated the 
remodeling of the left ventricle and progression to heart failure after 
myocardial infarction together with enhanced angiogenesis and reduced 
myocyte apoptosis (170). 
Despite the preclinical evidence demonstrating the therapeutic 
potential of over-expression of protective genes in or near the 
myocardium, the efficacy of these therapies for patients with coronary 




For patients suffering from occlusive coronary or peripheral vascular 
diseases, gene therapy mediated stimulation of angiogenesis might be 
beneficial. Angiogenesis is initiated by a shifted balance between pro and 
anti-angiogenic factors. Subsequent degradation of the vascular basement 
membrane and endothelial cell migration and proliferation results in the 
formation of new capillary tubes (172). 
 Banai and colleagues have shown that intracoronary vascular 
endothelial growth factor (VEGF) protein delivery enhances the 
development of small coronary arteries supplying ischemic myocardium, 
resulting in marked improvement of maximal collateral blood flow delivery 
(173). In rabbits with operatively induced hindlimb ischemia plasmid DNA 
encoding each of the three principal human VEGF isoforms resulted in 
augmented collateral vessel development demonstrated by serial 
angiography, and improvement in calf blood pressure ratio (ischemic to 




ratio (174). Treatment of rabbits with an adenovirus expressing acidic 
fibroblast growth factor (aFGF) prior to coronary artery occlusion resulted 
in a 50% reduction of the risk region for myocardial infarction and an 
increase in length density of intramural coronary arterioles (175). 
Intramuscular administration of Ad mediated VEGF into rats and rabbits 
stimulates neovascularization in nonischemic skeletal muscle (176). Direct 
administration of a comparable vector to ischemic myocardium in pigs 
resulted in the formation of collateral vessels and a significant 
improvement in both myocardial perfusion and function. (177) 
 In humans, two relatively small placebo controlled trials for 
coronary disease are reported. In the first trial, plasmids mediating VEGF-
2 expression are applied intramyocardially (178), leading to a reduction in 
angina as well as to a significant improvement in cardiac perfusion and 
function. In the second trial, adenovirus vectors are used to mediate FGF 
expression intracoronary (179). This study also shows promising results. In 
peripheral artery disease, two phase-1 studies have been reported. The 
first study used adenoviral NV1FGF (FGF type 4 with the excretion signal 
of FGF type 1) and reported a decrease in rest pain, ulcer size and an 
improved the ankle: brachial index after gene transfer. However, no 
placebo group was present in this trial (180). The second study used VEGF 
and showed significant improvement in endothelial function (measured by 
acetlycholine infusion), and increased ankle: brachial index after VEGF 
gene transfer (181), indicating an improved blood flow to the foot. A larger 
phase 2 trial by Makinen and colleagues in patients with lower limb 
ischemia with both adenoviral and plasmid VEGF gene transfer at 
angioplasty showed increased vascularity (182). A complete overview of 




1.3 Targeting in gene therapy 
1.3.1 Targeting of adenovirus vectors 
As illustrated in the previous paragraphs gene therapeutic approaches in 
cardiovascular disease are promising. However, gene therapy is 
hampered by the relative lack of vectors capable of directing tissue 
specific expression of the therapeutic transgene. Targeting of the vectors 
provides a means to direct the expression towards the desired cells and 
thus enhance the efficacy of gene therapeutic approaches. 
 
Understanding the CAR mediated and integrin assisted infection pathways 




to specific cell types. Regardless of the strategy chosen to target the virus, 
two critical problems have to be solved; 1) the native tropism for the CAR 
should be eliminated to prevent uptake of the vector by the liver and 2) a 
novel tropism for an alternative cellular receptor should be generated. 
Sequestration of the virions by the liver, via CAR mediated uptake by 
parenchymal cells severely compromises the efficacy of the therapy. 
Moreover many target cells relevant to gene therapeutic intervention 
including tumors macrophages or endothelial cells do not, or hardly 
express CAR rendering them resistant to Ad infection. To overcome these 
limitations, several targeting strategies have been developed, which can 
be divided into two distinct categories: (I) genetic modification of the virus 
vector or (II) the use of adapter proteins facilitating the binding of the virus 
to specific cell types. Both approaches require a ligand-receptor 
interaction with the receptor present on the target cell and the ligand fused 
to the Ad virus. 
 
 
1.3.1.1 Genetic targeting 
In genetic targeting, the viral capsid proteins responsible for binding to 
target cells are modified in such a way that affinity is induced for other 
cells. In principal all of the viral capsid proteins (hexon, penton, pIX, or 
fiber) can be used for the insertion/ addition of ligands. The choice of the 
particular protein or peptide and the position of the ligand in the capsid 
protein should be dictated by the following considerations: Incorporation of 
the ligand should not interfere with Ad assembly and only minimally affect 
the Ad protein in which it is inserted, not hampering its function. The ligand 
should be presented in such a way that it adopts its correct configuration 
and therefore is able to bind its target receptor. These modifications have 
been achieved via pseudotyping of the fibers or via cloning of ligands for 
novel receptors into the HI-loop or the C-terminal domain of the fiber knob, 




Different adenovirus serotypes have different tropisms due to variations in 
the structure of the fiber and knob of the virus capsid (94). Exchange of 
CAR-binding fibers with fibers of serotypes not having affinity for CAR, a 
process called pseudotyping, alters the tropism of the vectors. For 
instance, improved infection of airway epithelial cells was obtained with 




delivery to umbilical vein endothelial cells, saphenous vein segments and 
smooth muscle cells was improved by pseudotyping Ad5 with fibers 
originated from Ad16, a subgroup B virus. (185). Improvement of infection 
of several cell lines from hematopoietic origin with Ad5 was observed 
when replacing the endogenous fibers with subgroup B fibers (186;187). 
Switching Ad5 fibers with serotype 30 fibers enhances the affinity for 
human endothelial cells in culture (188). Serotype 4 and 11 enhance the 
infectivity of Ads to vascular endothelial cells (189). Caution should be 
taken when shifting serotypes as fibers are also important for the 
intracellular trafficking of the virus as was demonstrated with fibers from 
Ad35. The latter fibers are able to enhance the delivery of the virion to the 
nuclear membrane but also mediated trafficking back to the cell surface 
(190). From the above, it will be obvious that targeting via pseudotyping is 
limited to naturally occurring fiber polymorphisms.  
 
 
1.3.1.1.2 Capsid and fiber modification 
The genetic approach in targeting consists of the insertion of ligands for 
cellular receptors in the capsid of the virion. Effective targeting should 
ideally abolish the affinity for CAR and induce affinity for a novel receptor. 
The fibers of the virion normally involved in cellular entry are therefore the 
most obvious candidates although the insertion of FLAG epitopes in the 
penton bases of the fiber and subsequent addition of ligand-αFLAG 
antibody fusion-proteins strategies has also been successful (191), as well 
as modifications of capsid protein pIX (191;192). As for the fiber, ligands can 
either be inserted in the HI-loop, a lose structure protruding from the fiber 
knob, or they can be attached to the C-terminus of the fiber. Both 
strategies have resulted in successful targeting of the virus. Introduction of 
peptides, including RGD, in the HI-loop (108;193-199) or the C-terminus 
(200;201) conferred a high affinity for several receptor including αV-integrins. 
Affinity for heparan sulfate protyoglycans was induced via a lysine stretch 
linked to the C-terminus (196). As the ligands are inserted during virion 
synthesis, they should be compatible with the structure of the fiber, not 
changing its configuration as this is important for its function and proper 
virion assembly. Insertion of large peptides to the C terminus was shown 
to disturb fiber trimerization preventing proper virus assembly (202). 
Because Ad particles are assembled in the nucleus of the host cell, all 
capsid proteins are transported to the nucleus directly after translation. 
Therefore the ligands should not require any posttranslational 
modifications not available in the cytosolic or nuclear compartment. 
Polypeptides of up to 63 residues have been inserted into the HI-loop 




this insertion site. Since generation and amplification of Ad5 vectors relies 
on cell lines expressing CAR, it should be recognized that a successfully 
retargeted Ad vector, one that has lost affinity for CAR and has acquired a 
novel specificity, may require a specially adapted cell line for generation 
and amplification.  
 A novel approach replaces the entire fiber of the virus with a virion-
anchoring domain of the endogenous fiber and the oligomerization domain 
of reovirus attachment protein sigma1. This approach ablates the native 
adenovirus tropism as demonstrated by a 35-fold reduced infection on 293 
cells. The His tag incorporated into the chimeric attachment protein 
conferred His-tag-dependent tropism to the AdV, which resulted in a 12- to 
40-fold greater infection efficiency on two different cell lines expressing a 
His-tag-binding receptor. (203) 
 
 
1.3.1.2 Conjugate based targeting 
1.3.1.2.1 Covalent cross linking systems 
Conjugate-based targeting approaches involve the use of bifunctional 
linker proteins, which on the one hand bind to the adenovirus and on the 
other hand bind to the target cell.  
Several approaches have proven to be successful in providing a 
means to bind the adenovirus. One of the approaches involves the use of 
antigen binding fragments (Fab) or single chain antigen binding fragments 
(scFv) of virus binding antibodies. Antibodies can be selected for high 
affinities to Ad and the neutralization of infection, which likely aids to 
minimize the endogenous uptake by the liver (107), reviewed by (204). The 
use of monoclonal antibodies, however, is associated with specialized 
chemical conjugation of the moieties conferring target cell specificity. An 
alternative approach uses a CAR fragment to bind the virus. This CAR 
receptor has an affinity in the low nanomolar range (205) and after binding 
to the adenovirus reduces the endogenous tropism by competition, 
making it suitable for targeting strategies (206;207). Furthermore, CAR 
fragments can be produced by Escherichia coli (E. coli) ((208) relatively 
easily and in large amounts.  
Introduction of a ligand for a cell specific receptor in the targeting 
protein results in tropism for the target cell. In antibody based approaches 
several strategies have proven to be successful i.e.: (I) A virus neutralizing 
scFv antibody fragment was isolated from a phage library and a C-
terminal fusion protein with epidermal growth factor (EGF) constructed. 
The efficiency of viral infection could be markedly enhanced by using this 




on the previous strategy is the fusion of two antibodies. Haisma and 
colleagues generated a bifunctional antibody containing two epitopes, one 
directed against the adenovirus fiber to one directed against the epidermal 
growth factor receptor (210). This fusion antibody markedly enhanced the 
infection efficiency of adenoviral vectors in epidermal growth factor 
receptor expressing cell lines. In cultured endothelial cells, an anti-E-
selectin monoclonal antibody conjugated to an anti-FLAG antibody 
enhanced the uptake of an adenovirus vector expressing the FLAG 
peptide in its capsid cultured 20-fold (211). A bispecific antibody 
synthesized by covalent linkage of an adenovirus fiber protein antibody to 
a CD70 antibody enhanced infection of Epstein-Barr virus-transformed 
lymphoblastoid cell lines 10- to 20-fold (212). 
In CAR based fusion proteins, generation of an epidermal growth 
factor-CAR fusion protein has proven to be successful in mediating Ad 
infection of EGF-receptor positive, CAR negative cells (206). Pereboev and 
colleagues constructed a fusion protein of CAR and a CD40 ligand via a 
trimerization motif. This fusion protein enhanced gene transfer to bone 
marrow derived dendritic cells to over 70% infection efficiency, compared 
to undetectable infection using untargeted Ad5 (207). A CAR- scFv 
antibody against c-erbB-2 oncoprotein constructed by Kashentseva and 
colleagues proved efficient in infecting c-erbB-2 overexpressing cells up to 
130-fold increase in comparison with untargeted Ad complexed with 
sCARf control protein (213). An extensive overview of conjugate based 
targeting strategies has been given by Krasnykh (214). 
One of the challenges of the above approaches is to overcome the 
complicated chemistry associated with the conjugation step and 
subsequent purification. In addition, a number of CAR based fusion 
proteins are produced as single proteins, meaning that for each novel 
specificity a new targeting protein needs to be designed and produced.  
 
 
1.3.1.2.2 Non-covalent cross linking systems 
An alternative approach within the conjugate based targeting strategies is 
the use of non-covalent cross-linking systems to target virus particles. In 
non-covalent cross linking systems, the virus binding moiety and the 
receptor binding ligand are not covalently linked. An advantage of this 
approach is that the chemistry is often easier as compared to the 
chemistry involved in direct coupling. This approach results in a relatively 
flexible system to equip Ad with a variety of ligands. For example, Rogers 
used an anti-Ad Fab fragment coupled to phenylboronic acid (PBA) and 
attached FGF2 -dihydroxybenzohydroxamic acid (DHBHA) thus exploiting 




(215). Smith and Parrott applied the avidin-biotin interaction to retarget 
adenovirus vectors (216;217). Smith has chemically biotinylated adenovirus 
particles and targeted them to biotinylated cells via an avidin bridge. When 
equipping the virus with biotinylated monoclonal antibodies anti-CD117, -
CD34 or –CD44, via the avidin bridge various kinds hematopoietic cell 
subsets could be infected (216). Parrott et al. introduced a biotin acceptor 
peptide (BAP) in the C-terminus of the fiber of Ad5 (217). After metabolic 
biotinylation of the virus particle, it could be equipped with a variety of 
ligands via an avidin bridge. Using this system, it was shown that Ad5 
could be equipped with biotinylated monoclonal antibodies, biotinylated 
manose and biotinylated -oligonucleotides and targeted to primary 
dendritic cells (217). Introducing this BAP into capsid protein IX and the 
subsequent equipment with transferrin (via avidin) allowed for the 
targeting to CD71 (218). Li and colleagues followed a different approach in 
Ad targeting. They developed a fusion ligand protein consisting of CAR 
and the antibody Fc-binding domain from protein A (219). Because the Fc-
binding domain in protein A is capable of binding to any immunoglobulin, 
this strategy can be adapted to target a wide variety of tissues or cells, as 
long as an antibody recognizing a membrane marker on the target tissue 
or cell is available.  
 
 
1.4 Outline of the thesis 
The studies in this thesis describe a novel technology to target adenovirus 
vectors to novel receptors. In chapter 2, the characterization of an 
oligonucleotide dA2G10 ligand capable of mediating drug delivery through 
interaction with scavenger receptor A present on macrophages is 
described. This ligand was shown capable of mediating the uptake of a 
liposomal drug carrier particle both in vitro and in vivo. In chapter 3, a 
novel linker protein, CAR-Avidin, to equip Ad vectors with novel ligands is 
designed and characterized. This linker protein consists of the virus-
binding moiety of CAR, genetically fused to avidin. As a proof of principle, 
the ligand developed in chapter 2 is applied in a slightly modified form, 
and used to aid the infection of primary and transformed macrophages by 
adenovirus vectors. In chapter 4, the versatility of the CAR-Avidin linker 
protein is demonstrated as it is used to equip Ad vectors with a cRGD 
peptide ligand specific for αVβ3/5 integrins and subsequently aid the Ad 
infection of human umbilical cord endothelial cells, bovine and murine 
endothelial cell lines and primary murine vascular smooth muscle cells. 
Chapter 5 describes the challenges associated with the targeting of Ad 
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Macrophages play an important role in inflammatory processes and are 
crucially involved in the onset and progression of atherosclerosis and 
tumorigenesis. Therefore, macrophages are regarded as an excellent 
target for therapeutic intervention. Since the scavenger receptor class A 
(SRA) is highly expressed on macrophages, we developed in the present 
study an SRA-specific particulate drug carrier by providing 
phosphatidylcholine liposomes with a targeting ligand for SRA. To enable 
firm association with liposomes, the high-affinity SRA ligand 
decadeoxyguanine was covalently attached via a linker to lithocholic 
oleate (LCO-dA2dG10). Incorporation of LCO-dA2dG10 into liposomes 
resulted in an increased electronegative surface charge and a dramatically 
enhanced serum clearance (t½ < 2 min versus > 5 h). The LCO-dA2dG10-
induced liposome clearance was fully dependent on SRA, as the 
clearance could be efficiently inhibited by the SRA competitor polyinosinic 
acid. LCO-dA2dG10 enhanced the affinity of liposomes for SRA in vivo 
selectively, since introduction of overall or clustered negative charges by 
other modifications (e.g. oxidation, inclusion of phosphatidylserine, or 
exposure of glutamic acid residues) did not affect their serum clearance 
substantially, albeit that these modifications resulted in an at least equally 
high negative surface charge. LCO-dA2dG10 also increased the 
association of liposomes with RAW264.7 cells, resulting in an enhanced 
intracellular delivery and bioactivity of encapsulated dexamethasone-
phosphate. Therefore, the SRA-specificity of LCO-dA2dG10-liposomes may 
be applied for the specific delivery of drugs to macrophages, which may 
be of therapeutic benefit in general inflammatory disorders, 
atherosclerosis, and tumorigenesis. 
 
 
Key words: atherosclerosis; dexamethasone; drug targeting; liposome; 
macrophage; oligodeoxynucleotide; polyanion; scavenger receptor. 
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Introduction 
Macrophages are crucially involved in inflammatory responses, and play 
an essential role in the body’s innate defense system by protecting the 
host during the early phase of an infection. On the other hand, 
macrophages in the arterial wall contribute to atherosclerosis at all phases 
of disease progression (reviewed in (1;2)). Upon differentiation of 
monocytes into intimal macrophages, scavenger receptors such as 
scavenger receptor class A (SRA) type I/II, CD68/macrosialin, and CD36 
are substantially upregulated. These receptors recognize a range of 
(poly)anionic macromolecules including polyinosinic acid (polyI) (3), 
lipopolysaccharide (LPS) (4), oligodeoxynucleotides (5), anionic 
phospholipids such as phosphatidylserine (PS) (6), and modified 
lipoproteins such as oxidized LDL (oxLDL) and acetylated LDL (acLDL) 
(7;8). Although the capacity of macrophages to recognize and internalize 
LPS and PS may be beneficial for the clearance of pathogens and 
apoptotic cells (9), the uptake of oxLDL is thought to be deleterious as it 
results in foam cell formation due to massive accumulation of cholesterol 
(10;11). These foam cells secrete an array of mediators (i.e. pro-
inflammatory cytokines, mitogens, and chemokines), thereby amplifying 
oxidative reactions and stimulating the proliferation of smooth muscle cells 
into the atherosclerotic plaque. Moreover, besides their adverse 
contribution to atherosclerosis, macrophages also play a major role in 
tumor growth (12). 
The various scavenger receptors show different substrate 
specificities. SRA type I/II (13:14) is highly expressed on liver endothelial 
cells as well as on macrophages, and recognizes both acLDL and oxLDL 
(7;8). Both acLDL and oxLDL are mainly cleared by the liver, a process 
which can be effectively blocked by polyI (15). However, whereas the 
hepatic clearance of acLDL is mainly exerted by endothelial cells (16), the 
uptake of oxLDL is attributable to Kupffer cells (15) and mainly mediated by 
a specific oxLDL receptor (17), i.e. CD68/macrosialin (18). In addition, the 
class B scavenger receptor CD36 is also able to bind and internalize 
acLDL and oxLDL (19;20). CD36 is expressed on macrophages and 
adipose tissue, but not in the liver (21). Besides recognizing modified 
lipoproteins, CD36 also strongly binds PS-containing liposomes (6;22-24), 
but not the broad array of other polyanion ligands for SRA such as polyI 
and polyG (20). Peritoneal macrophages isolated from mice that lack both 
SRA and CD36 fail to accumulate modified LDL (25), indicating the 
importance of these two receptors in macrophage foam cell formation. 
The crucial involvement of macrophages in atherogenesis has 
been illustrated by the observation that hypercholesterolemic mice that 
lack macrophages are extremely resistant to atherosclerosis (26). 




therapeutic intervention in atherosclerosis (2;27). Macrophage-directed anti-
atherogenic therapies could be aimed at inhibition of scavenger receptor 
activities to reduce the influx of cholesterol, lowering of inflammatory 
responses e.g. by dexamethasone (28), and increasing ABCA1/apoE-
mediated cholesterol efflux e.g. by LXR activation (29). However, these 
goals require that drugs are selectively targeted to macrophages within 
atherosclerotic lesions. General inhibition of scavenger receptors or 
systemic attenuation of the inflammatory response will negatively interfere 
with innate immunity [9], and synthetic LXR agonists cause liver steatosis 
and hypertriglyceridemia by stimulating VLDL secretion by hepatocytes 
(30). 
 Therefore, the goal of this study was to develop a liposomal drug 
carrier with high affinity for macrophage SRA. For this purpose, we 
provided long circulating phosphatidylcholine liposomes (31) with a 
decadeoxyguanylic acid residue (dG10) with high affinity for SRA (32). 
Hereto, dG10 was equipped with lithocholic oleate (LCO) that shows stable 
association with liposomes in vivo (33;34). We show that dG10 results in the 
efficient and highly specific targeting of liposomes to SRA in mice in vivo, 
and leads to increased intracellular delivery of encapsulated 
dexamethasone phosphate in a biologically active form into macrophages 
in vitro. Therefore, these SRA-specific liposomes are considered to be 




Material and methods 
Synthesis of LCO-dA2dG10 and LCO-EE. LCO-dA2dG10 was synthesized 
and purified essentially as described previously (35). In short, 5'-C12-NH2-
AAG GGG GGG GGG-3’ (NH2-dA2dG10, Eurogentec, Seraing, Belgium) 
was precipitated as a lithium salt with 10 volume equiv of 3% LiClO4 in 
acetone. Next, the oligodeoxynucleotide was dissolved in H2O and 
precipitated again with 10 volume equiv of acetone to remove residual 
traces of LiClO4. NH2-dA2dG10 (100 nmol) was dissolved in 350 µl of H2O/ 
N,N-dimethylformamide (DMF)/ 1,4-dioxane (1:4:2, v/v/v). Subsequently, 
5β-cholanic acid-3α-ol-pentafluorophenyl ester (lithocholic oleate, LCO, 
Sigma, St. Louis, USA) (1 µmol) dissolved in 100 µl of dioxane, and 35 
µmol of N,N-diisopropylethylamine (DiPEA) were added. The mixture was 
incubated for 48 h at 37°C. Solvents were removed in a speed-vac 
concentrator, and the residue was taken up in 200 µl of dichloromethane 
and 200 µl of H2O. The layers were separated by centrifugation, and the 
organic layer was washed twice with 200 µl of H2O. The H2O fractions 
were combined and freeze-dried. LCO-dA2dG10 was separated from 
nonconjugated dA2dG10 by gel electrophoresis in a 1% LM-MP agarose 
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gel (Boehringer Mannheim, Mannheim, Germany ) containing 0.1% Tween 
20, in 0.5× TBE [45 mM Tris-borate and 0.1 mM EDTA (pH 8.4)]. The gel 
slice containing LCO-dA2dG10 was melted for 5 min at 65°C. The agarose 
was digested with agarase (40 U/ml of gel) (Boehringer Mannheim, 
Mannheim, Germany) at 45°C in 30 mM Bis-Tris,10 mM EDTA (supplied 
with the enzyme) for 2 h. LCO-dA2dG10 was precipitated with 10 volume 
equiv of acetone. To remove traces of undigested agarose, the precipitate 
was taken up in 200 µl of H2O and passed over a filter paper (no. 589, 
Schleicher and Schüll). For the synthesis of LCO-EE, N-glutamyl glutamic 
acid (N-EE, 100 µmol) (Bachem, Bubendorf, Germany) was dissolved in 3 
ml of H2O/ DMF/ 1,4-dioxane (1:4:2, v:v:v), and 5β-cholanic acid-3α-ol-
pentafluorophenyl ester (110 µmol) in 1.0 ml of H2O/ 1, 4-dioxane/ DiPEA 
(330 µmol) was added. The mixture was incubated for 48 h at room 
temperature after which the solvents were removed under reduced 
pressure. The residue was extracted with dichloromethane/ acetic acid 
(0.1 M). The organic phase was washed twice with 0.1 M acetic acid. The 
oily residue was chromatographed over Kieselgel 600 (Merck, Darmstadt, 
Germany) using dichloromethane/ methanol/ acetic acid (100:5:1, v:v:v) as 
eluent. All chemicals were of analytical grade. 
Preparation and characterization of liposomes. Liposomes were 
prepared as described (31). Phosphatidylcholine (PC) liposomes were 
prepared by mixing egg yolk phosphatidylcholine (EYPC) (Fluka, Buchs, 
Switzerland) and cholesteryl oleate (CO) ( Janssen, Beerse, Belgium) in 
CHCl3/CH3OH (1:1, v:v) (25:1, w:w), and PC/phosphatidylserine (PS) 
liposomes from EYPC, 3-sn-phosphatidyl-L-serine (from bovine brain, 
Fluka), and CO (12.5:12.5:1, w:w:w). For preparation of radiolabeled 
liposomes, 50 µCi of [1α,2α-3H]CO (Amersham Biosciences, Little 
Chalfont, UK) was included in the lipid mixture. Solvents were evaporated 
under N2. For preparation of liposomes containing oxidized PC (oxPC), 
EYPC was exposed to air (72 h at 60°C) before addition of [3H]CO. Lipids 
were hydrated in 10 ml of 0.1 M KCl, 10 mM Tris.HCl, pH 8.0, and 
sonicated for 1 h using a Soniprep 150 (output 10 µm) at 54°C under 
Argon to prevent (further) oxidation. PC and oxPC liposomes were purified 
and concentrated by density gradient ultracentrifugation and harvested by 
aspiration (31). PC/PS liposomes were dialyzed against PBS, pH 7.4, to 
prevent salt-induced particle aggregation. PC concentrations were 
determined using the Phospholipid enzymatic colorimetric test kit (Roche, 
Basel, Switzerland) with Precipath as internal standard. When indicated, 
PC liposomes were incubated (30 min at 37°C) with LCO-dA2dG10 (50-500 
molecules per particle) or LCO-EE (1000 molecules per particle). These 
calculations were based on 7.62x1013 liposomes per mg of phospholipid 
(31) and the molecular weights of LCO-dA2dG10 (Mw = 4588) and LCO-EE 




residue was radioiodinated, showed complete incorporation into the 
liposomes up to 3333 molecules per particle, as evidenced by 
colocalization of LCO-[125I]YE with [3H]CO-labeled liposomes (not shown). 
Assuming that LCO-dA2dG10 and LCO-EE show a similar affinity for the 
liposomes as LCO-YE, it can thus be expected that complete 
incorporation of these compounds into liposomes will be achieved at only 
1000 molecules per particle. The PC, oxPC, and PC/PS liposomes were 
homogenous particle populations with mean sizes of 30±2 (n=8), 32±2 
(n=2), and 33±4 nm (n=2), respectively, as determined by photon 
correlation spectroscopy using a Malvern 4700 C system (Malvern 
Instruments, Malvern, UK) at 27°C and a 90° angle between laser and 
detector. Liposomes were stored under Argon and used within 2 weeks 
after preparation. When indicated, 50 mg dexamethasone 21-phosphate 
(dexaP, Sigma) was added to the buffer before sonication, and liposomes 
were concentrated and purified from non-encapsulated dexaP by density 
gradient ultracentrifugation as described above (31). Assuming an 
incorporation efficiency of 0.55 µl/mg of phosholipid for 30 nm-sized 
liposomes, as we have previously determined by [3H]inulin incorporation 
studies (31), it can be calculated that 1 nM PC liposomes corresponds to 
40 nM of loaded dexaP. 
Agarose gel electrophoresis. The electronegative surface charge of the 
liposomes was determined by electrophoresis (2 h at 60 mA) on agarose 
gel [0.75% agarose (Eurogentec) in 7.5 mM Tris, 8.0 mM hippuric acid, 
6.5 mM EDTA, pH 8.8]. After fixation (75% ethanol, 5% acetic acid, 3% 
glycerol) and drying of the gel, liposomes were visualized using Sudan 
Black B [1.5 mg/ml Sudan black B, 50 mg/ml zinc acetate in ethanol/ water 
(1:1, v:v)]. Excess Sudan Black B was removed from the gel using 55% 
ethanol, 2% glycerol. All liposome preparations migrated as single spots, 
and their electrophoretic mobility was determined relative to the front 
marker bromophenol blue. 
Distribution of liposomes in mice. 10-12-wk-old male C57Bl/6KH mice 
of mass 22-24 g from Broekman Instituut BV (Someren, The Netherlands), 
fed ad libitum with regular chow were used for the in vivo experiments. 
Mice were anesthetized by subcutaneous injection of a mixture of 
ketamine (120 mg/kg body weight, Nimatek, Eurovet, Bladel, the 
Netherlands), thalamonal (0.03 mg/kg fentanyl and 1.7 mg/kg droperidol, 
Janssen Pharmaceutica, Beerse, Belgium), and Hypnorm (1.2 mg/kg 
fluanisone and 0.04 mg/kg fentanyl citrate, Janssen Pharmaceutica), and 
the abdomens were opened. [3H]CO-labeled PC, oxPC, or PC/PS (1:1; 
w/w) liposomes (50 µg of PL) were injected via the inferior vena cava. 
When indicated, PC liposomes were incubated (30 min at 37°C) with LCO-
EE (1000 molecules per particle) or LCO-dA2dG10 (50 or 500 molecules 
per particle) before injection. In some cases, mice received a preinjection 
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of polyinosinic acid (polyI) (20 mg/kg, Sigma) at 1 min before injection of 
the liposomes. At the indicated times, blood samples (<50 µl) and liver 
lobules were taken and processed as described in detail (36). At 30 min 
after injection, the mice were killed, and their organs (liver, spleen, and 
lungs) were excised and weighed. 3H-radioactivity in 20 µl-serum samples 
was counted in 2.5 ml of Emulsifier Safe (Perkin Elmer, Boston, MA, 
USA). The total serum volumes of the mice were 1.068±0.066 ml, as 
previously determined (36). The tissue samples were solubilized in 
Soluene-350 (Packard) (approx. 150 mg tissue per mL of Soluene-350) for 
5 h at 65°C. Subsequently, their radioactivity was counted in 15 ml of 
Hionic Fluor (Packard) and corrected for the serum radioactivity present in 
the tissues at the time of sampling (36). 
Binding of liposomes to mouse macrophages. RAW264.7 cells were 
cultured at 37°C in RPMI 1640 (Biowhittaker, Verviers, Belgium) 
supplemented with 10% bovine calf serum (Biowhittaker), 100 units/ml 
penicilin, 100 µg/ml streptomycin (Biowhittaker) in a humidified 5% 
CO2/95% air atmosphere. Prior to experiments, cells were plated in 24-
well plates. When 70% confluency was achieved, cells were washed twice 
with RPMI/2% BSA (37°C) and pre-incubated (2 h) with RPMI/2% BSA 
after which cells were washed once with RPMI/2% BSA (4°C) and put on 
ice. Cells were incubated with indicated amounts of [3H]CO-labeled 
liposomes with or without polyI (100 µg/ml) in RPMI for 3 h at 4°C. After 
extensive washing (0.15 M NaCl, 2.5 mM CaCl2, 50 mM Tris, pH7.4), cells 
were lysed in 0.1 M NaOH. Protein concentrations were determined as 
described [37] using BSA as a standard. 3H-activity was counted in 
Emulsifier Safe (Packard), and was used to calculate the binding of 
liposomes as normalized for cell protein. 
Effect of liposomes on luciferase expression in mouse macrophages. 
RAW264.7 cells were seeded into 12-well plates in Dulbecco’s modified 
eagle medium (DMEM, Invitrogen, Carlsbad, CA, USA) without phenol red 
supplemented with 2% charcoal-stripped bovine calf serum (Gibco). After 
24 h, cells were cotransfected using lipofectamin (Roche) with a reporter 
gene construct encoding growth hormone responsive element-driven 
firefly luciferase (pTAT3-Luc), an expression vector containing the growth 
hormone receptor (pHR), and a construct encoding cytomegalovirus-
driven renilla luciferase (pRL-CMV; Promega) as an internal control for 
transfection efficiency (pTAT3-Luc and pHR were generated and 
generously supplied by Dr. O.C. Meijer, LACDR, Leiden). The molar ratio 
of pTAT3-Luc: pHR: pRL-CMV was 100: 100: 1, and the total amount of 
DNA used for transfection was 1.5 µg. At 16 h after transfection, cells 
were incubated (3 h) with dexaP or the indicated amounts of dexaP-
containing liposomes in the absence or presence of LCO-dA2dG10 (500 




after 16 h, lysed in Passive Lysis Buffer (Promega), and luciferase activity 
was determined using the Dual-Glo Luciferase Assay System (Promega) 




To generate a particulate drug carrier with high affinity for SRA, we 
combined the advantageous properties of the previously described SRA 
ligand oligodeoxyguanylic acid (dGn) (32) with PC liposomes that are stable 
under in vivo conditions and show a relatively long serum half-life of >5 h 
(31). Since a stretch of 10 deoxyguanylic acid residues appeared to be the 
shortest oligodeoxynucleotide sequence with maximum inhibiting effects 
on the cellular binding and uptake of AcLDL (32), we chose to couple dG10 
via a dA2 spacer to a highly lipophilic lithocholic oleate (LCO) structure, 









Figure 1. Chemical structure of LCO-dA2dG10. The oligonucleotide 
deoxy(adenosine)2 deoxy(guanosine)10 (dA2dG10) is attached via an amide 
bond to 3α(oleoyloxy)-5ß-cholanic acid (LCO). 
 
Incorporation LCO-dA2dG10 into PC liposomes. Previously, we showed 
by FPLC and agarose gel electrophoresis that the bile acid residue LCO 
mediates rapid and stable incorporation of antisense 
oligodeoxynucleotides (35) and cluster galactosides (33;34) into lipidic 
particles. To investigate the interaction of the presently derivatized 
oligodeoxynucleotide with liposomes, the effect LCO-dA2dG10 on their 
electrophoretic pattern was examined (Fig. (2)). Incubation of PC 
liposomes with increasing concentrations of LCO-dA2dG10 resulted in a 
dose-dependent increase of the liposome mobility on agarose gel, up to 
3.2-fold upon addition of 500 molecules per particle, suggesting that LCO-
dA2dG10 is readily incorporated into the liposomal bilayer thereby 
increasing the electronegative liposomal surface charge. 
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Figure 2. LCO-dA2dG10 increases liposomal surface charge. 
Liposomes (100 µg of PC) were incubated with LCO-dA2dG10 (0, 6, 15, 
and 30 µg, corresponding to 0, 100, 250, and 500 molecules per particle, 
respectively) (30 min at 37°C) and subjected to 0.75% agarose gel 
electrophoresis at pH 8.8. Liposomes were visualized with Sudan Black, 
and their electrophoretic mobilities were determined relative to the front 
marker bromophenol blue (BPB). Values are means ± S.D. of three 
experiments. 
 
SRA-dependent distribution of LCO-dA2dG10-laden PC liposomes in 
mice. In earlier studies, we observed that liposomally incorporated LCO-
derivatized cluster galactosides were retained on PC liposomes upon 
intravenous injection into mice, and induced efficient uptake of liposomes 
via asialoglycoprotein receptors on hepatocytes (33;34). To evaluate 
whether LCO-dA2dG10 would lead to efficient uptake of liposomes by SRA 
in vivo, we first determined the effect of LCO-dA2dG10 on the uptake of 
liposomes by the liver, which is the major organ responsible for the 
clearance of well-established SRA ligands (i.e. modified LDL) (8) (Fig. (3)). 
Upon injection into mice, the [3H]CO-labeled liposomes showed a low 
uptake by the liver (7.7±0.4% of the injected dose at 30 min after injection) 
and a high residual fraction retained in the serum (81.3±2.1%), as a 
consequence of their low affinity for the reticuloendothelial system (31;33). 
Incubation of the liposomes with LCO-dA2dG10 dose-dependently 
accelerated their serum clearance (Fig. (3), left panel), indicating that 




of its highly hydrophobic moiety, and does not readily redistribute to serum 
lipoproteins. The increased serum clearance of the liposomes was mainly 
caused by liver uptake, which was enhanced via 12.8±0.2% (50 molecules 
per particle) to 63.2±1.9% (500 molecules per particle) of the injected 
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Figure 3. LCO-dA2dG10 induces SRA-mediated liver uptake of PC 
liposomes in mice. [3H]CO-labeled liposomes (50 µg of PC) were 
injected into anesthetized mice, without (white circles) or with previous 
incubation with 50 (black triangles) or 500 (black circles) molecules of 
LCO-dA2dG10 per particle. At the indicated times, the serum decay (left) 
and liver uptake (right) were determined. Liver values are corrected for 
serum radioactivity. Values are means ± variation of two experiments. 
 
To establish the involvement of SRA in the tissue distribution of the LCO-
dA2dG10-laden PC liposomes, the effect of a preinjection of polyI on the 
liposome kinetics was evaluated, as polyI blocks the serum clearance of 
SRA ligands such as acLDL and oxLDL (15). Indeed, polyI almost 
completely prevented the LCO-dA2dG10-induced uptake of PC liposomes 
by both the liver and spleen, which is fully compatible with SRA-dependent 
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Figure 4. Effect of LCO-dA2dG10 on organ distribution of PC 
liposomes in mice. [3H]CO-labeled PC liposomes (white bars) or LCO-
dA2dG10 (500 mol/mol)-laden PC liposomes (black bars) (50 µg of PC) 
were injected into anesthetized mice, without or with preinjection of polyI 
(20 mg/kg) at 1 min before injection of the LCO-dA2dG10-laden liposomes 
(shaded bars). At 30 min after injection, the amount of liposomes 
remaining in the serum and the amount of liposomes taken up by the 
indicated organs was determined. Organ values are corrected for serum 
radioactivity. Values represent means ± variation of two experiments 
 
Selectivity of LCO-dA2dG10-laden PC liposomes for SRA-mediated 
distribution in mice. Subsequently, we evaluated the selectivity of the 
presently developed LCO-dA2dG10-laden liposomes with respect to SRA 
affinity in vivo as compared to other modifications of the liposomes that 
may confer binding to macrophage receptors such as SRA and CD36. 
Since both receptors are known to recognize electronegatively charged 
particle surfaces, we first prepared liposomes from negatively charged 
phospholipids consisting of either extensively oxidized PC or a PC/PS 
mixture (50:50; w/w). Both liposomes displayed a substantially increased 
negative liposomal surface charge, as demonstrated by a 4.1-fold (Rf 
0.53) and 5.5-fold (Rf 0.71) higher electrophoretic mobility on agarose gel 
as compared to PC liposomes, without affecting the particle size (32±2 
and 33±4 nm vs. 30±2 nm, resp.). Despite the increased surface charge, 
oxidation of PC did not alter the in vivo distribution of liposomes, 
suggesting that oxPC liposomes had a low affinity for scavenger receptors 
Chapter 2 
 
in vivo. Likewise, PS inclusion only marginally accelerated the serum 
clearance. Remarkably, whereas the uptake of the PC/PS liposomes by 
the liver was only 2-fold increased as compared to that of PC liposomes, 
the association with the spleen was enhanced to the same extent as for 
LCO-dA2dG10-exposing PC liposomes (Fig. (5)). This may indicate that the 
receptor recognition profile may differ between these particles and/or that 
two different scavenger receptor subtypes may be present in the spleen 
and liver. Finally, we evaluated whether the SRA-dependent liposome 
distribution as induced by LCO-dA2dG10 may be mimicked by attaching 
structurally unrelated negatively charged amino acids (i.e. glutamic acid) 
to the LCO anchoring structure (LCO-EE), resulting in three negative 
charges per molecule at physiological pH. Again, although incorporation of 
1000 molecules of LCO-EE per PC liposome did increase the negative 
liposomal surface charge to an even higher extent as LCO-dA2dG10 (Rf 
0.48 vs 0.35), the compound was unable to affect the serum decay of the 
liposomes, albeit that the affinity for the spleen was slightly enhanced (Fig. 
(5)). 
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Figure 5. Selectivity of LCO-dA2dG10-laden PC liposomes for SRA-
mediated distribution in mice. [3H]CO-labeled PC liposomes, oxPC 
liposomes, PC/PS (1:1; w/w) liposomes, LCO-EE (1000 
molecules/particle)-laden PC liposomes and LCO-dA2dG10 (500 
molecules/particle)-laden PC liposomes (50 µg of phospholipid) were 
injected into anesthetized mice. At 10 min after injection, the amount of 
liposomes remaining in the serum and the amount of liposomes taken up 
by the liver was determined. After 30 min, mice were killed, and the uptake 
of liposomes by the spleen was determined. Organ values are corrected 
for serum radioactivity. Values represent means ± variation of two 
experiments. 
 
SRA-mediated intracellular delivery of bioactive dexamethasone into 
macrophages. Since the LCO-dA2dG10-laden PC liposomes appeared 
superior over the other tested liposomes that bear overall (oxPC, PC/PS) 
or clustered (LCO-EE) negative surface charges with respect to in vivo 
SRA targeting, we next determined whether these liposomes may be 
effective in the SRA-mediated intracellular delivery of encapsulated 
agents, as would be aimed for in macrophage-directed therapies. First, an 
incubation study was performed with the mouse macrophage-like cell line 
RAW264.7 at 4°C, which permits receptor-mediated binding to the cell 
surface while cellular uptake activities are inhibited. This confirmed that 




cells approx. 3.1-fold, whereas LCO-EE was hardly effective (Fig. (6)). 
From the binding curves, it can be calculated that the LCO-dA2dG10-laden 
PC liposomes show a high affinity for RAW264.7 cells, with a calculated 
dissociation constant (Kd) of 5.1±1.9 nM and a maximal binding (Bmax) 
value of 27.8±5.1 µg PL/mg of cell protein, when normalized for the 
binding of PC liposomes (Fig. (6)). 



























Figure 6. LCO-dA2dG10 increases binding of PC liposomes to RAW 
264.7 cells. RAW264.7 cells were incubated (3 h at 4°C) with [3H]CO-
labeled PC liposomes without (white circles) and with previous association 
of LCO-EE (1000 molecules per particle, white triangles) or LCO-dA2dG10 
(500 molecules per particle, black circles). Subsequently, cells were 
washed, lysed, and cell protein and cell-associated radioactivities were 
determined. Values represent means ± S.D. of three experiments. 
 
As a read-out system for the LCO-dA2dG10-mediated intracellular 
delivery of liposomally encapsulated dexaP (a model drug with strong anti-
inflammatory properties), we used a reporter gene analysis assay, in 
which dexaP binds to the transfected growth hormone receptor. After 
nuclear translocation of this complex it activates the growth hormone 
responsive element in the promotor that drives luciferase expression, 
which can be quantified (Fig. (7)). Liposomal dexaP was able to dose-
dependently induce luciferase activity in transfected RAW264.7 cells. 
LCO-dA2dG10 did not affect the luciferase activity as induced by 1 nM 
liposomes (~40 nM of dexaP), since the LCO-dA2dG10-liposome 
concentration is well below the calculated Kd value (i.e. 5.1 nM). In 
contrast, the compound did increase the luciferase activity-inducing effect 
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of 5 nM liposomes (~200 nM of dexaP) by 65%, thereby reaching an equal 
activity as induced by 1000 nM unencapsulated dexaP. These data 
indicate that after internalization and degradation of the liposomes, dexaP 
was able to diffuse into the cytoplasm and exert its biological effect. 
Moreover, specific uptake of dexaP liposomes by SRA as mediated by 



































Figure 7. LCO-dA2dG10 increases intracellular delivery of dexaP into 
RAW 264.7 cells. RAW264.7 cells were cotransfected with a reporter 
gene construct encoding growth hormone responsive element-driven 
firefly luciferase (pTAT3-Luc), an expression vector containing the growth 
hormone receptor (pHR), and a construct encoding cytomegalovirus-
driven renilla luciferase (pRL-CMV) as an internal control for transfection 
efficiency. After 16 h, cells were incubated (3 h) with dexaP or the 
indicated amounts of dexaP-containing liposomes in the absence or 
presence of LCO-dA2dG10 (500 molecules per particle). After 16 h, cells 
were lysed, luciferase activity was determined, and corrected for the 





Macrophages play an important role both in innate immunity, 
tumorigenesis, and the initiation and progression of atherosclerosis, 




carriers using scavenger receptors as a target. For example, maleylated 
bovine serum albumin (38-40) and oxLDL (41) have been used for the 
macrophage-targeted delivery of photosensitizers. Scavenger receptor-
dependent uptake of photosensitizers could indeed be demonstrated both 
by macrophages in vitro (39-41) and into areas of intimal hyperplasia in vivo 
(38). However, the limited loading capacity of maleylated BSA and the 
potentially adverse properties of oxLDL impede their therapeutic 
applicability, which may be overcome by using synthetic particulate drug 
carriers. 
In the present study, therefore, we evaluated the possibility to 
generate a macrophage-targeted liposomal carrier with both a high drug 
loading capacity and a high affinity for SRA. In addition, the versatile 
properties of liposomes allow for the incorporation of both hydrophilic, 
amphipathic and hydrophobic compounds into their aqueous core or 
phospholipid bilayer, thereby obviating the need for drug modification. We 
took advantage of the high SRA affinity of oligodeoxyriboguanines that 
have previously been shown to be very effective inhibitors of the binding 
and degradation of acLDL by SRA in vitro, by virtue of their high affinity for 
the highly cationic extracellular collagenous receptor domain (32). Since it 
appeared that dG10 is the minimal oligodeoxyriboguanine motif to display a 
high affinity for SRA (32), we have equipped this residue with the 
hydrophobic moiety LCO to enable anchoring onto the liposomal surface. 
We observed that the LCO-dA2dG10 ligand dose-dependently enhanced 
the tissue distribution of liposomes in vivo, as related to the distribution of 
SRA in the different districts of the body. The involvement of SRA was 
underscored by the observation that the increased liposomal clearance 
rate could be completely blocked by polyI. Interestingly, the extent of SRA-
dependent LCO-dA2dG10-induced liposome clearance by the liver (i.e. 
63% of the injected dose) was much higher than we previously observed 
for free 32P-labeled dG10dT6 (i.e. 32%) (5). Apparently, liposomal 
incorporation of dG10 further increases the intrinsic affinity of dG10 for SRA, 
which may relate to 1) the multivalent exposure on liposomes, 2) a more 
efficient formation of base-quartet-stabilized quadruplex structures or 3) 
oligonucleotide aggregation on the liposomal surface, which have all been 
shown to increase the affinity of oligodeoxyriboguanines for SRA (32;42). 
Thus, our data do not only confirm the high affinity of dG10 for SRA as 
observed by others (32;43-45), but also demonstrate for the first time the 
applicability of dG10 as an efficient targeting device for SRA in vivo. 
Moreover, the high efficiency of dG10-induced liposome targeting to 
SRA in vivo indicates that the LCO-dA2dG10 ligand is retained on the 
liposomes upon intravenous administration, and does not readily 
redistribute to endogenous serum (lipo)proteins. Indeed, in vitro transfer 
studies in the presence of excess amounts of HDL showed only a minor 
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and slow redistribution of the LCO anchor from the liposomes to HDL 
(data not shown). This illustrates the broad applicability of this LCO group 
to anchor specific ligands for various receptors on macrophages and other 
cell types. In fact, we have previously reported that derivatization of 
triantennary galactosides with LCO affords a ligand for the highly efficient 
targeting of liposomes to the asialoglycoprotein receptor on hepatocytes in 
vivo (33;34). 
It is intriguing to speculate about the mechanism underlying the 
high affinity of liposomal dG10 for SRA. Since SRA binds a broad array of 
(poly)anionic ligands such as LPS (4), polyI (3) and modified LDL (7;8), it 
may be argued that the ligands bind to the cationic extracellular 
collagenous domain of SRA simply through electrostatic interaction. 
However, the fact that polyA, polyC, and polyU do not bind to SRA 
suggests that the spatial distribution of the positively and negatively 
charged side chains in the collagenous domain, as well as the overall 
chemical structure, could play a critical role in the recognition of 
polyanions. Our surprising observation that liposomes bearing overall 
(oxPC, PC/PS) or clustered (LCO-EE) negative surface charges show an 
unaltered or marginally increased clearance, despite the fact that these 
modifications result in an at least equally high negative surface charge as 
compared to LCO-dA2dG10 incorporation, demonstrates the high specificity 
of dG10 for SRA targeting in vivo and confirms that negative charges per 
se do not confer affinity for SRA. 
In addition to SRA, CD36 has also been implicated in the binding 
and internalization of anionic ligands, such as acLDL and oxLDL (19;20), but 
also PS-containing liposomes (23,24,46). However, CD36 is probably not 
involved in the hepatic clearance of LCO-dA2dG10-exposing liposomes, as 
CD36 is not expressed by the liver (21). In addition, CD36 does not seem 
to contribute to the extrahepatic clearance of these liposomes (e.g. by the 
spleen) since the serum clearance was almost completely blocked by 
polyI, whereas CD36 is insensitive to polyI (20). Interestingly, inclusion of 
50% PS into the liposomes did not increase their uptake by the liver 
substantially, indicating that PC/PS liposomes do not or only hardly 
interact with SRA. These data are in agreement with an earlier in vitro 
study showing that transfection of Chinese hamster ovary cells with SRA 
type I or II did not affect the uptake of PS-containing liposomes, whereas 
that of AcLDL was greatly enhanced (48). In contrast, PC/PS liposomes 
were selectively taken up by the spleen, which is in line with previous 
observations (49). Collectively, these data indicate that the expression 
pattern of SRA and CD36 differ markedly: whereas SRA is preferentially 
expressed by the liver, CD36 is mainly expressed by the spleen, thus 
offering the appealing opportunity to preferentially target specific subsets 




In conclusion, we have demonstrated in the present study the 
feasibility to use a short oligodeoxyguanosine ligand (i.e. dG10) for the 
efficient targeting of particulate systems via SRA to macrophages, thereby 
improving the intracellular delivery of encapsulated dexaP in a bioactive 
form. Our studies add to the recent in vitro observations that tethering of 
dG10 to antisense oligonucleotides (43) or dG6 to CpG 
oligodeoxynucleotides (44) improves their SRA-mediated cellular delivery 
and efficacy, and that conjugation with dG10 markedly improves the 
macrophage-activating properties of muramyl dipeptide, resulting in an 
increased cytotoxic activity against tumor cells (45). Furthermore, we have 
now demonstrated for the first time that dG10 can be used for efficient SRA 
targeting in vivo. Since the versatility of LCO-dA2dG10-exposing liposomes 
allows for the encapsulation of a broad array of therapeutic agents, 
including photosensitizers, anti-inflammatory agents, and LXR agonists, 
the application of these liposomes for macrophage targeting in vivo, either 
systemically (intravenous administration) or locally (incubation within 
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AcLDL, acetylated LDL; CO, cholesteryl oleate; dA2dG10, 
deoxy(adenosine)2 deoxy(guanosine)10; dexaP, dexamethasone 
phosphate; DMEM, Dulbecco’s modified Eagle medium; DMF, N,N-
dimethylformamide; EE, glutamyl glutamic acid; EYPC, egg yolk 
phosphatidylcholine; LCO, 3α(oleoyloxy)-5ß-cholanic acid (lithocholic 
oleate); oxPC, oxidized phosphatidylcholine; PBS, phosphate-buffered 
saline; polyI, polyinosinic acid; PS, phosphatidyl serine; SRA, scavenger 
receptor class A. 
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Background The application of serotype 5 adenoviruses (Ad5) in 
macrophages is hampered by the absence of the endogenous Coxsackie 
Adenovirus Receptor (CAR). 
Methods To overcome this limitation, we first generated a linker protein 
consisting of the virus-binding domain of CAR and the C-terminus of 
avidin. Second, to target macrophages, this linker protein was equipped 
with the biotinylated (bio) oligonucleotide dA6G10, which was previously 
shown to display a high affinity for the scavenger receptor A (SR-A). 
Results As compared to non-targeted virus, the linker protein equipped 
with biodA6G10 showed a 500-fold increased reporter gene expression in 
mouse macrophage RAW264.7 cells. A linker protein equipped with a bio-
dA16 control oligonucleotide was inactive. Moreover, the bio-dA6G10 
equipped linker showed a 390-fold increased luciferase expression in the 
macrophage cell line J774 and a, respectively, 276- and 150-fold 
increased reporter gene expression in primary peritoneal and bone 
marrow derived macrophages. Using bone marrow derived macrophages 
from SR-A knockout mice, it was shown that the dA6G10-mediated uptake 
is predominantly SR-A mediated. 
Conclusions Thus, we have developed a novel tool to link biotinylated 
ligands to a virus-binding fragment of CAR and have exploited this linker 
protein to extend the applicability of Ad5 to infect transformed and primary 
macrophages. 
 
Keywords: Targeting, Macrophages, Adenovirus, Gene Therapy, 
Atherosclerosis 
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Introduction 
Adenovirus (Ad) mediated gene transfer is widely used as a powerful 
method to introduce novel genes in cells in vitro and in vivo (reviewed by 
(1). The vast majority of adenoviruses generated and used to date involve 
serotype 5 (Ad5). These Ad5 bind specifically to the Coxsackie 
Adenovirus receptor (CAR) (2;3). This interaction is mediated via the C-
terminal knob domain of the Ad5 fiber protein and represents the first step 
in the uptake of Ad5. Subsequent interactions between Arg-Gly-Asp 
(RGD) motifs in the penton base of the viral particle and integrins αvβ3 
and αvβ5 present on the host cell mediate internalization via receptor 
mediated endocytosis (4-6). After escape from the endosome, the virion is 
shuttled to the nuclear envelope after which its genome is translocated 
into the nucleus. 
The tropism of Ad5 is determined by the tissue specific expression 
pattern of the CAR. This receptor is highly, but not exclusively, expressed 
on parenchymal cells in the liver, thus explaining the high level of infection 
of the liver after systemic application of Ad5 (7). However, many cell types, 
including tumors, endothelial cells (8) as well as macrophages (9) express 
CAR at very low levels, or not at all and are therefore resistant to 
adenoviral infection. Specific agents that target adenoviruses to cells of 
interest could, in theory, overcome this limitation. Ideally, retargeting 
induces affinity for a novel cell specific receptor and at the same time 
ablates the intrinsic affinity for the endogenous CAR. Two types of 
strategies have been used thus far to target adenoviruses to specific cells: 
genetic-based and conjugate-based targeting. 
In genetic targeting, the viral capsid proteins responsible for 
binding to target cells are modified in such a way that affinity is induced for 
other cells. This modification can be achieved via pseudotyping (10-14) or 
via cloning ligands into the HI-loop (15-19) or the C-terminal domain of the 
fiber knob (20-28). For the latter two approaches, insertion of ligands must 
not interfere with fiber trimerisation during virus assembly (20). Thus, the 
challenge in the genetic approach is to avoid impairment of virus assembly 
and production by the inserted ligand. Moreover, each novel tropism 
requires that the virus is redesigned. 
Conjugate-based targeting approaches involve the use of 
bifunctional linker proteins, which on the one hand bind to the adenovirus 
and on the other hand bind to the target cell. To confer affinity for the 
virus, either a Fab fragment of a virus binding (neutralizing) antibody (29), 
reviewed by (30) or the virusbinding domain of CAR (31) can be used 
(reviewed in (32). Introduction of a ligand for a cell specific receptor in the 
targeting protein induces a new tropism for the target cell. Generally, 




for each novel receptor a new targeting protein is designed, or the 
different components are covalently fused after production of the separate 
components. An extensive overview of conjugate based targeting 
strategies has been given by Krasnykh (32).  
An alternative approach within the conjugate based targeting 
strategies, consists of the use of non-covalent cross-linking systems to 
target virus particles. This approach results in a flexible system to equip 
Ad with a variety of ligands. For example, Rogers used an anti-Ad Fab 
fragment coupled to phenylboronic acid (PBA) and attached FGF2 -
dihydroxybenzohydroxamic acid (DHBHA) and thus exploited the binding 
of PBA to DHBHA to redirect Ad to FGF-receptor positive cells (33). Smith 
and Parrott applied the avidin-biotin interaction to retarget adenovirus 
vectors (27;34). Smith biotinylated adenovirus particles chemically and 
targeted them to biotinylated cells via an avidin bridge. When equipping 
the virus with biotinylated monoclonal antibodies anti-CD117, anti-CD34 or 
anti–CD44 via the avidin bridge, hematopoietic cells expressing the 
respective receptors could be infected, (34). Parrott et al. introduced a 
biotin acceptor peptide in the C-terminus of the fiber of Ad5 (27). After 
metabolic biotinylation of the virus particle, it could be equipped with a 
variety of ligands via an avidin bridge. Using this system, it was shown 
that Ad5 could be equipped with biotinylated monoclonal antibodies, 
biotinylated manose and biotinylated -oligonucleotides and targeted to 
primary dendritic cells.(27). Introduction of the biotin acceptor peptide into 
capsid protein IX and the subsequent attachment of transferrin (via avidin) 
allowed for the targeting to CD71 positive cells (35). Here, we have further 
expanded upon the application of the avidin-biotin link to generate a 
conjugation based targeting system that can be applied without direct 
virus modification. 
Thus, a bifunctional linker protein to target adenoviruses to novel 
receptors was developed. This linker protein consists of the virus-binding 
domain of the CAR genetically fused to avidin, which is used as a scaffold 
to dock novel ligands equipped with a biotin moiety. The genetic fusion 
between CAR and avidin ensures a single protein without the need for 
chemical modification. Moreover, many receptor-specific ligands are 
available commercially in biotinylated or easily biotinylatable form. We 
show the utility of the CAR-Avidin linker protein in combination with a 
biotinylated oligonucleotide dA6G10, that specifically binds to the 
scavenger receptor class A (SR-A), to redirect Ad5 to a variety of 
transformed and primary macrophages which are notoriously difficult to 
infect with Ad. 
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Materials and Methods 
Cells Cos-1, Hela, J774 and RAW264.7 cells were cultured in DMEM 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS (Invitrogen), 
100 units/ ml Penicillin (Invitrogen), 100 µg/ml Streptomycin (Invitrogen) 
and glutamax (Invitrogen). Peritoneal macrophages from C57bl6 female 
mice were isolated 4 days after 1 ml of 3% Brewers Thioglycollate (Difco, 
Amsterdam, The Netherlands) was injected intraperitonealy. Peritoneum 
was flushed with 10 ml ice-cold culture medium (RPMI-1640 (Invitrogen) 
complemented with 6.5% FCS, 100 units/ ml Penicillin, 100 µg/ml 
Streptomycin and glutamax. After gentle but thorough washing cells were 
seeded in 12 well plates (Greiner), 5*105 cells per well. Bone marrow cells 
were isolated by flushing femurs from C57bl6 or SR-A knockout mice with 
ice cold PBS. The femurs of the SR-A knockout mice were a generous gift 
from dr. Menno de Winther (Maastricht, The Netherlands). After washing 
with PBS, cells were cultured on bacterial plastic in RPMI-1640 
complemented with 10% fetal calf serum, 100 units/ ml Penicillin, 100 
µg/ml Streptomycin, glutamax and 15% L929 conditioned medium as a 
source for macrophage colony stimulating factor for 8 days. One day prior 
to experiments cells were detached from plastic with 4 mg/ml lidocain/ 10 
mM EDTA in PBS and seeded into 12 well plates, 1.5*105 cells per well. 
All cells were cultured in a humidified atmosphere of 5% CO2
Viruses The generation of recombinant adenoviral vectors carrying the β-
galactosidase gene (Ad.LacZ) under the control of the cytomegalovirus 
promoter has been described previously and were kindly provided by dr. 
Thomas Willnow and dr. Joachim Herz (Dallas, USA). The recombinant 
adenoviral vector expressing firefly luciferase under the control of the 
cytomegalovirus promoter (Ad.Luc) was kindly provided by prof. Rob 
Hoeben (Leiden, The Netherlands). Recombinant adenoviruses carrying 
the green fluorescent protein under control of the cytomegalovirus 
promoter (Ad.GFP) were constructed using the Ad-Easy-1 system as 
previously described (36). The recombinant adenovirus vectors were 
propagated on PerC6 cells (37) and titrated on the Ad5 E1-transformed 
human embryonic kidney cell line 911 as described previously (38). Briefly, 
for large-scale production of recombinant adenovirus lots, 1750 cm2 of 
nearly confluent PerC6 monolayers were infected with adenovirus at a 
multiplicity of infection (MOI; in plaque forming units per cell) of 5-10. After 
48 to 60 hours, the nearly completely detached cells were harvested and 
collected in 1 ml PBS/1% horse serum (Invitrogen). Virus was released 
from the producer cells by three rounds of freeze thawing and subsequent 
centrifugation. The lysate was subjected to two rounds of CsCl gradient 




extensive dialysis against storage buffer (25 mM Tris, 137 mM NaCl, 5 
mMKCl, 0.73 mM Na2HPO4, 0.9 mM CaCl2, 0.5 mM MgCl2; pH 7.45), at 
4°C. Virus stocks were stored at -80°C. Routinely virus titers ranged from 
1-5*1010 plaque forming units per ml (pfu /ml). 
Design and cloning of the linker proteins. The extracellular domain of 
the Coxsackie Adenovirus Receptor (CAR) was obtained by PCR using 
pCAR as template using oligo's 5'-GCG GCC GCG GGT ACC CAC GGC 
ACG GCA G-3' and 5'-CTA GCT AGC AGC TTT ATT TGA AGG AGG 
GAC-3'. pCAR, an expression vector containing the entire Coxsackie 
adenovirus receptor cDNA, was kindly provided by prof. Rob Hoeben 
(Leiden, The Netherlands). The generated PCR fragment was cloned into 
pCRII Topo (Invitrogen) after which it was subcloned into pSG8, in front of 
the VSV and His6 tag already present, using restriction enzymes NotI and 
NheI, thus creating pSG8CAR. The pSG8 vector was a generous gift from 
prof. Henk Stunnenberg (Nijmegen, the Netherlands) The avidin fragment 
was obtained by RT-PCR on total RNA from chicken fibroblasts with 
random hexamer oligonucleotides and subsequent PCR using primers 5'-
CGC GGA TCC GCC AGA AAG TGC TCG CTG -3' and 5'- CCA TCG 
ATG GTC ACT CCT TCT GTG TGC G -3'. The PCR fragment was cloned 
into cloning vector pBluescript (Stratagene, La Jolla, CA, USA) and 
subcloned in frame into pSG8CAR using restriction enzymes BamHI and 
ClaI. The CAR-Stop construct was obtained by site directed mutagenesis 
of the BamHI site in pSG8CAR from GGATCC to GTATCC resulting in a 
stop codon immediately behind the tags using the site directed 
mutagenesis kit from Promega (Madison, WI, USA) according to the 
protocol supplied by the manufacturer. All constructs were sequence 
verified. 
Production and purification of the linker protein. Cos-1 cells were 
transfected with pSG8CAR-Avidin or pSG8CAR-Stop using Fugene6 
(Roche, Basel, Switzerland). Eight hours after transfection, cells were 
placed on serum-free and biotin-free culture medium for 32 hours after 
which the culture supernatant, containing the linker proteins, was 
harvested. Linker proteins were purified from the supernatant by 
immobilized metal affinity chromatography using Talon metal affinity resin 
(Clontech, Palo Alto, USA). Equilibrated culture supernatant (300 mM 
NaCl, pH = 7.0 and 20% glycerol) was incubated for 20 minutes at room 
temperature with Talon. After extensive rinsing with buffer (50 mM NaPO4, 
300 mM NaCl, 20% glycerol, pH = 7.0) the resin was pre-eluted with 4 
volumes pre elution buffer (50 mM NaPO4, 300 mM NaCl, 2,5 mM 
imidazole, 20% glycerol) after which it was eluted with 10 volumes elution 
buffer (50 mM NaPO4, 300 mM NaCl, 150 mM imidazole, 20% glycerol). 
Samples of all purification steps were tested for the presence of the linker 
proteins via SDS-PAGE and western blotting analysis using Hybond ECL 
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nitro cellulose membranes (Amersham Biosciences, Buckinghamshire, 
UK) and antibodies P5D4 (α-VSV) and sheep-α-mouse-HRP for the CAR-
Stop protein or α-Avidin (Abcam, Cambridge, UK) and goat-α-rabbit-HRP 
for the CAR-Avidin protein according to standard protocols (39). Analysis 
showed that the linker protein was only present in elution fractions 3 to 5 
that were subsequently extensively dialyzed against PBS and used in all 
experiments. Western analysis of the CAR-Stop protein revealed a minor 
contamination of approximately 25 kD. Quantification of the band 
intensities was performed by analyzing the digital images with Tina® 
version 2.09 software (Raytest, Staubenhardt, Germany). The 
contaminating protein accounted for approximately 5 % of the total amount 
of protein. 
Analysis of the linker protein. Elution samples that tested positive on 
western blotting analysis were submitted to a biotin binding assay. 10 µl 
samples of the indicated elution fractions or an avidin calibration range of 
0.3 - 10 pM avidin were incubated with 0.2 µl 3H-Biotin (Du Pont NEN 
Research Products, Boston, MA, USA). After 1 hour the total reaction 
mixture was applied on a Sephadex G-50 column to separate the CAR-
Avidin bound biotin from the free biotin. All elution fractions were counted 
for 3H-Biotin radioactivity using 5 ml of Hionic fluor scintillation cocktail 
(Packard Instrument Co., Perkin Elmer, Boston, MA, USA) in a Packard 
1500 TriCarb liquid scintillation analyzer. The summed radioactivity in 
peak fractions 3 to 5 correlated with the amount of avidin present in the 
sample (R2= 0.997). As having the highest concentrations elution fraction 
3 was used for experiments and stored at –80°C. A yield in the order of 
900-1000 µg was typical.  
Affinity of the CAR-Avidin linker protein for the bio-dA6G10 ligand 
was calculated from the occupied fraction at different linker protein to 
ligand ratio’s using Graphpad Prism software (San Diego, CA, USA) and a 
one-site binding model. 
Infection assays. Twenty-four hours before infection cells were seeded 
into 12 wells plates (Greiner, Sigma Aldrich, St Louis, MO, USA), 
RAW264.7, J774 and bone marrow derived macrophages at 2.0*105 cells 
per well, Hela at 5.0*105 cells per well. CAR-Avidin and bio-dA16 or bio-
dA6G10 were incubated at the indicated molar ratios for 1 hour in PBS at 
room temperature, after which Ad.Luc, Ad.GFP or Ad.LacZ were added 
and incubated for 1 hour. Cells were infected for 1 hour at 37°C with the 
virus-targeting protein complex after which the virus containing solution 
was replaced with normal culture medium. Experiments were terminated 
36 hours after infection. Ad.luc infected cells were lysed in reporter lysis 
buffer (Promega) and luciferase activity in the lysate was determined 




protocol supplied by the manufacturer. Luciferase activity was corrected 
for protein concentration determined by BCA assay (Pierce, Rockford, 
USA) using BSA as standard. Ad.LacZ infected cells were washed with 
PBS and fixed in 5.4% formaldehyde, 0.8% gluteraldehyde in PBS. LacZ 
expression was visualized by adding staining solution (5 mM potassium 
ferricyanide, 5 mM potassium ferrocyanide, 0.2 mM MgCl2, 0.1% 5-bromo-
4-chloro-3-indolyl- β-D-galactoside (X-Gal) in PBS) to the wells until 
sufficient color intensity had been reached. Ad.GFP infected cells were 
rinsed once with PBS and subsequently fixed with 4% formaldehyde 
(Merck, Darmstadt, Germany) in PBS. 
In vivo infection assays For the in vivo experiments, 10-12-wk-old 
female C57Bl/6 mice of weight 22-24 g from Broekman Instituut BV 
(Someren, The Netherlands) were used and fed ad libitum with regular 
chow diet. On day 0, mice were injected with either untargeted or targeted 
1*109 pfu Ad.LacZ. Generation of the targeted Ad.LacZ was performed as 
described above for the in vitro experiments. Five days after injection, the 
experiment was terminated and livers were removed and snap frozen in 
liquid nitrogen. 10µm sections were stained for LacZ activity. Sections 
were O/N incubated with staining solution (5 mM potassium ferricyanide, 5 
mM potassium ferrocyanide, 0.2 mM MgCl2, 0.1% 5-bromo-4-chloro-3-
indolyl- β-D-galactoside (X-Gal) in PBS). 
Statistics Experiments were performed in triplicate and presented as 
mean ± standard deviation (s.d.). P-values were calculated by a two-tailed 
unpaired student’s T-test. Data were considered to be significantly 




Design and generation of the linker proteins To modulate the tropism 
of Ad5 to alternative cell surface receptors, a bifunctional linker protein 
was designed containing the extracellular domain of the CAR, a VSV tag, 
a His6 tag, and a biotin-binding avidin fragment (figure 1A). The 
extracellular domain of the CAR enables binding to the fiber knob (2;40), 
and is preceded by the original signal peptide to ensure effective secretion 
of the linker protein into tissue culture supernatant after transfection. The 
tags were introduced to facilitate visualization (VSV) and purification 
(His6) of the protein. Truncated chicken avidin (nucleotides 116 – 499) (41) 
was used as a scaffold to bind biotinylated ligands for receptors of 
interest. A negative control linker protein (CAR-Stop) was constructed by 
introducing a stop codon directly behind the His6 tag (figure 1A).  
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Figure 1. Linker protein design and characterization. (A) The CAR-
Avidin linker protein was constructed by cloning the extracellular domain 
of the CAR (first 236 aa, ) into a pSG8 expression vector which 
contained the VSV and His tag ( ). Avidin amino acids 25 to128 ( ) were 
cloned immediately behind the tags. Ligands for specific receptors are 
attached to the avidin moiety of the linker protein via biotin ( ). The CAR-
Stop control protein was constructed by introducing a stop codon 
immediately behind the tags. (B) CAR-Avidin and CAR-Stop were 
produced by transient transfection in COS-1 cells. Presence of the 
proteins was shown by subjecting culture supernatant to SDS-PAGE 
(12%) and Western analysis using antibodies P5D4, directed against the 
VSV tag, and sheep-anti-mouse-HRP. 
 
Expression constructs encoding the linker proteins CAR-Avidin and 
CAR-Stop were transfected into Cos-1 cells and the supernatant was 
subjected to SDS-PAGE and Western blotting analysis. Figure 1B shows 
that the predominant products are 50 and 30 kD proteins, which is very 
close to the calculated mass of CAR-Avidin and CAR-Stop (45 kD and 28 
kD respectively). Western analysis also indicated a minor protein 
contamination of approximately 25 kD in the CAR-Stop sample 
(approximately 5% of the total amount of protein within the sample). 
Large-scale protein productions were performed by transient transfection 
in Cos-1 cells under biotin-free and serum-free conditions and subsequent 
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purification of the linker proteins from the culture supernatant using His6 
mediated immobilized metal affinity chromatography (IMAC). 
Quantification and binding characteristics of the linker proteins The 
concentration of CAR-Avidin in the purified preparations was determined 
via a 3H-biotin binding assay. The assay was calibrated using avidin. 
Bound 3H-biotin was separated from unbound 3H-biotin using gel filtration 
analysis (insert Fig. 2A). The radioactivity recovered in fractions 3-5 
(bound 3H-biotin) correlated excellently with the amount of avidin in the 
sample over a concentration range from 1.6 to 16.6 µg/ml (Fig 2).  
The ability of the linker protein to bind both biotin and adenovirus 
was investigated by surface plasmon resonance spectrometry using a 
Biacore 2000 apparatus and a biotin coated sensor chip. Control injections 
of streptavidin led to rapid and avid association to the chip and confirmed 
biotin binding to the chip (data not shown). Injection of the CAR-Stop 
protein (figure 2B left panel, dark arrow) did not result in an increase in 
response units indicating that this protein did not bind to biotin present on 
the chip. Repeated injections of CAR-Avidin on the other hand clearly 
showed an increase in response units reflecting saturable binding of this 
linker protein to biotin on the chip (figure 2B left panel, light arrows). To 
determine the ability of CAR-Avidin to bind adenoviruses, CAR-Avidin was 
conjugated to a biotin coated sensor chip. Figure 2B (right panel) shows 
that Ad5 binds to CAR-Avidin coated chips but not to a streptavidin coated 
control chip. The affinity of the virus for CAR-Avidin appeared to be in the 
low nanomolar range, which is comparable to the reported affinity of the 
virus for the endogenous CAR (Kd: 3 nM, (42). 
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Figure 2. Quantification of the linker protein. (A) CAR-Avidin and an 
avidin concentration range were incubated with 3H-Biotin. Total mixture 
was applied to a sephadex G50 column to separate avidin bound (small 
graph elution fractions 3-5) from the free 3H-Biotin (small graph elution 
fraction 8-12). The avidin associated radioactivity correlated to the avidin 
concentration (R2= 0.997). (B left) Biotin was immobilized on the sensor 
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surface of a Biacore chip after which CAR-Stop (once, black arrow ) or 
CAR-Avidin (5 times, gray arrows) were injected at a flow rate of 35 µl / 
min. The protein content of the purified CAR-Stop stock was assessed by 
western blot analysis and using CAR-Avidin as internal reference; equal 
amounts of CAR-Stop and CAR-Avidin protein were used (B right) 
Streptavidin or CAR-Avidin was bound to the sensor chip through 
conjugation to immobilized biotin. Ad5 was injected at a flow rate of 2 µl / 
min for 27 minutes. 
 
Generation of an adenovirus targeting construct The applicability of 
the linker protein to enhance the infection of macrophages was 
investigated using the mouse monocyte derived macrophage cell line 
RAW264.7. This cell line is refractory to adenovirus infection and only at 
very high, and cytotoxic, titers infection of less than 1% percent of cells 
can be observed (data not shown (43). On macrophages, the SR-A is an 
obvious candidate for targeting, since it is abundantly expressed and 
mediates the rapid internalization of bound substrates including modified 
lipoproteins, lipopolysaccharide, specific oligonucleotides and Fucoidan 
(44). A synthetic oligonucleotide ligand for SR-A was generated: dA6G10 
consisting of 6 deoxyadenosines serving as a spacer, and 10 
deoxyguanosines, which confer specificity for the SR-A (44). It was 
biotinylated to allow docking on the CAR-Avidin linker protein. A synthetic 
oligonucleotide, bio-dA16, served as a negative control since the 
adenosine stretch does not bind to SR-A (44) while having similar chemical 
and anionic properties.  
Optimization of the infection protocol was performed in two steps. 
The optimal molar ratio between CAR-Avidin and ligand was determined. 
Hereto, CAR-Avidin at a fixed concentration of 5.0*10-8 M was incubated 
with varying amounts of bio-dA6G10 and the residual biotin binding 
capacity was assessed in the 3H-Biotin binding assay. Figure 3A shows 
that at a molar ratio of CAR-Avidin: bio-dA6G10 higher than 1.0 the 
complex did not display any residual 3H-Biotin binding capacity, indicating 
that at this ratio all biotin binding sites within the linker protein are 
occupied. From the saturation binding plot (the relative degree of 
occupation plotted against the concentration of bio-dA6G10, Fig. 3A, insert) 
we were able to calculate the apparent Kd for bio-dA6G10 binding to CAR-
Avidin (2.3*10-9 M; R2= 0.91). Thus, although the affinity of CAR-Avidin for 
bio-dA6G10 is decreased as compared to the affinity of native avidin for 
biotin (Kd = 10-15 M), the resulting interaction between the biotinylated 
ligand and CAR-Avidin is similar in avidity as compared to that of CAR to 
the adenovirus (Kd = 3*10-9 M) and thus not likely to limit the adapter 
function in vitro or in vivo. 
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The binding equilibrium is sensitive to molar ratio’s and the 
absolute concentration of the individual binding partners and for an 
effective association concentrations that exceed the dissociation constant 
are imperative. In our analyses, we therefore preferred to keep the CAR-
Avidin/ligand concentration constant. Thus, an increasing amount of CAR-
Avidin-dA6G10 was added to a fixed amount of Ad.Luc and the level of 
gene transfer was determined. Luciferase activity was found to increase in 
a concentration dependent manner (Fig. 3B). At a concentration of 50 nM 
CAR-Avidin-dA6G10 the luciferase activity reached 50% of the maximum 
























































































Figure 3. Optimization of the linker protein to ligand ratios and 
targeting construct to virus ratios. (A) Optimal CAR-Avidin to dA6G10 
ratios was determined by adding CAR-Avidin (concentration 5.0*10-8) to 
dA6G10 in a molar ratio varying from 0.01 to 3. Subsequently the residual 
and the occupied 3H-Biotin binding was determined (R2= 0.85). (B) The 
optimal CAR-Avidin-dA6G10 concentration was determined by adding 
CARAvidin-dA6G10 (at a concentration ranging from 7.5*10-8 to 1.5*10-6 M) 
to Ad.Luc. after which RAW264.7 cells were infected (MOI of 100) with the 
virus suspension. Cells were lysed and luciferase activity was determined 
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and corrected for protein concentration. Results are mean ± s.d. of 
triplicate experiments. 
 
Characterization of adenovirus targeting specificity The specificity of 
the CAR-Avidin-dA6G10 conjugate was investigated by comparison with 
CAR-Avidin-dA16. PolyA has been reported to lack affinity for the SR-A 
(44). Thus bio-dA16 or bio-dA6G10 equipped CAR-Avidin was incubated 
with Ad.Luc and its effect on adenoviral gene transfer was assessed as 
described. Infection of RAW264.7 cells at a multiplicity of infection (MOI) 
of 100 plaque forming units per cell (pfu) with CAR-Avidin-dA16 targeted 
Ad.Luc resulted in a luciferase activity that was comparable to non-
targeted virus, whereas CAR-Avidin-dA6G10 targeted virus showed a 45 
fold increase in luciferase activity (P= 0.0001) establishing that the cellular 
infection with Ad.Luc via dA6G10 is specific and most likely involves the 
SR-A (Fig. 4A).  
Retargeting implies acquisition of novel specificity and concomitant 
loss of the intrinsic specificity. To investigate whether the linker protein 
ablated the affinity for cells expressing the CAR, Ad.Luc was incubated 
with the CAR-Stop protein after which the complex was used to infect Hela 
cells (MOI 230). Hela cells are known to express CAR and are therefore 
readily infected even at low adenovirus titers (2). Figure 4B shows a 75% 
decrease in luciferase expression after addition of the CAR-Stop protein to 
















































Figure 4. Effect of CAR-Avidin-dA6G10 targeting on gene activity in 
different cell lines (A) CAR-Avidin-dA6G10 or CAR-Avidin-dA16 (1:1 M:M) 
was added to Ad.Luc after which RAW264.7 cells were infected (MOI 




corrected for protein concentration. Results are mean ± s.d. of triplicate 
experiments. (B) Hela cells were infected with Ad.Luc (MOI of 277) pre 
incubated in the presence (right bar) or absence (right bar) of the CAR-
Stop protein. For the pre incubation the same protein concentration had 
been used as is used for the CAR-Avidin. Cells were lysed and luciferase 
activity was determined and corrected for protein concentration. Results 
are mean ± s.d. of triplicate experiments. 
 
To investigate whether gene transfer to primary cells could be 
enhanced using CAR-Avidin-dA6G10, an adenovirus expressing GFP 
(Ad.GFP) was targeted to RAW264.7 cells and peritoneal macrophages. 
Scoring the GFP positive cells revealed a 21-fold increase in GFP positive 
RAW264.7 cells (P = 0.02) and 237-fold increase in GFP positive 
peritoneal macrophages (p = 0.04) after targeting with CAR-Avidin-dA6G10 
as compared to non-targeted Ad.GFP (Fig 5A). To investigate whether the 
CAR-Avidin-dA6G10 construct could also facilitate the adenoviral infection 
of other transformed or primary macrophages, RAW264.7 cells, J774 cells 
and bone marrow derived macrophages were infected as previously 
described at increasing MOI (50, 100, 200 pfu per cell). CAR-Avidin-
dA6G10 increased the infection efficiency by 536-fold in RAW264.7 cells (p 
< 0.04), up by 392-fold in J774 cells (p < 0.013) and by 101-fold in bone 
marrow derived macrophages (p < 0.013) (Fig. 5B; please note the 
logarithmic scale of this figure). 
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Figure 5. Effect of CAR-Avidin-dA6G10 targeted infection of different 
cell types with Ad.Luc (A) CAR-Avidin was added to dA6G10 at a molar 
ratio of 1:1. Ad.GFP was incubated with CAR-Avidin-dA6G10 at a 
concentration of 5.0*10-8 M after which RAW264.7, and peritoneal 
macrophages were infected (MOI 100). 40 hours after infection wells were 
checked for GFP positive cells. (B) CAR-Avidin was added to dA6G10 at a 
molar ratio of 1:1. Ad.Luc was incubated with CARAvidin-dA6G10 at a 
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concentration of 5.0*10-8 M after which RAW264.7, J774 and bone marrow 
derived macrophages (BM MF) were infected with different MOI’s (50 , 
100 , 200 ). Cells were lysed and luciferase activity was determined and 
corrected for protein concentration. Results are mean ± s.d. of triplicate 
experiments. Please note that the scale of this figure is logarithmic in 
contrast to scales of the other figures in this paper. 
 
To further investigate the specificity for the SR-A, the dA6G10 
equipped linker protein was used to target Ad.Luc to bone marrow derived 
macrophages isolated from wt or SR-A-/- mice. Figure 6 shows a clear 
increase in infection efficiency in macrophages isolated from the wt mice 
whereas this increase is much more modest in the macrophages isolated 
from SR-A-/- mice when compared to untargeted Ad.Luc, indicating that 
the increased infection efficiency via CAR-Avidin-A6G10 is predominantly 
SR-A mediated. The infection efficiency of targeted Ad.Luc was found to 
be significantly higher than that of untargeted virus at MOI > 100 pfu per 
























Figure 6. Effect of CAR-Avidin-dA6G10 targeting on Ad.Luc infection 
in macrophages isolated from SR-A+/+ versus SR-A-/- mice CAR-
Avidin was added to dA6G10 at a molar ratio of 1:1. Ad.Luc was incubated 
with CAR-AvidindA6G10 at a concentration of 5.0*10-8 M after which bone 
marrow derived macrophages isolated from either wt or SR-A-/- were 
infected with different MOI’s (50 , 100 , 200 , 400  pfu/cell). Cells 
were lysed and luciferase activity was determined and corrected for 
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protein concentration. Results are mean ± s.d. of triplicate experiments. * 
indicates p<0.02 
 
To investigate whether the targeting would change the 
biodistribution of Ad, wild type mice received either untargeted or CAR-
Avidin-dA6G10 targeted Ad.LacZ. Five days after injection, clear 
redistribution of β-galactosidase staining within the liver was observed. 
After infection with untargeted virus, all parenchymal liver cells were found 
to stain blue (fig 7, left panel). Targeting led to a reduced infection of the 
parenchymal cells, whereas that of non-parenchymal cells was increased 
(fig 7, right panel). Based on morphology and localization within the tissue, 
these non-parenchymal cells most likely are Kuppfer cells (fig 7, right 
panel, dark arrow). These data suggest that the virus-targeting complex is 
stable in vivo and suggest that it might be possible to redirect Ad5 from 
parenchymal liver cells to Kuppfer cells. 
Untargeted dA6G10
 
Figure 7 Effect of CAR-Avidin-dA6G10 targeting of Ad.LacZ on 
biodistribution in the liver in vivo. Wt female mice received a dose of 
1*109 pfu of untargeted or targeted Ad.LacZ. CAR-Avidin was added to 
dA6G10 at a molar ratio of 1:1. Ad.LacZ was incubated with CAR-Avidin-
dA6G10 at a concentration of 5.0*10-8 M. Five days after infection mice 
were sacrificed and livers were isolated and stained for LacZ activity. The 
experiment was performed in duplo, representative sections are shown at 




In this paper we present the generation and characterization of a 
CAR-Avidin linker protein to expand the applicability of adenoviruses to 




linker with an SR-A ligand (oligonucleotide bio-dA6G10) results in a 
targeting construct which increases the Ad5 mediated reporter gene 
transfer to both primary and transformed macrophages by up to 500-fold. 
Thus, in contrast to untargeted adenovirus, the CAR-dA6G10 construct 
results in significant levels of adenovirus mediated gene transfer to 
macrophages.  
Although the dA6G10 ligand is highly specific for macrophages in 
vitro and in vivo (44), our analysis of the receptor specificity using 
macrophages derived from SR-A knockout mice suggests that the effect is 
not completely SR-A specific, since the SR-A -/- macrophages are also 
infected by the dA6G10 equipped Ad, albeit at a significantly lower level (fig 
6). This may be explained by the presence of alternative members of the 
(presumably) scavenger receptor family also capable of taking up polyG 
oligonucleotides (45). In the constitutive absence of the SR-A, these 
receptors may even be upregulated as part of a compensatory pathway. 
On the other hand, these alternative receptors may contribute to the 
uptake of the dA6G10-equiped Ad even in the presence of the SR-A. 
Evidence for a constitutive background activity comes from the 
observation that at low MOI both SR-A-/- and SR-A+/+ macrophages are 
infected by dA6G10-equiped Ad at a low level. 
Macrophages play, via the secretion of proinflammatory cytokines, 
a role in a wide variety of biological and pathogenic processes including 
angiogenesis, inflammation, HIV infection, chronic granulomatous 
disease, atherosclerosis, lysosomal storage disorders, diabetes and lupus 
erythematosus. Because of this central role, much effort has been put into 
finding approaches to modulate gene expression in macrophages. One of 
the approaches to intervene in macrophage biology involves the use of 
gene therapy (reviewed by (43). Several strategies have been pursued to 
facilitate the use of adenovirus vectors for the modulation of macrophage 
gene expression, including the insertion of a poly-lysine stretch in the fiber 
knob (20). Although successful, this strategy is not easily applicable to the 
majority of existing and available adenoviral vectors. 
The CAR-Avidin linker protein equipped with a biotinylated ligand is 
physically separated from the virus. This renders the targeting construct 
applicable to all Ad5 based vectors and in addition precludes problems 
associated with the generation and propagation of some of the genetically 
modified viruses (19;46). The majority of cell lines used for generating and 
propagating recombinant adenoviruses (911, 293 and PerC6) are infected 
via interaction of the virus with the CAR receptor present on the packaging 
cell line. Because the virus itself remains unaltered, virus assembly or 
propagation in the commonly used adenovirus production cell lines will not 
be affected. 
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Binding of native biotin to avidin results in the formation of avidin-
biotin tetramers (47). Addition of sugar moieties, or other compounds, to 
avidin or biotin is known to affect the binding between avidin and biotin in 
a negative manner (48) and the femtomolar affinity between avidin and 
biotin is generally solely reached with unmodified components. Our biotin 
binding experiments revealed a Kd of 2.3 nM for interaction of CAR-Avidin 
with biotin-dA6G10. In analogy, the dissociation constant of a biotinylated 
17-mer peptide was found to be as low as 0.15 nM (data not shown). 
Thus, the affinity of avidin for biotin indeed appears to be affected by 
attached structures. However, while the affinity may be lower than that of 
native avidin and biotin, it is significantly higher than that of monomeric 
avidin and biotin (Kd= 10-7 M) and, in fact, is comparable to the affinity of 
CAR for Ad5 (3 nM). We thus conclude that the high stability of the CAR-
avidin and bio-ligand interaction will not limit application of the targeting 
construct. The nM affinity of CAR-Avidin for bio-dA6G10 is suggestive for 
the formation of multimers, although this remains to be demonstrated 
directly. 
The avidin docking scaffold will allow the use of a whole range of 
biotinylated ligands including glycosides (49-51), peptides (20;52-55), entire 
proteins (29;56-58) or oligonucleotides (44;59;60) to confer affinity for the cell of 
interest. The affinity of the avidin biotin dyad, even after attachment of 
bulky structures, warrants sufficiently tight association between the 
adenovirus-binding moiety and the novel homing device and obviates 
complex coupling reactions and purification steps (reviewed by (32). The 
avidin-biotin binding takes place at room temperature in any physiological 
buffer and unbound biotinylated ligands, if present, can be removed via 
dialysis. 
The CAR-avidin based targeting strategy to adapt the tropism of 
Ad vectors, that is presented in this study, differs in essential aspects from 
previously described approaches based on avidin and biotin. As compared 
to the approach of Smith et al., which uses chemically biotinylated Ad 
vectors and avidin partially occupied with biotinylated ligands (34), the 
application of a CAR-avidin adapter obviates the chemical modification 
step of the ad vector and at the same time ablates the intrinsic affinity for 
cellular CAR. In addition, with regards to the maximum number and 
specific sites of attachment, the CAR-Avidin approach is more well 
defined. On the other hand, the approach using biotinylated Ad vectors 
does not require the generation of the CAR-Avidin linker protein. An 
alternative targeting approach is based on a biotin acceptor peptide that 
has been inserted into the virus knob (27) or into protein IX (35) of the Ad 
vector and that is biotinylated metabolically during production of the virus. 




achieved via an avidin bridge. This genetic approach results in well 
defined targeting complexes and obviates the need for linker proteins such 
as CAR-Avidin. On the other hand, genetic targeting is not readily 
applicable to already available Ad5 type vectors and thus requires 
regeneration of the Ad vectors. Thus, the specific requirements for the Ad 
targeting that are desired will determine which system is most appropriate. 
The in vivo experiment using the dA6G10 equipped linker protein 
with adenoviruses shows that the virus-linker protein complex remains 
stable after in vivo administration and, based on morphological 
characteristics, suggest a redistribution of the virus from the parenchymal 
liver cells to, most likely, Kuppfer cells (Fig 7). From these data, it cannot 
be concluded whether the redistribution of the Ad is caused by the 
specificity of dA6G10 equipped Ad for Kuppfer cells, or whether the 
redistribution is caused by de-targeting of the endogenous CAR on the 
liver parenchymal cells. The preliminary observation that dA16 equipped 
Ad resulted in low to very low level infection of Kuppfer cell like cells (data 
not shown) indicates that part of the dA6G10-specific Kuppfer cell infection 
is caused by nonspecific uptake as a consequence of parenchymal cell-
specific CAR de-targeting. 
In conclusion, we have demonstrated the application of a CAR-
Avidin linker protein in association with a biotinylated ligand to mediate 
adenovirus infection. Equipping the linker protein with an appropriate 
biotinylated ligand can considerably increase adenoviral gene transfer to 
refractory cell types. The CAR-avidin linker protein is, when equipped with 
a biotinylated dA6G10 oligonucleotide, able to increase the infection 
efficiency of multiple primary and transformed macrophage cell lines. The 
versatility of the avidin moiety within the linker protein readily allows an 
expansion of the number and nature of the ligands that can be attached 
via a biotin moiety, thus enabling the application of the targeting protein for 
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Vascular smooth muscle (VSMC) and endothelial cells (EC) are 
particularly resistant to infection by type 5 adenovirus (Ad) vectors. To 
overcome this limitation and target Ad vectors to ubiquitously expressed 
aVb3/5 integrins, we have generated a linker protein consisting of the 
extracellular domain of the coxsackie adenovirus receptor (CAR) 
connected via avidin to a biotinylated cyclic (c) RGD peptide. After 
optimization of CAR to cRGD and to Ad coupling, infection of mouse heart 
endothelial cells (H5V) could be augmented significantly, as demonstrated 
by 600-fold increased transgene expression levels. In EOMAs, a 
hemangioendothelioma-derived cell line, the fraction of infected cells was 
enhanced 4- to 6-fold. Furthermore, the fraction of infected primary mouse 
VSMC was increased from virtually 0% to 25%. Finally, in human umbilical 
vein endothelial cells, the number of GFP positive cells was enhanced 
from 2% to 75%. In conclusion, CAR-cRGD is a versatile and highly 
efficient construct to target Ad vectors to both transformed and primary 
VSMC and EC. 
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Recombinant type 5 adenovirus (Ad) vectors are extensively used to 
modulate gene expression in a wide variety of cells and organs, both in 
vitro and in vivo. Part of this popularity can be ascribed to their relatively 
straightforward generation and amplification to high titers (1). Ad entry and 
infection of cells requires at least two distinct interactions. First, 
attachment of the virus particle occurs via interaction of its fiber knob with 
the Coxsackie adenovirus receptor (CAR) present on the cell surface (2–5). 
Second, the Arg-Gly-Asp (RGD) motifs present in the viral penton base 
will bind to aVb3 and aVb5 integrins on the target cell surface and trigger 
internalization via receptor-mediated endocytosis (6–8). In addition, recent 
data have shown the involvement of heparan sulfate glycosaminoglycans 
(HSGs) in adenoviral entry in vivo (9). Recombinant Ad vectors encoding 
numerous wild type and mutant genes, as well as short hairpin RNA 
molecules have been generated. However, the application of Ad vectors in 
CAR negative cell lines, such as vascular smooth muscle cells (VSMC) 
and endothelial cells (EC) (10–12) is hampered by low infection efficiencies 
at low multiplicity of infection (MOI) and Ad associated cytotoxicity at high 
MOI. To expand the applicability of Ad-mediated gene transfer, various 
strategies to modify Ad tropism have been undertaken. In the genetic 
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modification approach, peptide ligands have been incorporated into the 
HI-loop of the Ad fiber knob (13-16), added to the C-terminus of the fiber 
knob (17) or inserted into the hexon protein (18). However, it is not possible 
to predict which peptide or protein ligands will be tolerated and do not 
disturb fiber trimerization and/ or capsid function. In addition, for each 
specific targeting application, rederivatization of the original recombinant 
Ad vectors is obligatory. Alternatively, bifunctional targeting proteins have 
been generated consisting of an Ad-binding domain coupled to a peptide 
or protein that confers a novel specificity (19). This strategy enables the 
utilization of existing recombinant Ad vectors, but the generation of the 
bifunctional targeting protein may require chemical linkage and 
subsequent purification steps. In addition, Parrot and co-workers have 
introduced a novel approach to target viral vectors. They launched the 
concept of metabolically biotinylated vectors (20;21) and demonstrated the 
utility of the avidin–biotin based system for vector targeting. Recently we 
have combined the advantages of the latter two targeting strategies, by 
developing a bi-functional linker protein that exploited the avidin–biotin 
concept (Gras, personal communication). This linker protein consists of 
the extracellular domain of the CAR fused to chicken avidin, which 
functions as a universal docking site for biotinylated ligands. It was 
demonstrated that a biotinylated dA6G10 oligonucleotide coupled to the 
CAR-Avidin linker confers macrophage specificity (Gras, personal 
communication). In this study, the CAR-Avidin linker protein is coupled to 
a biotinylated cyclic RGD peptide (bio-cRGD) to increase infection 
efficiency of EC and VSMC. This cRGD peptide has a high affinity for 
αVβb3 and αVβb5 integrins (22), which are expressed ubiquitously on 
transformed cell lines and most primary cells. It is demonstrated that 
linking of Ad to the CAR-cRGD targeting construct resulted in a highly 
significant improvement of infection efficiencies of transformed and 
primary VSMC and EC at all MOI used.  
 
 
Materials and methods 
Cell culture. Chinese hamster ovary (CHO) cells, H5V (mouse endothelial 
cell line derived from heart) and EOMA (mouse hemangioma-derived 
micro vascular cell line), were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (Gibco-BRL). Ramos cells (Burkitt lymphoma cells) and 
K-562 cells (chronic myelogenous leukemia cells from blast crisis) were 
cultured in RPMI 1640 medium. All media were supplemented with 10% 
fetal calf serum, 100 U/ml penicillin, 100 lg/ml streptomycin, and glutamax 
(Invitrogen). Human umbilical vein endothelial cells (HUVECs) were a 





Netherlands) and were isolated as previously described (23;24) and grown 
in medium 199 with 10% human serum. Mouse VSMC were isolated from 
aorta from male C57Bl6 mice as previously described (25) and cultured in 
DMEM with 10% newborn calf serum (NCS). All cells were maintained at 
37 °C in a humidified atmosphere of 5% CO2. 
Production of recombinant Ad vectors. Recombinant E1, E3-deleted 
Ad-vectors expressing b-galactosidase gene (Ad.LacZ) and firefly 
luciferase (Ad.Luc) under the control of the cytomegalovirus promoter 
(CMV) were kindly provided by, respectively, Dr. Willnow (Houston, USA) 
and Dr. Hoeben (LUMC, Leiden, The Netherlands). Recombinant 
adenovirus vector carrying the green fluorescent protein under control of 
CMV (Ad.GFP) was constructed using the Ad-Easy-1 system as 
previously described by (26). Additionally, the viruses were propagated in 
PERC6 cells as described (27). The purification process involved two 
rounds of CsCl ultracentrifugation and dialysis against dialysis buffer (25 
mmol/L Tris, 137 mmol/L NaCl, 5 mmol/L KCl, 0.73 mmol/L NaH2PO4, 0.9 
mmol/L CaCl2, and 0.5 mmol/L MgCl2, pH 7.45) followed by dialysis 
against the same buffer supplemented with sucrose (50 g/L). Plaque 
titration was performed on 911 cells according to standard techniques (28). 
Aliquots of 50 ll virus were stored at -80 °C. Generally, virus titers of the 
stocks varied from 1 * 1010 to 1 * 1011 pfu/ml.  
Generation CAR-Avidin linker protein. The CAR-Avidin linker protein 
was generated by joining a series of PCR-generated fragments. In short, 
the extracellular domain of the coxsackie adenovirus receptor (CAR) was 
obtained by PCR using the plasmid pCAR (kind gift of Prof. R. Hoeben, 
LUMC, Leiden) as template (oligos: 5’-GCG GCC GCG GGT ACC CAC 
GGC ACG GCA G-3’ and 5’-CTA GCT AGC AGC TTT ATT TGA AGG 
AGG GAC-3’). The avidin fragment was obtained by RT-PCR on total 
RNA from chicken fibroblasts with random hexamer oligonucleotides and 
subsequent PCR using primers 5’-CGC GGA TCC GCC AGA AAG TGC 
TCG CTG –3’ and 5’-CCA TCG ATG GTC ACT CCT TCT GTG TGC G –
3’. The CAR fragment was cloned into the pSG8 vector (generous gift of 
Prof. Henk Stunnenberg, Nijmegen, The Netherlands), in front of the VSV 
and His6 tag. Avidin was cloned in-frame into pSG8CAR behind the VSV 
and His6 tag. All constructs were sequence verified. 
Production and purification CAR-Avidin linker protein. For production 
Cos-1 cells were transfected with pSG8CAR-Avidin using Fugene6 
(Roche, Basel, Switzerland). Forty hours after transfection (serum-free, 
biotin-free culture medium), the supernatant, containing the linker proteins, 
was harvested. Linker proteins were purified from the supernatant by 
immobilized metal affinity chromatography using Talon metal affinity resin 
(Clontech, Palo Alto, USA). Equilibrated culture supernatant (300 mM 
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NaCl, pH 7.0, and 20% glycerol) was incubated with Talon, 20 min at 
room temperature. After extensive rinsing (50 mM NaPO4, 300 mM NaCl, 
and 20% glycerol, pH 7.0), resin was pre-eluted (4 volumes; 50 mM 
NaPO4, 300 mM NaCl, 2,5 mM imidazole, and 20% glycerol) prior to its 
elution (10 volumes; 50 mM NaPO4, 300 mM NaCl, 150 mM imidazole, 
and 20% glycerol). Presence of linker protein in the purified samples was 
detected by SDS–PAGE and Western blotting analysis using Hybond ECL 
nitro cellulose membranes (Amersham Biosciences, Buckinghamshire, 
UK) and antibodies P5D4 (a-VSV) or a-Avidin (Abcam, Cambridge, UK). 
Elution fractions 3–5 contained the linker protein and were dialyzed 
against PBS. 
Quantification of CAR-Avidin linker protein. The linker protein was 
quantified by a biotin binding assay. Ten microliters of the linker protein 
elution fraction or an avidin calibration range of 0.3–10 pM avidin was 
incubated with 0.2 µl [3H]Biotin (Du Pont NEN Research Products, Boston, 
MA, USA) for 1 h. The total reaction mixture was applied on a Sephadex 
G-50 column to separate CAR-Avidin bound biotin from the free biotin. 
The elution fractions were counted for [3H]biotin radioactivity using 5 ml of 
Hionic fluor scintillation cocktail (Packard Instrument, Perkin Elmer, 
Boston, MA, USA) in a Packard 1500 TriCarb liquid scintillation analyzer. 
The summed radioactivity in peak fractions 3–5 correlated with the amount 
of avidin present in the sample (R2 = 0.997). Elution fraction 3, which had 
the highest concentrations, was used for experiments and stored at -80 
°C. A yield of the order of 900–1000 µg was typical. 
Biotin binding assay. CAR-Avidin (5 ll of 30 nM) was incubated for 1 h at 
RT with bio-cRGD (cdFK(e-C6-biotin)RGD), from Asynth Service BV 
(Roosendaal, Netherlands), at molar ratios ranging from 1:0.001 to 1:3, 
after which 2 µl of [3H]biotin (NEN) was added and the mixture was 
incubated again for 1 h. To separate the CAR-Avidin-(3H- or cRGD-) biotin 
bound fractions from free [3H]biotin, the mixture was applied on a 
Sephadex G-50 column. [3H]Biotin radioactivity in the elution fractions was 
measured after addition of 5 ml Hionic Fluor scintillation cocktail (Packard 
Instrument) in a Packard 1500 tricarb liquid scintillation analyzer. The 
summed radioactivity in peak fractions 4–6 corresponded to the [3H]biotin 
binding capacity of the CAR-Avidin. This value is plotted for each sample 
containing different molar ratios of CAR-Avidin to biocRGD (1:0.001 to 
1:3).  
Infection assay. Twenty-four hours before infection, cells were seeded 
into 12 well plates (Greiner). The CHO, H5V, and HUVEC at 4 * 104, 
VSMC at 6 * 104, Ramos and K-562 at 1 * 105, and EOMA at 1.2 * 105 
cells per well. At the day of infection, three wells were tryp to calculate the 





bio-cRGD in a total volume of 50 µl PBS. Then, the CAR-cRGD targeting 
construct was added and incubated for 1 h with different amounts of 
Ad.Luc, Ad.GFP or Ad.LacZ. Subsequently 300 ll of cRGD-Ad diluted in 
PBS/2% horse serum was added to the cells. After 1 h at 37 °C, the media 
were changed and infection efficiency was determined 40 h after infection. 
Ramos and K-562 (suspension) cells were washed by centrifugation for 5 
min at 1000 rpm in between the incubation steps. Ad.luc infected cells 
were lysed in 300 µl reporter lysis buffer (Promega). Luc activity 
(Promega) and protein content (BCA assay, Pierce) were measured 
according to the protocol supplied by the manufacturer. The Ad.LacZ 
infected cells were washed with PBS and fixed for 5 min at 4 °C in 5.4% 
formaldehyde, 0.8% glutaraldehyde in PBS after which staining solution (5 
mM potassium ferricyanide, 5 mM potassium ferrocyanide, 0.2 mM MgCl2, 
and 0.1% 5-bromo-4-chloro-3-indolyl-b-D-galactoside (X-Gal) in PBS) was 
added. After 4 h and LacZ positive cells were visual and scored 
microscopically. Ad.GFP infected cells were trypsinized gently, 
homogenized in PBS supplemented with 2% fetal calf serum, and kept on 
ice until further analysis by flow cytometry (Becton–Dickinson). GFP 
fluorescence was detected at 530/30 nm FACscan (FL1 channel) following 
excitation with an argon ion laser source at 488 nm. The forward-
scatter/side-scatter plot was gated to exclude cellular debris from the 
analysis. The number of events/FL1 (which reflects the fluorescence 
intensity) is plotted against the total number of cells, and the percentage of 
GFP-positive cells was determined. For each sample, 10,000 events were 
collected. 
Statistical analysis. Results are presented as means ± SD values of 
three samples. The significance of differences between the experimental 
groups was calculated using a two-tailed Students t test. The level of 




Generation and optimization of the adenovirus targeting construct To 
target Ad to αVβ3/5 integrins, the bi-functional linker protein CAR-Avidin 
was equipped with the targeting peptide bio-0?>cRGD to yield CAR-
cRGD. TcRGD, resulting in a complete occupation of all available biotin-
binding sites, was determined by a [3H]biotin binding assay. Figure 1A 
shows the amount of [3H]biotin that is still able to bind to CAR-Avidin at a 
molar ratio of CAR-Avidin to bio-RGD ranging from 1:0.001 to 1:3. At a 
molar ratio of more than 1:0.3, no residual [3H]biotin-binding capacity 
could be detected, indicating that at this ratio all biotinbinding sites of 
CAR-Avidin were occupied. In all the following experiments, a slight 
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excess of CAR-Avidin to bio-cRGD was used (ratio 1:1) to generate the 
CAR-cRGD targeting construct. To determine the optimal ratio of Ad to 
CAR-cRGD targeting construct, a fixed amount of Ad.LacZ was incubated 
with various concentrations of CAR-cRGD and added to αVβ3/5-positive 
mouse heart endothelial cells (H5V) (29). Two days after infection, the cells 
were fixed and stained for LacZ activity. The number of LacZ positive cells 
was enhanced in a CAR-cRGD concentration dependent manner (Fig. 1B) 
ranging from 1 to 270 positive cells per microscope field. The increase in 
infection efficiency leveled off at a concentration of 1.2 µM CAR-cRGD. 
Therefore in the subsequent experiments, a concentration of 1.2 µM CAR-
cRGD was used.  
 

























































Figure 1. Optimization of Ad: CAR-Avidin/cRGD ratio. (A) CAR-Avidin 
(30 nM) preincubated with different molar ratios of biotin-cRGD was 
incubated with an excess of [3H]biotin. CAR-biotin (-3H or -cRGD) 
radioactivity was counted. (B) Ad.LacZ was preincubated with either BSA 
(Ad) or with different amounts of the targeting construct, CAR-cRGD 
(cRGD-Ad), and subsequently added at a titer of MOI 1000 to mouse 
endothelial cells for 1 h. Forty hours post-infection, cells were fixed and 
stained for LacZ activity for 4 h. Multiple microscope fields were counted 
for positive cells. Values represent means ± SD of three samples. 
 
cRGD mediated adenoviral gene transfer in CAR deficient and αVβ3/5 
positive cells The ability of the CAR-cRGD targeting construct to achieve 
CAR-independent gene transfer was determined in the CAR-negative, but 
αVβ3/5 positive, cell line CHO (30). Near confluent CHO cells were infected 
with untargeted Ad versus targeted Ad-vectors expressing luciferase 





were evaluated for luciferase expression (Fig. 2A). As expected, Ad.Luc 
was incapable of infecting CHO cells even at an MOI of up to 500. In 
contrast, already at MOI 100, the cRGD-Ad.Luc vector resulted in a 3 to 4 
log-fold enhancement of luciferase expression, demonstrating that the 
cRGD-equipped Ad.Luc achieves gene transfer through a CAR-
independent cell entry pathway. The specificity of targeting Ad to αVβ3/5 
integrins was investigated by comparing gene transfer of Ad versus 
cRGD-equipped Ad in human leukemia cell lines, Ramos and K-562. In 
both cell lines moderate levels of CAR are present, however only K-562 
cells express αVβ3 and αVβ5 integrins (31). Ad.GFP plus or minus cRGD 
was applied to both cell lines at an MOI ranging from 100 to 2500. After 24 
h, the cells were monitored for GFP expression by FACS analysis (Figs. 
2B and C). In both the αVβ3/5 integrin negative as well as positive cell 
line, gene transfer mediated by unmodified Ad.GFP was low but dose-
dependently increased. In Ramos cells, which do not express αVβ3/5 
integrins, cRGD-mediated gene transfer did not increase infection 
efficiency at MOI 500, as compared to unmodified Ad. Moreover, at MOI 
2500 cRGD-mediated gene transfer remained low, resulting in a 
significantly lower percentage of GFP positive cells as compared to 
unmodified Ad.GFP. In contrast, in the αVβ3/5 integrin positive K-562 cell 
line, cRGD-mediated gene transfer resulted in an approximately 10-fold 
increase in the number of GFP positive cells as compared to those 
infected with untargeted Ad.GFP at all MOIs used. Thus, cRGD-Ad 
markedly enhanced gene transfer only in the αVβ3/5 integrin positive K-
562 cell line, suggesting that the αVβ3/5 integrins are involved in the 
uptake of cRGD equipped Ad vectors.  
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Figure 2. Analysis of aVb3-/aVb5-integrin and CAR-dependent gene 
transfer of cRGD equipped Ad. For all subfigures  Ad.Luc,  cRGD-
Ad.Luc (A) CAR-negative CHO cells were exposed for 1 h to Ad.luc, 
preincubated with BSA (Ad) or 1200 nM CARcRGD (1:1 M) (cRGD-Ad) at 
different MOI. Forty hours after infection luciferase expression was 
measured and corrected for protein levels. Values represent means ± SD 
of three samples. (B) Ramos and (C) K-562 cells were infected with an 
increasing titer of unmodified Ad (Ad.GFP) or cRGD equipped Ad-vector 
(cRGD-Ad.GFP). CAR-Avidin was prebound to cyclic RGD at a 1:1 molar 
ratio and 1200 nM of the complex was incubated with Ad. Twenty-four 
hours after infection FACs analysis was performed. Values represent 
means ± SD of three samples. 
 
Quantification of targeting efficiency in transformed vascular cell 
lines The optimized targeting conditions were used to determine the 
efficiency of Ad-mediated gene delivery to murine vascular cell lines. 
Mouse heart endothelial (H5V) cells (32) were incubated with increasing 
concentrations of Ad.Luc or cRGD-Ad.Luc. Luciferase expression levels 
showed a titer-dependent increase. As compared to gene delivery with 
untargeted Ad.Luc, cRGD-Ad.Luc showed a 59-fold increased luciferase 
expression at MOI 250 and a 650-fold increased luciferase expression at 
MOI 2500 (Fig. 3A). To verify these results, the experiment was 
reproduced in a second mouse cell line, the hemangioma-derived micro 
vascular endothelial cell line (EOMA) (33;34). The EOMA cells were infected 
with either Ad.GFP or cRGD-equipped Ad.GFP virus. FACS analysis 
showed that EOMA cells were refractory to infection with untargeted 
Ad.GFP, as judged by 8% GFP positive cells at the relatively high MOI of 
1000. However, infection efficiency increased 4-to 6-fold after equipping 










































Figure 3. Ad mediated gene transfer of cRGD equipped vectors to 
mouse EC. For all subfigures  Ad.Luc,  cRGD-Ad.Luc (A) Ad.Luc was 
pre-incubated with either BSA (Ad.Luc) or 1200 nM of CARcRGD (1:1) 
(cRGD-Ad.Luc) and the complex was exposed to H5V cells at different 
MOI. Luciferase expression was measured 40 h post-infection. Results 
were normalized for protein concentration. (B) EOMA cells were exposed 
to different titers of Ad.GFP or cRGD equipped Ad.GFP. cRGD was bound 
to CAR-Avidin at a 1:1 molar ratio and 1200 nM of the CAR-cRGD 
conjugate was incubated with Ad.GFP. Values represent means ± SD of 
three samples. 
 
Quantification of targeting efficiency in primary mouse VSMs and 
human EC Next, cRGD-mediated Ad targeting to primary vascular cells 
was examined. Primary mouse VSMC isolated from aorta and HUVECs 
were infected with either Ad.GFP or Ad.GFP equipped with the CAR-
cRGD construct. Two days after infection, FACS analysis was performed 
to determine GFP expression levels. Primary VSMC were highly resistant 
to infection, as only 0.02% of the cells were infected with untargeted 
Ad.GFP (MOI 500) and 13% at high MOI (2500). In contrast, cRGD-
Ad.GFP mediated gene transfer resulted in a titer-dependent increase in 
GFP positive cells up to 46.5% at MOI 2500 (Fig. 4A). At MOI 500, this 
amounted to a 25-fold increased infection efficiency of primary VSMC 
using cRGD equipped Advectors. Improvement of gene transfer was also 
tested in HUVECs. Gene transfer using untargeted Ad.GFP resulted in a 
very low percentage of GFP positive cells (2%), while cRGD targeting of 
Ad led to a 36-fold increase (MOI 100) of infected HUVECs (Fig. 4B).  
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Figure 4. Ad mediated gene transfer of cRGD equipped vectors to 
primary cells. (A) For all subfigures  Ad.Luc,  cRGD-Ad.Luc. Mouse 
vascular smooth muscle cells and (B) HUVECs were exposed for 1 h to 
different MOI of Ad.GFP or to cRGD-Ad.GFP. CAR-Avidin was bound to 
cyclic RGD at a 1:1 molar ratio and 1200 nM of this complex was 
incubated with Ad.GFP. Forty hours after infection FACs analysis was 




In the present study, we show that coupling of recombinant Ad vectors to 
a CAR-cRGD linker protein results in a significantly improved infection 
efficiency of both transformed and primary VSMC and EC. Conjugation of 
CAR-cRGD to Ad reporter vectors markedly enhanced gene transfer to 
the established endothelial cell lines H5V and EOMA (up to 59-fold), as 
well as to primary HUVEC (36-fold) and VSMC (25-fold). This was 
associated with a considerable increase in the percentage of infected 
cells. Thus, the CAR-cRGD targeting construct expands the utility of Ad 
vectors to CAR-negative cell types that do express αVβ3- and αVβ5 
integrins. The biotin–avidin based coupling of a ligand to the CAR adaptor 
molecule is straightforward and highly efficient due to the femtomolar 
affinity of biotin for avidin (35;36). As compared to chemical modifications, 
this obviates the use of complex reaction mixtures and purification steps 





optimal CAR-Avidin/biotin-cRGD ratios by a [3H]biotin binding assay. 
Moreover, the CARAvidin adaptor may be coupled to a wide variety of 
biotinylatable ligands and has recently been successfully applied to target 
Ad vectors to macrophages using a biotinylated oligonucleotide (Gras, 
personal communication). Application of cRGD-Ad vectors expressing 
GFP increased the number of infected vascular cells rather than that it 
boosted gene expression in a limited cell population, as compared with 
untargeted Ad (Figs. 3B, 4A and B). Thus, CAR-cRGD mediated targeting 
of recombinant Ad vectors allows the use of considerably reduced MOIs to 
obtain near-quantitative gene transfer, thereby decreasing the vector 
related toxicity. This is particularly important for those cells that are 
sensitive to Ad-mediated toxicity. For example, only 2% of HUVECs were 
infected with unmodified Ad.GFP at MOI 100, whereas the same titer of 
cRGD equipped Ad.GFP resulted in 75% infected cells (Fig. 4B). To 
obtain a similar level of infection with unmodified Ad.GFP, MOI’s > 1000 
would be required, which coincides with cytotoxicity (data not shown). In 
addition to a lower virus dose, the near quantitative infection of HUVECs 
enables the application of Ad vectors encoding inserts that require 
quantitative infection, such as short hairpin (sh)RNA constructs to knock 
down gene function. αVβ3- and αVβ5 integrins are known to be up-
regulated on proliferating EC and subsequently have been exploited as 
targets to develop anticancer drugs. For this purpose, linear- and cyclic 
RGD peptides have been developed and used as a targeting moiety to 
selectively deliver drugs to angiogenic blood vessels (37;38). Pfaff et al. (22) 
have shown that a cyclic RGD peptide displayed a higher affinity for αVβ3- 
and αVβ5 integrins than the linear RGD peptide. We have confirmed this 
observation, showing a 4-fold increased LacZ activity utilizing cRGD-Ad 
vectors compared to linear RGD equipped Ad vectors (data not shown). 
The mechanism of cRGD-Ad mediated gene transfer was further 
characterized by infection of cell lines that differ in their expression levels 
of aVb3/5 integrins and CAR. CHO and K-562 cells, which express 
αVβ3/5 integrins but not CAR, were efficiently transduced by cRGD-Ad 
vectors. On the other hand, Ramos cells, which do not express aVb3/5 
integrins, were almost completely resistant to infection by cRGD targeted 
Ad vectors. These results demonstrated that the entry route of our CAR-
cRGD targeted Ad vectors is CAR independent and most likely mediated 
via aVb3/5 integrins. Conversely, in all these three cell lines very low 
infection efficiencies were obtained for untargeted Ad vectors. At the high 
MOI of 2.500, only the integrin expressing cell lines, CHO and K-562, 
were infectable. Apparently, at this very high MOI, the local concentration 
of Ad particles was high enough to bind via their RGD motifs present in 
the viral penton base to the αVβ3/5 integrins and trigger internalization. In 
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several cell types and tissues which represent important targets for gene 
therapy, like the vascular system, the expression level of the endogenous 
adenovirus receptor CAR is low (39;12;40). On the other hand, αVβ3/5 
integrins are abundantly expressed on activated and proliferating EC and 
VSMC, which are present during angiogenesis, neovascularization, and 
inflammation (41–43). In vitro the majority of proliferating cells express 
αVβ3/5 integrins. Therefore, the bifunctional linker protein carrying 
specificity for Ad vectors on the one hand and for αVβ3/5 integrins on the 
other hand greatly expands the applicability of conventional Ad vectors. In 
addition to providing Ad vectors with a novel tropism, the CAR.cRGD 
construct likely prevents binding of the Ad vectors to CAR (data not 
shown) and thus ablates the intrinsic specificity. This may be useful in 
vivo, in applications where CAR mediated uptake is undesired. 
In summary, we have demonstrated the feasibility of the CAR.cRGD 
construct to target Ad-vectors with high efficiency to transformed 
endothelial cell lines as well as to primary endothelial and smooth muscle 
cells. It is conceivable that additional Ad resistant and aVb3/5 integrin 
expressing cell lines and tissues may become amenable to Ad infection 
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Systemic administration of adenovirus (Ad) vectors results in gene 
delivery to the liver. To modify Ad vector tropism, we have generated a 
linker protein consisting of the virus binding domain of the coxsacky 
adenovirus receptor (CAR) genetically fused to avidin. In association with 
a biotinylated ligand, this CAR-Avidin linker protein can successfully 
retarget Ad vectors in vitro. Here, we set out to apply this targeting 
strategy in vivo. Two biotinylated peptide ligands were used to, 
respectively, target integrin αVβ3/5 expressing cells and lung endothelium. 
Systemic administration of both types of targeted Ad vectors resulted in an 
up to 85-fold reduced hepatic transgene expression. However, neither of 
the targeted Ad vectors resulted in increased transgene expression in the 
intended target tissue. Moreover, a substantial portion of the targeted Ad 
could not be recovered from any of the organs, indicative of efficient Ad 
neutralization. Indeed we observed that the maximum half-life of Ad in the 
circulation after systemic lactoferin treatment, which completely blocks 
hepatic Ad uptake was 8’ as compared to 6’ for untargeted Ad suggesting 
the presence of efficient extrahepatic elimination pathways. Apparently, 
rapid neutralization of targeted Ad in the circulation efficiently prevents 




Adenovirus (Ad) mediated gene transfer is widely used as a powerful 
method to modulate gene expression in vitro and in vivo (reviewed by (1)) 
The vast majority of Ad used to date involves serotype 5 (Ad5). 
Application of Ad5 vectors is dependent on the expression of the cognate 
receptor, the Coxsackie Adenovirus Receptor (CAR) by the target cell (2;3). 
Infection of CAR deficient cells, such as many tumours, endothelial and 
hematopoietic cells, with Ad vectors is very ineffective and can be 
achieved only at high multiplicities of infection. Thus efficient infection of 
these cells requires modulation of Ad tropism.  
In vitro, several targeting approaches have been proven 
successful. In one of the strategies the capsid protein is genetic modified 
by inserting peptide ligands (4-22). Another approach for targeting Ad 
vectors is based on conjugates. Here, the vector is equipped with a 
bifunctional adapter molecule able to bind the virus on the one hand and a 
marker protein on the target cell on the other hand (23); (reviewed by (24;25-
28;29)). The adapter can either associate with the native virus or with 
chemically or genetically modified capsid proteins. This targeting approach 
is more versatile than the genetic modification based strategy, as it results 
in a flexible targeting system able to confer/ accommodate infection of a 
variety of cell types via the addition of different ligands. 
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Recently, we described the generation and in vitro characterization 
of linker protein CAR-Avidin for the targeting of Ad5 to alternative cell 
types. This linker protein consists of the virus-binding moiety of the 
endogenous receptor CAR, genetically fused to the biotin-binding moiety 
of avidin. Equipping CAR-Avidin with the oligodeoxy nucleotide ligand 
dA6dG10 or the cyclic peptide ligand GRGDSP (cRGD) resulted in efficient 
targeting in vitro of both transformed and primary macrophages (30) and to 
both transformed and primary vascular smooth muscle and endothelial 
cells (31), respectively. The aim of the current study was to determine 
whether in vivo targeting of Ad vectors to extrahepatic tissue such as 





Cells Cos-1, H5V and EOMA cells were cultured in DMEM (Invitrogen, 
Carlsbad, CA, USA) supplemented with 10% FCS (Invitrogen), 100 units/ 
ml Penicillin (Invitrogen), 100 µg/ml Streptomycin (Invitrogen) and 
glutamax (Invitrogen). Mouse VSMC were isolated from aorta from male 
C57Bl6 mice as previously described [46] and cultured in DMEM with 10% 
newborn calf serum (NCS). One day prior to transfection Cos-1 cells were 
detached from plastic with 1% Trypsine/ 10 mM EDTA in PBS and seeded 
to 50% confluency. Cells were cultured in a humidified atmosphere of 5% 
CO2 
Production of recombinant Ad vectors. Recombinant E1, E3-deleted 
Ad-vectors expressing beta-galactosidase gene (Ad.LacZ) and firefly 
luciferase (Ad.Luc) under the control of the cytomegalovirus promoter 
(CMV) were kindly provided by respectively Dr. Willnow (Houston, USA) 
and Dr. Hoeben (LUMC, Leiden, The Netherlands). Additionally, the Ad 
vectors were propagated in PERC6 cells as described [47]. The 
purification process involved two rounds of CsCl ultra centrifugation and 
dialysis against dialysis buffer (25 mmol/l Tris, 137 mmol/l NaCl, 5 mmol/l 
KCl, 0.73 mmol/l NaH2PO4, 0.9 mmol/l CaCl2, and 0.5 mmol/l MgCl2, pH 
7.45) followed by dialysis against the same buffer supplemented with 
sucrose (50 g/l). Plaque titration was performed on 911 cells according to 
standard techniques (48). Aliquots of 50 µl virus were stored at -80°C. 
Generally, virus titers of the stocks varied from 1 x 1010 to 1 x 1011 plaque 
forming units per ml (pfu/ml). 
Production, purification and characterization of the linker protein The 
CAR-Avidin linker protein was produced, purified and characterized as 
previously described [30]. In short: CAR-Avidin was produced by transient 




Basel, Switzerland) under serum free conditions. Thirty two hours after 
transfection the linker protein was harvested and purified from the 
supernatant by immobilized metal affinity chromatography using Talon 
metal affinity resin (Clontech, Palo Alto, USA). Culture supernatant was 
equilibrated (addition of 5M NaCl to an end concentration of 300 mM 
NaCl, pH was adjusted to 7.00 using 50% HCl in PBS, 100% glycerol was 
added to an end concentration of and 20% glycerol) and incubated for 20 
minutes at room temperature with Talon. After extensive rinsing with buffer 
(50 mM NaPO4, 300 mM NaCl, 20% glycerol, pH = 7.0), washing with 4 
volumes pre-elution buffer (50 mM NaH2PO4, 300 mM NaCl, 2,5 mM 
imidazole, 20% glycerol) the resin was eluted with 10 volumes elution 
buffer (50 mM NaH2PO4, 300 mM NaCl, 150 mM imidazole, 20% glycerol). 
SDS-PAGE and western blotting analysis of all purification steps and 
elution fractions showed that the linker protein was only present in elution 
fractions 3 to 5 that were subsequently extensively dialyzed against PBS 
and used in all experiments. The concentration of the active component 
was determined in the biotin binding assay as previously described using 
avidin (Sigma Aldrich, St Louis, MO, USA) as standard.  
Ligands The lung specific GFE1 peptide (CGFECVRQCPERC;[32]) was 
synthesized as N-terminally biotinylated peptide by standard Fmoc based 
solid-phase chemistry and provided by J.W. Drijfhout (LUMC, Leiden, The 
Netherlands). The quality was checked by high resolution LC-MS mass 
spectroscopy. The bio-cRGD (cdFK(e-C6-biotin)RGD) was obtained from 
Asynth Service BV (Roosendaal, Netherlands). 
Targeting conditions CAR-Avidin and peptide ligands were incubated at 
a 1: 1 molar ratio for 1 hour at room temperature, as was determined in 
previous experiments [30,31]). Complex formation of adenovirus and 
CAR-Avidin-ligand was facilitated by incubating CAR-Avidin-ligand at a 
concentration of 50 nM with the appropriate amount of virus for 1 hour at 
room temperature.
Bioluminescent reporter imaging 12 wks old female C57Bl/6JIco mice 
(Charles river, The Netherlands), fed standard chow diet (Hope Farms, 
Woerden, NL) ad libitum, were injected with Ad.Luc (2x109 pfu). 
Bioluminescent signals were determined 4 days after Ad injections using 
the Xenogen IVIS imaging system (IVIS 100). Approximately 5 minutes 
before imaging the living mice were injected luciferin, (150 mg/kg) 
intraperitoneally (ip). The mice were anaesthetized with 
isofluorane/oxygen and placed on the imaging stage. Total photon 
emission of each animal was acquired for 1 minute. Captured images 
were quantified using the Living Image software (Xenogen Corp, Almeda, 
CA) and the IGOR software (WaveMetrics Corp, Lake Oswego, OR). 
Bioluminiscence from the region of interest was expressed via a pseudo 
color scale (Red most intense and Blue least intense luminescence) and 
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data were presented as the cumulative photon counts collected within 
each region of interest. Because layers of tissue may limit photon 
emission from inner organs, 4 days after Ad injection the livers of mice 
were dissected to verify the results from the bioluminescent reporter 
imaging experiment by determination of the luciferase activity in liver 
lysates. 
Luciferase enzymatic assay The liver extracts were prepared by 
homogenisation with the minibead beater in reporter lysis buffer 
(Promega), two cycles of freeze-thawing and 2 min. of centrifugation at 
maximum speed. Supernatants were used for determining protein-
normalized luciferase activity by adding 100 µl luciferyl-CoA (Promega) to 
20 µl of liver extract in a monolight luminometer (BD Biosciences). Protein 
content was measured in a 96-well microtiter plate using the BCA protein 
assay kit (Pierce). Absorbance at 562 nm was determined in a microplate 
reader.  
Local gene transfer 9-10 weeks old ApoE-/- mice, fed regular chow diet 
ad libitum, were used for the local gene transfer studies. Local gene 
transfer was ensured using a procedure developed by Von der Thüsen (49) 
In short: with use of a midline neck incision, the left external carotid artery 
was looped proximally and tied off distally with 6-0 silk suture (Ethicon). 
Additional 6-0 silk ties were looped round the common and internal carotid 
arteries for temporary vascular control during the procedure. A transverse 
arteriotomy was made in the left external carotid artery, and a 0.36-mm 
flexible angioplasty guidewire was advanced by 1 cm via a transverse 
arteriotomy of the external carotid artery, and endothelial denudation of the 
common carotid artery was achieved by 3 rotational passes. In one 
experiment, the animals were inoculated i.v. with 1,5 ×109 pfu of Ad.LacZ 
or cRGD-Ad.lacZ in 200 µl of phosphate buffered saline one and five 
hours after denudation. In a second experiment, immediately after 
angioplasty, 10 µl of adenoviral suspension (1.5×109 pfu/ml) was instilled 
into the right common carotid artery via the external carotid. The 
suspension was left in situ for 10 min and was subsequently drawn off 
before ligation of the external carotid and closure of the skin wound with 
silk sutures.  
Tissue harvesting and histological analysis Five days after Ad 
incubations, carotid artery specimens were obtained and transverse 5 µm 
cryosections prepared after in situ perfusion fixation with formalin as 
described (50). Cryosections were routinely stained with hematoxylin 
(Sigma Diagnostics) and eosin (Merck Diagnostica, Darmstadt, Germany). 
ß-Galactosidase was demonstrated by incubation with staining solution (5 
mM potassium ferricyanide, 5 mM potassium ferrocyanide, 0.2 mM MgCl2, 




O/N. Sections were stained immuno histochemically with antibodies 
against α-SM-actin (clone 1A4; diluted 1:500; Sigma) and CD31(rat anti-
mouse, BD pharmingen; diluted 1:200). To detect specific Ab binding goat 
anti-mouse IgG peroxidase conjugate (dilution 1:100; Nordic, Tilburg, the 
Netherlands) was used as secondary antibodies, with 3,3'-diamino-
benzidine, nitro blue tetrazolium as enzyme substrates (all Sigma) and for 
CD31 the ABC-AP kit and Vector-Red Substrate was used (Vector 
laboratories). 
Biodistribution of GFE1 Recombinant avidin (SIGMA, St. Louis, USA) 
was radioiodinated at pH 10.0 with carrier free 125I according to a 
modification [51] of the ICI method [52]. Free 125I was removed by 
Sephadex G-25 gel filtration. GFE1 was incubated with 125I- Avidin at a 
molar ratio of 1: 1. For the in vivo bio-distribution experiments, 10-12-wk-
old female C57Bl/6 mice of weight 22-24 g from Broekman Instituut BV 
(Someren, The Netherlands) were used and fed ad libitum with regular 
chow diet. Mice were anaesthetized by subcutaneous injection of 
ketamine (75 mg/kg, Eurovet), droperidol (1 mg/kg), fluanisone (0.75 
mg/kg), and fentanyl (0.04 mg/kg) (all from Janssen-Cilag, Beerse 
Belgium). Mice were injected with indicated ligand via the tail vein. One 
hour after injection the experiment was terminated, organs were removed 
and the organ bound radioactivity determined. 
Bio-distribution of targeted Ad For the in vivo virus bio-distribution 
experiments, 10-12-wk-old female C57Bl/6 mice of weight 22-24 g from 
Broekman Instituut BV (Someren, The Netherlands) were used and fed ad 
libitum with regular chow diet. On day 0, mice were injected with 1*109 pfu 
of the appropriately targeted Ad.Luc or 100µl PBS in case of the 
uninfected control. Five days after injection, the experiment was 
terminated, the organs were removed and snap frozen in liquid nitrogen. 
Proteins were isolated after homogenisation of organ samples and 
subsequent solubilization in 1* reporter lysis buffer (Promega, Madison, 
WI, USA). Luciferase activity was determined according to the protocol 
supplied by the manufacturer. 
Decay study using lactoferrin 16-17 weeks old C57Bl/6JIco mice 
(Charles river, The Netherlands) were injected intravenously either with 
dissolvent or bovine lactoferrine (Serva, Brunschwig Chemie), 70mg/kg at 
t = -2 min. At t = 0 min, both groups of mice received 1,5.109 pfu/mice 
Ad.Luc intravenously. Blood samples were taken by tail bleeding at 5 min, 
60 min, 6 hours and 24 hours. At day 5 liver, heart, spleen and lung were 
isolated. To assess the presence of circulating infectious particles, AT3 
cells were incubated for 1 hour with the blood samples. After 24 hours, 
protein extracts were prepared by addition of reporter lyses buffer 
(Promega) to the AT3 cells and two cycles of freeze-thawing followed by 2 
min. of centrifugation at maximum speed. Supernatants were used for 
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determining protein-normalized luciferase activity by adding 100 µl 
luciferyl-CoA (Promega) to 20 µl of AT3 extract in a monolight 
luminometer (BD Biosciences). Protein content was measured in a 96-well 
microtiter plate using the BCA protein assay kit (Pierce). Absorbance at 
562 nm was determined in a microplate reader. T½ were calculated from 
the luciferase activity at different timepoints using Graphpad Prism, 
software and a one-phase exponential decay model. 
Statistics Experiments were performed in triplicate and presented as 
mean ± standard deviation (s.d.). P-values were calculated by a two-tailed 
unpaired student’s T-test. Data were considered to be significantly 




Systemic administration of cRGD equiped Ad into mice. To examine 
the capability of integrin targeted Ad vectors to mediate extrahepatic gene 
transfer and reduce the liver uptake normally seen after systemic 
application of Ad, either untargeted Ad expressing luciferase (Ad.Luc) or 
Ad.Luc equipped with CAR-Avidin-cRGD (cRGD-Ad.Luc) was injected 
intravenously into mice. Two and four days after injection, in  vivo gene 
transfer was monitored in situ via a high resolution CCD camera. 
Luciferase expression accumulated in time and was solely observed in the 
liver and not in other organs of both the Ad.Luc as well as cRGD-Ad.Luc 
treated mice. Compared to Ad.Luc treated mice, luciferase expression 





































































Figure 1. Effect of cRGD mediated targeting of adenovirus on 
luciferase expression in the liver. (A) Female C57Bl/6 mice received 
2x109 pfu Ad.Luc (i.p.). After 96 hours luciferin (150 mg/kg) was 
administered by i.p. injection and bioluminescent signals were recorded 
under full anesthesia for 1 minute. Data are presented as cumulated 
photon counts. (B) Liver lysates were prepared by homogenisation and 
subsequent freeze-thawing. Supernatants were used for determining 
luciferase activity using. Luciferase activity was corrected for protein 
concentration using BSA as standard. P<0.05 is indicated by an asterix.  
 
Because layers of tissue may limit photon emission from inner organs, 
luciferase activity was also measured in liver lysates. These data 
confirmed that the liver had indeed been infected and that transgene 
expression by liver was considerably reduced after cRGD targeting (11.5 
fold; P<0.01) (Fig 1B). 
To determine whether the decreased luc activity after targeting 
was caused by a reduction in the percentage of infected cells and not only 
by a reduction of virus particles entering a cell, untargeted Ad expressing 
β-galactosidase (Ad.lacZ) or targeted Ad.LacZ (cRGD-Ad.LacZ) was 
injected systemically. Four days after intravenous administration, β-
galactosidase staining of the livers of mice that had received cRGD-
Ad.LacZ revealed only 1% LacZ+ cells. In comparison, approximately 80% 
of hepatic cells stained positive for β-galactosidase Fig. 2). In addition, 
with cRGD targeted Ad the cellular staining intensity seemed to be 
quenched as compared to untargeted Ad (Fig. 2).  




Ad.LacZ cRGD-Ad.LacZ  
Figure 2. Effect of cRGD mediated targeting of adenovirus on ß-
galactosidase expression in the liver. Female C57Bl/6 mice received 
cRGD-Ad.LacZ or untargeted Ad.LacZ (1x109 pfu; i.v. injection). Five days 
after infection mice were sacrificed, livers were excised and cryosections 
were made and stained for ß-galactosidase or with hematoxylin/ eosin. 
 
Administration of cRGD equipped Ad to mice with carotid artery 
injury. To determine whether the endothelium constituted a barrier to 
infection, a carotid artery segment was injured by guide wiring prior to 
systemic virus administration. The guide wire injury will result in activation 
of flanking endothelial cells and medial vascular smooth muscle cells 
(VSMC) and subsequently in an increase in αVβ3/5 integrin expression. 
Systemic administration of cRGD-Ad.LacZ 1 or 5 hours after denudation of 
the internal carotid artery did not result in an increased amount of LacZ+ 
cells in the vessel wall (data not shown). Because the anatomical position 
of the carotid artery could be incompatible with the dynamics of Ad 
infection, we also administrated Ad focally by instillation in an uninjured or 
a denuded carotid artery segment. Similar to above, cRGD equipped Ad 
vectors did not enhance transgene expression in intact endothelium nor in 








Figure 3. Effect of cRGD mediated targeting of adenovirus on LacZ 
expression in the vessel wall. The right common carotid artery of ApoE-
/- mice was denuded by 3 rotational passes of a 0.36 mm guide wire. 
Subsequently, Ad (1.5 × 109 pfu) was instilled into the denuded common 
carotid artery segment via the external carotid artery after prior ligation of 
the common carotid artery proximal and distal to the bifurcation point. The 
Ad was left in situ for 15’ and removed. Five days after infection mice were 
sacrificed, tissues were isolated and cryosections of the common carotid 
arteries were stained for ß-galactosidase or with hematoxylin/ eosin 
 
Lung specific targeting of Ad vectors. To determine whether Ad 
retargeting would be successful with an alternative ligand for a more 
accessible organ, we have explored the potential of a lung specific 
peptide, GFE1 [32], in CAR-Avidin aided gene transfer in vivo. First, 
biodistribution to the lung of this peptide was confirmed by systemic 
administration of biotinylated GFE1 coupled to 125I labelled avidin. Figure 4 
shows the specific organ uptake of the avidin125-I bound peptide 1 hour 
after systemic injection. Biotin was included as a negative control.  
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Figure 4. Biodistribution of 125I-Avidin-GFE1 after intravenous 
injection into mice. 125I-avidin-biotin (light grey), or 125I-avidin-GFE1 (dark 
grey) (molar ratio of 1: 1; 156749 dpm, in 100 µl PBS) was injected 
intravenously into female C57Bl/6 mice. Tissue distribution was 
determined 1h after injection. Tissue accumulation is expressed as % of 
the injected dose per gram wet tissue and was corrected for radioactivity 
associated with tissue-entrapped plasma. 
 
As expected and already reported by Trepel et al., avidin bound GFE1 
showed a much higher lung uptake than the biotin control (7-fold 
increase). Second, Ad.Luc was equipped with GFE1 (GFE1-Ad.Luc) for in 
vivo application. Biotin saturated CAR-Avidin (biotin-Ad.Luc) and 
untargeted Ad.Luc served as control. Five days after systemic injection, 
luciferase activity was determined in different organs. In comparison to 
Ad.Luc administration, the mice treated with biotin-Ad.Luc and GFE1-
Ad.Luc displayed an 85- and 19- fold reduction in hepatic luciferase 
activity, respectively (Fig. 5A). Figure 5B shows the overall organ 
distribution of the luciferase expression after administration of GFE1-
Chapter 5 
 
Ad.Luc, biotin-Ad.Luc or Ad.Luc. In most tissues, including lung, luciferase 
expression was found to be lower in the GFE1-Ad.Luc than when in 
Ad.Luc treated mice. Thus, similar to the results obtained with the cRGD 


















































Figure 5. Effect of GFE1 mediated targeting of adenovirus on 
biodistribution luciferase expression. (A) untargeted Ad.Luc (dashed 
bars), biotin-Ad.Luc (light grey) or GFE1-Ad.Luc (dark grey) were 
systemically administered to female C57Bl/6. Liver lysates were prepared 
120 hours after infection by homogenisation and subsequent freeze-
thawing. Supernatants were used for determining luciferase activity. 
Samples of untreated mice were included as controls (open bars). (B) The 
organ distribution profile of luciferase expression 120h after i.v. 
administration of GFE1-Ad.Luc, biotin-Ad.Luc, untargeted Ad.Luc or buffer 
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Determining Ad stability in vivo. As the previous experiments made 
clear, a substantial portion of Ad could not be recovered from any of the 
organs, therefore in vivo kinetics studies were performed. Untargeted 
Ad.Luc had a half-life of approximately 6 minutes in vivo (fig. 6A) and was 
efficiently cleared by the liver resulting in efficient infection. When animals 
were pre-treated systemically with lactoferrin, hepatic uptake of Ad virus 
particles was nearly completely blocked (fig. 6B). Under these conditions 
however, half-life of untargeted virus was only increased to 8 minutes (fig. 
6A). This relatively minor increase in half-life indicates that neutralization 
















































































Figure 6. Effect of systemic lactoferrin treatment on Ad half-life after 
i.v. administration. (A) Mice received bovine lactoferin (i.v., 70mg/kg) 
(black line, triangles) or PBS (grey line, squares) 2 minutes before Ad.Luc 
(1,5.109 pfu) administration. Presence of circulating infectious particles 
was determined by blood sampling and subsequent incubation of the 
samples on AT3 cells. Luciferase activity in AT3 cells is corrected for 
protein concentration and plotted against the time of blood sampling. (B) 
Luciferase activity in livers of mice determined 5 days after lactoferrin and 








In this paper we report our efforts to target adenovirus vectors to 
alternative cell types in vivo. Ad linked to either the integrin binding 
peptide cRGD (33;34) or the lung specific peptide GFE1 (32) via CAR-Avidin 
was able to reduce liver uptake after systemic administration. While 
cRGD-Ad has already been shown to be effective in delivering genes to 
vascular cells in vitro (14;35) and GFE1 was demonstrated to be lung 
specific in vivo, neither cRGD-Ad nor GFE1-Ad was able to increase 
transgene expression by respective target tissue in vivo. In addition we 
demonstrate that the half-life of adenovirus in blood is rather short even 
after ablation of liver uptake by lactoferrin suggesting that other elimination 
pathways are functional in the clearance of adenovirus. This could 
contribute to the apparent failure of efficient target organ uptake in vivo. 
Because of the clinical relevance, efficient in vivo targeting – in 
other words enhanced target organ uptake and quenching of the intrinsic 
tropism - of Ad vectors is highly desired. Though attempted extensively, 
successful targeting of Ad in vivo is limited to local (36-38) or intra-organ 
injections (39) of the virus. To our knowledge, increased target organ 
uptake of Ad after systemic injection has only been shown by Izumi and 
colleagues (40), who administered engineered Ad.luc containing CD40 on 
their fiber proteins in transgenic mice with lung vasculature specific CD40 
expression. The detour Izumi took to accomplish retargeting demonstrates 
the difficulty in retargeting Ad in vivo. 
In the current paper we succeeded in efficiently reducing liver 
uptake by applying the CAR-Avidin linker protein equipped with ligands for 
alternative receptors to Ad. Apparently, the CAR-Avidin linker protein is 
capabable of blocking the interaction of Ad fiber knob with its natural 
receptor, CAR. As both untargeted Ad and cRGD-Ad were from the same 
batch, we can exclude that batch-related factors are underlying the 
observed phenomena. Parallel in vitro studies confirmed that the cRGD 
Ad complexes were still functional, as they significantly enhanced gene 
transfer to vascular cells in vitro. Moreover, electron microscopy studies 
revealed that cRGD equipped Ad did not form large aggregates >100-150 
nm, that are unable to penetrate the fenestrae in the liver (data not 
shown). Thus, a major requirement for successful retargeting of Ad 
vectors to specific cell and tissue targets has been achieved.  
To redirect Ad vectors we have linked cRGD to Ad vectors via the 
CAR-Avidin linker protein. This peptide was shown to display a high 
affinity for αVβ3/5 integrins expressed on activated (angiogenic) endothelial 
cells and has been widely exploited in for targeting strategies of Ad (33;34) 
and other drug carriers i.e. liposomes (41). In the current study, cRGD 
equipped Ad vectors have been used to target mechanically injured 
carotid arteries. Unfortunately, cRGD-Ad failed to infect both quiescent 
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endothelial cells as well as activated endothelial cells flanking the site of 
injury after systemic administration in vivo. Furthermore, medial vascular 
smooth muscle cells at the site of injury were not infected as well. Since 
erythrocytes ubiquitously express integrins αVβ3 and αVβ5 it is conceivable 
that the cRGD ligand is an inappropriate targeting molecule for systemic 
application, and this could explain our negative results. This is in line with 
findings of Haubner and colleagues (42), who have investigated several 
RGD based compounds. Interestingly, we were unable to detect any 
infection of vascular cells by cRGD-Ad even after local incubation in the 
absence of erythrocytes, suggesting that erythrocyte scavenging cannot 
be held accountable for the lack of vascular targeting by Ad in vivo. 
Several studies have demonstrated enhanced αVβ3/5 expression on 
endothelial and vascular smooth muscle cells after injury (43-45). However, 
αVβ3/5 mediated uptake is relatively slow and we cannot exclude the 
possibility that the time frame of upregulation of αVβ3/5 expression is 
incompatible with the currently applied infection protocol. 
To avoid the possibility of erythrocyte mediated sequestration of 
cRGD-Ad or poor transendothelial permeation, a lung specific targeting 
moiety was used. The lung is a relatively large organ with high blood flow 
and thus easily accessible. Our targeting moiety was proven to be 
effective, since iodinated avidin-bioGFE1 was specifically taken up by 
lung. Nevertheless, the GFE1-Ad did not enhance transgene expression in 
the lung. It is possible that the in vivo stability of the ad vector and/or the 
local lung-specific blood flow conditions are incompatible with the 
attachment and uptake of the virus particles by the target cells. 
Completely blocking liver uptake with lactoferin had no dramatic 
effect on the half-life of the untargeted virus (only a 33% increase). Due to 
the high blood flow through the liver (24% of the cardiac output) the 
slightly prolonged retention in the blood is probably not sufficient for the 
aimed target organs to take up the virus. Upon inhibition of liver uptake, 
Ad is rapidly neutralized by erythrocytes through binding of RGD motives 
to αvβ3/ αvβ5. This compromises virus stability after intravenous 
administration. So any retargeting approach will have to compete with 
systemic neutralization, and apparently the two ligands we have selected 
are not capable of doing this.  
In conclusion CAR-Avidin has shown to efficiently detarget Ad from 
the liver upon equipping the Ad with novel ligands. This decrease in liver 
tropism however, was not accompanied by an increased transgene 









This work was performed in the framework of the Leiden Center for 
Cardiovascular Research LUMC-TNO and supported by grants from the 
Dutch Organization for Scientific Research (NWO 902-26-220), 
Netherlands Heart Foundation (NHS 2001-141, NHS 2003T201 and NHS 
99B149) and the Center of Medical Systems Biology (CMSB) established 
by the Netherlands Genomics Initiative/ Netherlands Organization for 




1. van Dijk KW, Kypreos KE, d'Oliveira C, Fallaux FJ: Adenovirus-mediated 
gene transfer. Methods Mol Biol 2003, 209: 231-247. 
2. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, Finberg RW, 
Brough DE, Kovesdi I, Wickham TJ: The coxsackievirus-adenovirus 
receptor protein can function as a cellular attachment protein for adenovirus 
serotypes from subgroups A, C, D, E, and F. J Virol 1998, 72: 7909-7915. 
3. Roelvink PW, Mi LG, Einfeld DA, Kovesdi I, Wickham TJ: Identification of a 
conserved receptor-binding site on the fiber proteins of CAR-recognizing 
adenoviridae. Science 1999, 286: 1568-1571. 
4. Havenga MJ, Lemckert AA, Grimbergen JM, Vogels R, Huisman LG, 
Valerio D, Bout A, Quax PH: Improved adenovirus vectors for infection of 
cardiovascular tissues. J Virol 2001, 75: 3335-3342. 
5. Knaan-Shanzer S, van dV, I, Havenga MJ, Lemckert AA, De Vries AA, 
Valerio D: Highly efficient targeted transduction of undifferentiated human 
hematopoietic cells by adenoviral vectors displaying fiber knobs of 
subgroup B. Hum Gene Ther 2001, 12: 1989-2005. 
6. Rea D, Havenga MJ, van Den AM, Sutmuller RP, Lemckert A, Hoeben RC, 
Bout A, Melief CJ, Offringa R: Highly efficient transduction of human 
monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus 
vectors enhances transgene-encoded antigen presentation to cytotoxic T 
cells. J Immunol 2001, 166: 5236-5244. 
7. Ophorst OJ, Kostense S, Goudsmit J, De Swart RL, Verhaagh S, 
Zakhartchouk A, Van Meijer M, Sprangers M, Van Amerongen G, Yuksel S, 
Osterhaus AD, Havenga MJ: An adenoviral type 5 vector carrying a type 35 
fiber as a vaccine vehicle: DC targeting, cross neutralization, and 
immunogenicity. Vaccine 2004, 22: 3035-3044. 
138  
Targeting adenovirus vectors reduces liver tropism but does not enhance specific 
organ uptake. 
 
8. Schoggins JW, Gall JG, Falck-Pedersen E: Subgroup B and F fiber 
chimeras eliminate normal adenovirus type 5 vector transduction in vitro 
and in vivo. J Virol 2003, 77: 1039-1048. 
9. Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, 
Belousova N, Curiel DT: An adenovirus vector with genetically modified 
fibers demonstrates expanded tropism via utilization of a coxsackievirus 
and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 
72: 9706-9713. 
10. Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT: 
Characterization of an adenovirus vector containing a heterologous peptide 
epitope in the HI loop of the fiber knob. J Virol 1998, 72: 1844-1852. 
11. Belousova N, Krendelchtchikova V, Curiel DT, Krasnykh V: Modulation of 
adenovirus vector tropism via incorporation of polypeptide ligands into the 
fiber protein. J Virol 2002, 76: 8621-8631. 
12. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, Han T, Curiel DT: Double 
modification of adenovirus fiber with RGD and polylysine motifs improves 
coxsackievirus-adenovirus receptor-independent gene transfer efficiency. 
Hum Gene Ther 2002, 13: 1647-1653. 
13. Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow 
GR, Baker AH: Ablating adenovirus type 5 fiber-CAR binding and HI loop 
insertion of the SIGYPLP peptide generate an endothelial cell-selective 
adenovirus. Mol Ther 2001, 4: 534-542. 
14. Wickham TJ, Tzeng E, Shears LL, Roelvink PW, Li Y, Lee GM, Brough DE, 
Lizonova A, Kovesdi I: Increased in vitro and in vivo gene transfer by 
adenovirus vectors containing chimeric fiber proteins. J Virol 1997, 71: 
8221-8229. 
15. Hidaka C, Milano E, Leopold PL, Bergelson JM, Hackett NR, Finberg RW, 
Wickham TJ, Kovesdi I, Roelvink P, Crystal RG: CAR-dependent and CAR-
independent pathways of adenovirus vector-mediated gene transfer and 
expression in human fibroblasts. J Clin Invest 1999, 103: 579-587. 
16. van Deutekom JC, Cao B, Pruchnic R, Wickham TJ, Kovesdi I, Huard J: 
Extended tropism of an adenoviral vector does not circumvent the 
maturation-dependent transducibility of mouse skeletal muscle. J Gene 
Med 1999, 1: 393-399. 
17. Bouri K, Feero WG, Myerburg MM, Wickham TJ, Kovesdi I, Hoffman EP, 
Clemens PR: Polylysine modification of adenoviral fiber protein enhances 




18. Gonzalez R, Vereecque R, Wickham TJ, Facon T, Hetuin D, Kovesdi I, 
Bauters F, Fenaux P, Quesnel B: Transduction of bone marrow cells by the 
AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in 
myeloma cells. Hum Gene Ther 1999, 10: 2709-2717. 
19. Gonzalez R, Vereecque R, Wickham TJ, Vanrumbeke M, Kovesdi I, 
Bauters F, Fenaux P, Quesnel B: Increased gene transfer in acute myeloid 
leukemic cells by an adenovirus vector containing a modified fiber protein. 
Gene Ther 1999, 6: 314-320. 
20. Yoshida Y, Sadata A, Zhang W, Saito K, Shinoura N, Hamada H: 
Generation of fiber-mutant recombinant adenoviruses for gene therapy of 
malignant glioma. Hum Gene Ther 1998, 9: 2503-2515. 
21. Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, Barry MA: 
Metabolically biotinylated adenovirus for cell targeting, ligand screening, 
and vector purification. Mol Ther 2003, 8: 688-700. 
22. Perlman H, Liu H, Georganas C, Woods JM, Amin MA, Koch AE, Wickham 
T, Kovesdi I, Mano T, Walsh K, Pope RM: Modifications in adenoviral coat 
fiber proteins and transcriptional regulatory sequences enhance transgene 
expression. J Rheumatol 2002, 29: 1593-1600. 
23. Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, Curiel DT: 
Targeted gene delivery by tropism-modified adenoviral vectors. Nat 
Biotechnol 1996, 14: 1574-1578. 
24. Curiel DT: Strategies to adapt adenoviral vectors for targeted delivery. Ann 
N Y Acad Sci 1999, 886: 158-171. 
25. Parrott MB, Adams KE, Mercier GT, Mok H, Campos SK, Barry MA: 
Metabolically biotinylated adenovirus for cell targeting, ligand screening, 
and vector purification. Mol Ther 2003, 8: 688-700. 
26. Pereboev AV, Nagle JM, Shakhmatov MA, Triozzi PL, Matthews QL, 
Kawakami Y, Curiel DT, Blackwell JL: Enhanced gene transfer to mouse 
dendritic cells using adenoviral vectors coated with a novel adapter 
molecule. Mol Ther 2004, 9: 712-720. 
27. Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT: 
Use of a novel cross-linking method to modify adenovirus tropism. Gene 
Ther 1997, 4: 1387-1392. 
28. Smith JS, Keller JR, Lohrey NC, McCauslin CS, Ortiz M, Cowan K, Spence 
SE: Redirected infection of directly biotinylated recombinant adenovirus 
vectors through cell surface receptors and antigens. Proc Natl Acad Sci U S 
A 1999, 96: 8855-8860. 
140  
Targeting adenovirus vectors reduces liver tropism but does not enhance specific 
organ uptake. 
 
29. Krasnykh V, J.T.Douglas: Targeted adenoviral vectors I: transductional 
targeting. In Adenoviral vectors for gene therapy. Edited by D.T.Curiel, 
J.T.Douglas. San Diego: Academic Press, Inc; 2002:205-245. 
30. Emile Gras JC, Verkuijlen P, Frants RR, Havekes LM, van Berkel TJ, 
Biessen EA, van Dijk KW: Specific and efficient targeting of adenovirus 
vectors to macrophages: application of a fusion protein between an 
adenovirus-binding fragment and avidin, linked to a biotinylated 
oligonucleotide. J Gene Med 2006, 8: 668-678. 
31. Krom YD, Gras JC, Frants RR, Havekes LM, van Berkel TJ, Biessen EA, 
van Dijk KW: Efficient targeting of adenoviral vectors to integrin positive 
vascular cells utilizing a CAR-cyclic RGD linker protein. Biochem Biophys 
Res Commun 2005, 338: 847-854. 
32. Trepel M, Grifman M, Weitzman MD, Pasqualini R: Molecular adaptors for 
vascular-targeted adenoviral gene delivery. Hum Gene Ther 2000, 11: 
1971-1981. 
33. Wickham TJ, Mathias P, Cheresh DA, Nemerow GR: Integrins alpha v beta 
3 and alpha v beta 5 promote adenovirus internalization but not virus 
attachment. Cell 1993, 73: 309-319. 
34. Wickham TJ, Carrion ME, Kovesdi I: Targeting of adenovirus penton base 
to new receptors through replacement of its RGD motif with other receptor-
specific peptide motifs. Gene Ther 1995, 2: 750-756. 
35. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, Yeh P: RGD 
inclusion in the hexon monomer provides adenovirus type 5-based vectors 
with a fiber knob-independent pathway for infection. J Virol 1999, 73: 5156-
5161. 
36. Uchida H, Tanaka T, Sasaki K, Kato K, Dehari H, Ito Y, Kobune M, 
Miyagishi M, Taira K, Tahara H, Hamada H: Adenovirus-mediated transfer 
of siRNA against survivin induced apoptosis and attenuated tumor cell 
growth in vitro and in vivo. Mol Ther 2004, 10: 162-171. 
37. Rein DT, Breidenbach M, Wu H, Han T, Haviv YS, Wang M, Kirby TO, 
Kawakami Y, Dall P, Alvarez RD, Curiel DT: Gene transfer to cervical 
cancer with fiber-modified adenoviruses. Int J Cancer 2004, 111: 698-704. 
38. Witlox AM, van Beusechem VW, Molenaar B, Bras H, Schaap GR, Alemany 
R, Curiel DT, Pinedo HM, Wuisman PI, Gerritsen WR: Conditionally 
replicative adenovirus with tropism expanded towards integrins inhibits 





39. Oberholzer C, Tschoeke SK, Bahjat K, LaFace D, Hutchins B, Clare-Salzler 
MJ, Moldawer LL, Oberholzer A: In vivo transduction of thymic dendritic 
cells with adenovirus and its potential use in acute inflammatory diseases. 
Scand J Immunol 2005, 61: 309-315. 
40. Izumi M, Kawakami Y, Glasgow JN, Belousova N, Everts M, Kim-Park S, 
Yamamoto S, Wang M, Le LP, Reynolds PN, Curiel DT: In vivo analysis of 
a genetically modified adenoviral vector targeted to human CD40 using a 
novel transient transgenic model. J Gene Med 2005, 7: 1517-1525. 
41. Schiffelers RM, Molema G, ten Hagen TL, Janssen AP, Schraa AJ, Kok RJ, 
Koning GA, Storm G: Ligand-targeted liposomes directed against 
pathological vasculature. J Liposome Res 2002, 12: 129-135. 
42. Haubner RH, Wester HJ, Weber WA, Schwaiger M: Radiotracer-based 
strategies to image angiogenesis. Q J Nucl Med 2003, 47: 189-199. 
43. Dufourcq P, Couffinhal T, Alzieu P, Daret D, Moreau C, Duplaa C, Bonnet 
J: Vitronectin is up-regulated after vascular injury and vitronectin blockade 
prevents neointima formation. Cardiovasc Res 2002, 53: 952-962. 
44. Kappert K, Blaschke F, Meehan WP, Kawano H, Grill M, Fleck E, Hsueh 
WA, Law RE, Graf K: Integrins alphavbeta3 and alphavbeta5 mediate 
VSMC migration and are elevated during neointima formation in the rat 
aorta. Basic Res Cardiol 2001, 96: 42-49. 
45. Li JM, Fan LM, Shah A, Brooks G: Targeting alphavbeta3 and alpha5beta1 
for gene delivery to proliferating VSMCs: synergistic effect of TGF-beta1. 
Am J Physiol Heart Circ Physiol 2003, 285: H1123-H1131. 
46. Michon IN, Hauer AD, der Thusen JH, Molenaar TJ, van Berkel TJ, Biessen 
EA, Kuiper J: Targeting of peptides to restenotic vascular smooth muscle 
cells using phage display in vitro and in vivo. Biochim Biophys Acta 2002, 
1591: 87-97. 
47. Fallaux FJ, Bout A, van dV, I, van den Wollenberg DJ, Hehir KM, Keegan J, 
Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, Valerio D, Hoeben 
RC: New helper cells and matched early region 1-deleted adenovirus 
vectors prevent generation of replication-competent adenoviruses. Hum 
Gene Ther 1998, 9: 1909-1917. 
48. Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, van Ormondt H, 
Hoeben RC, van der Eb AJ: Characterization of 911: a new helper cell line 
for the titration and propagation of early region 1-deleted adenoviral 
vectors. Hum Gene Ther 1996, 7: 215-222. 
142  
Targeting adenovirus vectors reduces liver tropism but does not enhance specific 
organ uptake. 
 
49. de Nooijer R, Verkleij CJ, der Thusen JH, Jukema JW, van der Wall EE, 
van Berkel TJ, Baker AH, Biessen EA: Lesional overexpression of matrix 
metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions 
but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol 
2006, 26: 340-346. 
50. der Thusen JH, van Berkel TJ, Biessen EA: Induction of rapid 
atherogenesis by perivascular carotid collar placement in apolipoprotein E-
deficient and low-density lipoprotein receptor-deficient mice. Circulation 
2001, 103: 1164-1170. 
51. van Tol A, Van Gent T, 't Hooft FM, Vlaspolder F: High density lipoprotein 
catabolism before and after partial hepatectomy. Atherosclerosis 1978, 29: 
439-448. 










General discussion and future perspectives 
Chapter 6 
 
General discussion and future perspectives 
In this thesis, the development of a targeting system for adenovirus (Ad) 
vectors is described. Adenovirus vectors (Ad) are powerful tools to 
modulate gene expression and are promising tools for (gene) therapeutic 
applications. Their applicability however, depends on the expression of the 
Coxsackie Adenovirus Receptor (CAR), by the target cell. Many cells 
interesting for either research or gene therapy do not, or only at low levels 
express CAR rendering them resistant to Ad mediated gene transfer.  
 
In chapter 2, a poly-A containing oligonucleotide ligand is 
characterized using liposomes as a model to present the ligand to the 
cells. Interestingly, the SRA-specific LCO-dA2dG10-mediated liposome 
clearance by the liver appeared to be higher than was previously observed 
for uncomplexed dG10dT6 by Biessen and colleagues (1). This 
demonstrates that increasing the avidity by clustering ligands on the 
liposome surface has a positive effect on the recognition and uptake by 
scavenger receptors. One of the further advantages of liposomes as 
ligand testing system, is that they can be produced relatively easily and at 
low cost. Moreover, liposomes are slowly cleared from the circulation 
(facilitating the investigation of targeting efficiency in vivo), and they can 
be radiolabed with various means. Although ligand-equiped liposomes are 
relatively poor agents to functionally deliver gene expression constructs in 
vivo, recent research in fusogenic peptides indicates that using liposomes 
for the delivery of genetic material is feasible (2-5). 
 
Targeting any drug to a specific cell type requires cell type-specific 
receptors and ligands. These receptors and ligands need to be 
characterized extensively to determine their tissue distribution pattern in 
different stages of development and pathology. This information is 
required to maximize the dose-response ratio and to minimize adverse 
effects of targeted drug therapy. Thus far, targeting approaches are 
hampered by the relative absence of both cell type-specific receptors and 
receptor-specific ligands for targeting receptors.  
Before the advent of genomics technology, selecting cell-type 
specific receptors and ligands from a large set of candidates was a rather 
laborious task. By exploiting databases with cell type specific gene and 
protein expression patterns obtained by micro-array and proteomics 
technologies, it can be expected that candidate selection will be more 
straight forward in the foreseeable future. In addition to database 
searches, selection strategies have been developed for the identification 
of receptor or cell-type specific ligands. One such section strategy is the 
phage display technology. These phages display ligands in their capsid 
proteins and thus present peptides in a natural conformation. The 
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selection strategy is based on repeated rounds of binding of a pool of 
different phages and subsequent re-isolation of these bound phages. 
Ideally, primary cells should be used for gathering information on 
cell type-specific receptors and ligands. Culturing cells ex vivo 
unambiguously induces changes in the protein expression profile of the 
cell, specifically cell surface receptors that are now in contact with an 
artificial medium (being either or both the tissue culture plastic and the 
growth medium). This is demonstrated by integrin expression by 
endothelial cells (see below). For targeting to be effective, especially 
variations between comparable cell types need to be mapped in detail, i.e. 
endothelial cells in different organs or vessel types, differences between 
normal and tumor cells. Since it is also likely that the method used for 
isolation of specific cell types or tissues affects the expression of specific 
proteins (i.e. enzymatic treatments), it is obvious that it remains a major 
challenge to identify suitable candidate receptors and ligands. 
 
The CAR-Avidin linker protein described in chapter 3 is designed 
to be highly flexible and versatile. The avidin moiety in the linker protein 
can accommodate the attachment of a variety of ligands to the virus 
including poly-nucleotides (Chapter 3) and peptides (Chapter 4) via biotin. 
Since the CAR-Avidin linker protein, the biotinylated ligand and the virus 
are all generated as separate entities, the targeting system can be applied 
to all pre-existing Ad5 vectors without the need to redesign and modify 
any of the components. 
One of the motivations to apply the avidin-biotin bridge in our 
targeting strategy was also the multimerization of biotin-bound ligands to 
avidin. Multimerization greatly improves the avidity of the complex. For 
example, Molenaar and colleagues observed that (avidin-mediated) 
multimers of the peptide ligand TM-11 displayed a much higher affinity for 
P-Selectin than monomers (6), Thoma and colleagues show an increased 
affinity of an E-Selectin inhibitor when presented as a multimers (7). 
Although the affinity of CAR-avidin for biotin indicates that multimerization 
has taken place (fig 3 chapter 3), we failed to supply biochemical evidence 
that multimerization had occurred. This is likely caused by the stickiness of 
the chicken avidin fragment that was applied in the linker protein. Since 
streptavidin has been reported to be less sticky, it is possible that 
incorporation of a streptavidin fragment in our construct further improves 
the applicability.  
 
For research purposes, the CAR-Avidin strategy enables testing of 
a variety of vectors with different gene expression constructs and virus 
backbones. Likewise, any biotinylatable ligand can be implemented 




subsequently be utilized in a genetic targeting strategy, by for example, 
cloning into the HI loop. Once the best virus backbone, promoter, 
transgene and ligand combination are fully characterized and clinical 
application becomes feasible, a 1 or 2 component system may be 
favorable. Fewer components mean fewer variables to take into account 
resulting in a simpler, better-defined system. Direct incorporation of the 
novel ligand into the fiber and simultaneously prevent CAR mediated 
uptake, would result in a single component system. In the case of 
oligonucleotides or other chemical compounds serving as ligands, a tool to 
couple them to the virus is still required. Biotinylation of the ligand in 
combination with incorporation of a biotin binding peptide in the fiber, as 
was demonstrated by Parrot and colleagues (8), results in a 2-component 
system.  
Combining physical targeting with CAR-Avidin and genetic 
targeting by cell type specific promoters can further improve the specificity 
of targeting Ad vectors. Any virus taken up by cells other than the intended 
target tissue, would remain silent since the non-target cells do not have 
the appropriate transcription machinery to ensure transgene expression. 
The efficacy of genetic targeting is demonstrated by Curiel and colleagues 
(9-12) and Haisma and colleagues (10;13).  
 
The in vivo targeting experiments reported in chapter 5 
demonstrate that expression in the liver was dramatically reduced upon 
equipping Ad with the linker protein in combination with various ligands. 
This linker protein was designed to block the CAR mediated uptake and 
apparently was able to do so. Alternative Ad vector uptake pathways have 
been described, such as sulfate glycosaminoglycan-mediated uptake (14). 
However, our results indicate that these pathways do not play a 
quantitative role in hepatic uptake of targeted Ad vectors. 
 
An extensive effort was made to target Ad vectors towards the 
endothelium in the carotid artery by equipping the vector with a ligand for 
the integrins αVβ3/5 (chapter 5). However, gene delivery to endothelial cells 
in both normal and injured carotid arteries after systemic administration 
was never observed. Integrins have long been regarded as prime targets 
to mediate the uptake of (Ad) vectors (reviewed in (15) and (16) or other 
drugs (17) (18) for several reasons: (I) Integrins are abundantly expressed 
by a broad range of cell types, (II) Upon binding integrins are capable of 
internalizing particles, (III) They recognize short peptide motifs, making it 
relatively simple to target them. Most of the research in targeting Ad 
vectors focusses on in vitro targeting before applying the ligands in vivo. 
Many in vitro cell culture systems however, select towards adhering cells. 
Since integrins mediate cell survival (19), adherence and proliferation 
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(20;21), it is likely that integrin expression is influenced by the in vitro tissue 
culture conditions. Published data on integrin expression in vivo may be 
somewhat contaminated by the information available from in vitro studies, 
and should therefore be handled with care. Besides altered integrin 
expression it is conceivable that the expression of other surface proteins is 
altered as well, emphasizing the need for using primary cells when 
selecting surface structures for the targeting of vectors. However, since 
we have not mapped the integrin expression of endothelial or vascular 
smooth muscle cells in our studies, we cannot fully address these issues. 
 
Since erythrocytes ubiquitously express integrins αVβ3 and αVβ5 it is 
conceivable that the RGD-equiped Ad vectors are sequestered by 
erythrocytes after systemic application and thus are rapidly inactivated. 
Akiyama has shown that to increase the effective Ad dose in the blood it is 
necessary to block both CAR mediated uptake as well as αvβ3/5 mediated 
infection (Akiyama, 14). However, this does not explain our negative 
results obtained after local incubation in the absence of erythrocytes. 
Interestingly, others have obtained similar negative results in their efforts 
to locally target integrins on vascular cells (22). Although enhanced αVβ3/5 
expression on endothelial and vascular smooth muscle cells after injury 
has been demonstrated, we cannot exclude the possibility that the time 
frame of upregulation of αVβ3/5 expression is incompatible with the applied 
infection protocols. 
 
An alternative explanation for the absence of target tissue uptake 
of targeted Ad could be the local flow conditions (too fast or turbulent), in 
combination with the high blood flow through the liver (24% of the cardiac 
output). Particles need time to bind the receptor and be internalized by the 
target cell, and although the retention in the blood is somewhat prolonged, 
unfavorable flow conditions may prohibit binding and uptake resulting in 
failure of the target cells to express the transgene. Unfavorable local flow 
conditions alone however, cannot account for the absence of increased 
Ad mediated transgene expression in the lung. The GFE1 ligand used for 
these experiments was isolated from a phage display library; Phages 
capable of binding endothelium in the lung were isolated and purified. The 
receptor-ligand combination is thus capable of binding spherical 
“particles”. Since phages are roughly similar in size to Ad GFE1, size 
alone cannot explain the failure of this targeting approach for targeting 
lung endothelium. Apparently other processes in the pathway that should 
result in transgene expression are inhibited in GFE1 mediated targeting of 
Ad.  
The in vivo data in chapter 3 indicate that targeting Ad vectors to 




and colleagues have shown that under normal conditions, viral uptake by 
Kuppfer cells does not result in transgene expression (23). Furthermore, 
observations from Akiyama showed that the administration of double 
ablated vectors, unable to be taken up via CAR and αVβ3/5 integrins, and 
thus taken up via alternative routes, does not result in transgene 
expression (24). This suggests that transgene expression is dependent on 
the intra-cellular trafficking of the virus: while uptake generally leads to 
degradation of the virus, dA6G10 mediated uptake via the scavenger 
receptor results in transgene expression.  
 
The primary goal in targeting research is obviously the ability of the 
combination of vector and targeting system to enhance transgene 
expression in the target cell. This endpoint however, is the result of a 
sequence of events including in vivo vector transportation, vector binding, 
uptake, intra-cellular trafficking and expression of the transgene. Any 
problem in this chain of events can cause failure to reach this goal. All 
steps, from initial administration to transgene expression, should therefore 
be closely monitored. Recently, non-invasive in vivo imaging of 
fluorescently labeled markers using highly sensitive CCD cameras has 
become feasible (25;26). This technology enables more direct monitoring of 
the fate of targeted vectors after in vivo adminstration, making it possible 
to distinguish the different steps resulting in transgene expression. This 
should give in more insight into the critical steps in ad vector targeting. 
 
A somewhat disturbing picture arises from these data: Will retargeting in 
vivo ever be achievable? Successful attempts published thus far for ad 
targeting in vivo are extremely scarce. Our data seem to indicate that an 
important problems lies in the rapid inactivation of ad vectors after 
systemic administration. Detargeted Ad vectors (in the presence of 
lactoferrin) are cleared with a half life of 8 minutes, versus a half life of 6 
minutes for hepatic clearance of control Ad vectors. Whether scavenging 
by erythrocytes or Kupfer cells in the liver is responsible for this 
phenomenon remains to be determined. Nevertheless, insight in the 
mechanism responsible for Ad neutralization will be required for Ad 
targeting to become effective. 
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In this thesis, the development of a targeting system for adenovirus (Ad) 
vectors is described. Ad vectors are powerful tools to modulate gene 
transcription both in vitro and in vivo in both quiescent and dividing cells. 
Their applicability however, depends on the expression of the Coxsackie 
Adenovirus Receptor (CAR), by the target cell. Parenchymal cells in the 
liver and a variety of other cell types express CAR. However many cells 
relevant to (gene) therapy, including endothelial cells, macrophages, 
vascular smooth muscle cells and many tumors do not, or only at low 
levels express CAR rendering them resistant to Ad mediated intervention. 
Efficient and specific intervention starts with the delivery of the vector to 
the appropriate cells only. For this targeting to be successful, affinity for 
the CAR must be ablated and at the same time the vector should be 
equipped with an appropriate ligand to induce affinity for the target cell.  
In chapter 2, the development of a ligand for macrophages in vitro 
and in vivo is described. Macrophages play, via the secretion of pro-
inflammatory cytokines, a central role in a wide variety of biological and 
pathogenic processes including innate immunity, tumorigenesis, and the 
initiation and progression of atherosclerosis, prompting several research 
groups to develop macrophage-specific drug carriers, using scavenger 
receptors as a target. Oligodeoxyriboguanines have a known affinity for 
the scavenger receptor class A (SR-A) abundantly expressed by 
macrophages in vitro. Pearson and colleagues found that dG10 is the 
minimal oligodeoxyriboguanine motif to display a high affinity for SRA 
{Pearson, 1993 124 /id}. This residue was coupled to a dA2 spacer and the 
hydrophobic lithochololeate (LCO) anchor to ensure anchoring into the 
surface of the liposome. The LCO-dA2dG10 ligand dose-dependently 
enhanced the tissue distribution of liposomes in vivo in a strictly SR-A -
dependent manner, since the increased liposomal clearance rate by the 
liver could be completely blocked by polyI. These data demonstrate the 
applicability of dG10-based ligands for targeting to SR-A.  
Having a ligand for the delivery of spherical particles via SR-A to 
macrophages in hand, we set out in chapter 3 to develop and 
characterize the linker protein CAR-Avidin to target adenovirus vectors. 
This linker protein is composed of the virus-binding domain of the CAR 
genetically fused to avidin. Equipping this linker protein with a suitable, 
biotinylated ligand results in a targeting protein capable of retargeting Ad 
vectors. The utilization of this linker protein is demonstrated by equipping 
it with the slightly modified dA2G10 ligand, the spacer is increased from dA2 
to dA6 to ensure clear separation of the SR-A binding moiety dG10 from the 
bulky avidin-biotin moiety in the linker protein. An up to 500-fold increased 
transgene expression in both primary and transformed macrophages 
known to be notoriously difficult to infect with adenovirus vectors, in vitro 
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was found. Preliminary in vivo experiments suggest a redistribution in the 
liver uptake from parenchymal cells to Kupffer cells, based on β-
Galactosidase expression and cell morphology. Experiments with 
macrophages from SR-A knockout mice however, suggest that the dA6G10 
mediated uptake, though highly macrophage specific in vitro as well as in 
vivo, is not completely SR-A specific. It appeared that SR-A-/- 
macrophages are also infected by the dA6G10 equipped Ad, though at a 
significantly lower level.  
In chapter 4 the versatility of the linker protein CAR-Avidin is 
demonstrated. Since most chemical substances can be biotinylated, a 
variety of compounds, i.e. peptides, oligonucleotides, proteins, antibodies 
and chemically synthesized compounds can be used to target Ad vectors. 
Here, we describe the utilization of the biotinylated circular peptide ligand 
RGD to facilitate infection via the αVβ3/5 integrins of several endothelial cell 
lines and vascular smooth muscle cells in vitro. Equipping reporter Ad 
vectors with cRGD via CAR-Avidin markedly enhanced gene transfer to 
the established endothelial cell lines H5V (up to 600fold increase in 
reporter gene expression) and EOMA (4 to 6-fold increase), as well as to 
primary HUVEC (from 2% to 75% of cells infected upon targeting) and 
VSMC (from 0% to 25% of cells infected). 
In chapter 5 we report our efforts to retarget adenovirus vectors 
using the linker protein CAR-Avidin. Experiments with the reporter gene 
luciferase expressing adenovirus equipped with cRGD or biotin via CAR-
Avidin- indicate an up to 85-fold reduction in liver infection after systemic 
administration. This observation is supported when using the GFE1 ligand, 
indicating that addition of novel ligands to the virus knob of adenovirus 
vectors reduces the liver uptake of the vectors in vivo. Though successful 
in vitro, the cRGD nor the GFE1 peptide ligand were able to increase Ad 
uptake by the target tissues in vivo. This inability to increase adenovirus 
vector mediated transgene expression by target tissues cannot be 
ascribed to inaccessibility of the ligand for the receptor or complex 
formation due to addition of the linker protein. Furthermore, blocking liver 
all uptake by lactoferin resulted in a minor increased virus half-life, 
suggesting the presence of efficient extrahepatic elimination pathways. 
Apparently, rapid neutralization of (targeted) Ad in the circulation efficiently 
prevents uptake by target organs other than the liver. 
Taken together, our data show that targeting of Ad in vitro by the 
CAR-Avidin technology to primary endothelial cells, primary macrophages, 
primary vascular smooth muscle cells, endothelial cell lines, and 
macrophage cell lines appears to be successful. The CAR-Avidin linker 
protein proves to be a versatile tool to target Ad to previously refractory 




reduced transgene expression by the liver, but does not result in tissue-




Nederlandstalige samenvatting  
Atherosclerose, ook wel aderverkalking genoemd is een ziekte die wordt 
gekenmerkt door de vorming van vetophopingen, zogenaamde plaques, in 
de middelgrote slagaders. Met name de vaten die het hart van bloed 
voorzien blijken erg gevoelig voor het ontstaan van plaques die kunnen 
ontstaan door vele factoren waaronder overgewicht, te hoge bloeddruk en 
verhoogd LDL-cholesterol (het “slechte cholesterol”). Door deze factoren 
stapelen vetten zich op op op specifieke plaatsen in da vaatwand 
waardoor de cellen die de vaten aan de binnenkant bekleden (endotheel 
cellen) chronisch geïrriteerd raken. Andere cellen in de vaatwand, 
macrofagen, hebben tot taak om stoffen die niet thuis horen in een 
bepaald orgaan of weefsel op te ruimen. Macrofagen zijn echter niet in 
staat de cholesterol af te breken en slaan het dus op, het worden dan 
zogenaamde “schuimcellen”. Deze schuimcellen zorgen, samen met de 
geïrriteerde endotheel cellen voor een ontstekingsreactie in de vaatwand. 
De cellen van het immuun systeem komen op deze ontsteking af en 
activeren de vaatwand nog meer waardoor een vicieuze cirkel ontstaat die 














Figuur 1 Ontsteking reactie in de vaatwand die leidt tot vernauwing 
 
Een plaque is een zwakke plek die kan barsten waardoor het 
ontstekingsmateriaal in het vat terechtkomt. Wordt het vat helemaal 
geblokkeerd dan ontstaat een hartinfarct. Gebeurt dit in de hersenen dan 
spreekt men van een herseninfarct. 
Omdat de endotheelcellen en de macrofagen zo’n cruciale rol spelen in 
het ontstaan én het in stand houden van atherosclerose zijn ze interessant 
voor (gen)therapeutische interventie.  
In dit proefschrift wordt een nieuwe technologie beschreven om 
adenovirussen selectief door bepaalde cellen opgenomen te krijgen 
(“targeten”). Adenovirussen zijn krachtige instrumenten om cellen te 




materiaal (DNA) voor therapeutisch interessante eiwitten zijn ze in staat 
cellen nieuwe eiwitten te laten maken (gentherapie), of de productie van 
andere eiwitten te remmen. Ook kunnen ze na aanpassing bijvoorbeeld 
het groei gedrag van cellen beïnvloeden waardoor ze bijvoorbeeld ook 
gebruikt kunnen worden voor de behandeling van kanker. Het adenovirus 
is in staat om zowel delende als niet delende cellen te infecteren en te 
beïnvloeden. Om adenovirussen te kunnen gebruiken moeten de cellen 
die ze moeten gaan beïnvloeden een specifieke receptor op het oppervlak 
hebben, de Coxsackie Adenovirus Receptor (CAR). Een interactie tussen 
deze receptor en een eiwit aan de buitenkant van het virus (ligand) zorgt 
ervoor dat het virus aan de cel bindt om deze vervolgens binnen te 
dringen. Eenmaal in de cel zorgt het virus ervoor dat het DNA dat het virus 
meeneemt gebruikt wordt om nieuwe eiwitten te gaan maken die een 
positief effect hebben op de cel.  
De eerder genoemde CAR komt vooral, maar niet uitsluitend op de lever 
voor. Indien het originele virus zou worden gebruikt wordt dus 
voornamelijk de lever bereikt. Als dit orgaan ook het bedoelde orgaan voor 
de therapie is, is dit geen probleem. Veel andere cellen echter, die 
interessant zijn voor (gen)therapie hebben deze CAR niet op hun 
oppervlak en zijn dus niet of zeer moeilijk te infecteren door het virus. Tot 
deze groep behoren onder andere de cellen die de binnenkant van de 
bloedvaten bekleden (endotheel cellen) en veel soorten tumorcellen. Als 
je dus een orgaan, anders dan de lever, wil bereiken zul je een manier 
moeten vinden om (I) de opname door de lever te blokkeren en (II) de 
opname door de CAR negatieve cel mogelijk te maken. 
 In hoofdstuk 2 wordt beschreven hoe een ligand is gevonden en 
onderzocht dat gebruikt kan worden het adenovirus in staat te stellen 
macrofagen te infecteren. Macrofagen hebben een bepaalde receptor op 
hun oppervlak, de “Scavenger receptor” (SR-A). Deze receptor komt bijna 
uitsluitend voor op macrofagen en kan daarom goed gebruikt worden om 
opname van het virus door deze cellen te bevorderen. Pearson en 
collegae hebben ontdekt dat een bepaalde stof, oligodeoxyriboguanine 
(dG10) erg sterk bindt aan deze receptor. Om te onderzoeken of deze 
interactie tussen de SR-A en dG10 geëxploiteerd kon worden voor de 
targeting van adenovirussen is een zijstap gemaakt naar model deeltjes 
met een vergelijkbare grootte, liposomen. Liposomen zijn kleine 
vetachtige deeltjes die gemakkelijk gemaakt kunnen worden en gebruikt 
kunnen worden om geneesmiddelen door het lichaam te vervoeren. Voor 
deze fase van het onderzoek is gebruik gemaakt van liposomen omdat ze 
relatief gemakkelijk, goedkoop en snel te maken zijn. Daarnaast zijn ze 
gemakkelijk te merken (labelen) waardoor goed te onderzoeken is in 
welke organen ze worden opgenomen. De liposomen die uitgerust waren 
met dG10 bleken via de SR-A opgenomen te worden door de lever van 
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muizen. Deze conclusie kon worden getrokken omdat voorbehandeling 
van de dieren met een stof waarvan bekent is dat hij bindt aan de SR-A de 
liposoom opname door de lever sterk reduceerde. Deze gegevens laten 
zien dat het dG10 een veelbelovend ligand is voor gestuurde opname van 
adenovirussen. 
In hoofdstuk 3 wordt de ontwikkeling van CAR-Avidin beschreven. 
CAR-Avidin is een fusie eiwit dat bestaat uit het virus bindende deel van 
de CAR receptor, en het eiwit avidine. Avidine is een eiwit dat een erg 
sterke binding kan aangaan met biotine. Biotine is een klein molecuul dat 
gemakkelijk langs chemische weg aan liganden gekoppeld kan worden. 
Op deze manier ontstaat een systeem dat werkt als dubbelzijdig plakband: 
de ene kant plakt aan het virus, de andere kant plakt aan een ligand 
waarvoor de receptor aanwezig is op de cel of het weefsel dat je wilt 
infecteren. Doordat het ligand niet direct aan het virus bindende deel vast 
is gemaakt, is een flexibel systeem ontstaan waarbij je voor een ander cel 
type niet het hele fusie eiwit opnieuw hoeft te ontwerpen en produceren, je 






Doel cel IDoel cel IILever cel
 
Figuur 2 Het principe van het “dubbelzijdig plakband” CAR-Avidine 
 
 Om adenovirussen macrofagen te kunnen laten infecteren is het 
dG10 ligand uit hoofdstuk 2 gebruikt. Er is een stukje aan vast gezet (dA6) 
om ervoor te zorgen dat het ligand niet “klem” komt te zitten in het avidine 
en daardoor de avidine-biotine interactie of de dG10-SR-A interactie 
negatief beïnvloedt. Een adenovirus is vervolgens uitgerust CAR-Avidin-
dA6G10 en getest op diverse typen macrofagen. Dit virus zorgt ervoor dat 
de geïnfecteerde cellen luciferine gaan maken, een eiwit dat makkelijk 
meetbaar is. CAR-Avidin-dA6G10 bleek in staat om ervoor te zorgen dat 
adenovirussen zowel macrofaag lijnen als primaire macrofagen konden 




vergelijking tot virussen die niet waren uitgerust met CAR-Avidin-dA6G10. 
CAR-Avidin-dA6G10 is ook in muizen getest waarbij het opnamepatroon 
van het adenovirus door de lever verschoven leek naar in de lever 
aanwezige macrofagen. Experimenten met macrofagen afkomstig van 
muizen die geen SR-A hebben laten echter zien dat, hoewel het dG10 
ligand erg macrofaag specifiek is, het ook bindt aan andere receptoren 
dan SR-A, mogelijk andere typen scavenger receptoren. 
 In hoofdstuk 4 wordt de flexibiliteit van CAR-Avidin beschreven 
aan de hand van experimenten in endotheelcellen. Omdat endotheelcellen 
de CAR niet op hun oppervlak hebben is het normaal gesproken praktisch 
onmogelijk voor adenovirussen ze te infecteren. Zelfs bij grote 
hoeveelheden virus wordt maar een fractie van de cellen geïnfecteerd. 
Door CAR-Avidin nu uit te rusten met een ander soort ligand, genaamd 
cRGD, blijkt het mogelijk voor adenovirussen endotheelcellen te 
infecteren. Dit ligand blijkt selectief te binden aan verschillende typen 
endotheelcellen, zowel van muizen als van mensen en zo de infectie sterk 
te verhogen (toename van 2% naar 75% van de aanwezige cellen). Op 
primaire gladde spiercellen (ander type cel in de wand van bloedvaten) 
bleek een toename de hoeveelheid geïnfecteerde cellen van praktisch 0 
naar 25% wanneer het adenovirus werd uitgerust met CAR-Avidin-dA6G10.  
 In hoofdstuk 5 worden de pogingen om adenovirussen in muizen 
te targeten naar specifieke cellen/ organen beschreven. Omdat de dA6G10 
en RGD liganden in staat bleken om de infectie van adenovirussen in vitro 
te bevorderen werd tevens onderzocht of deze liganden ook in staat 
waren om adenovirussen in intacte dieren naar andere organen te sturen. 
Zoals eerder aangegeven worden deze virussen normaal gesproken 
opgenomen door de lever. Door de adenovirussen echter uit te rusten met 
cRGD of GFE1 (een ligand waarvan bewezen is dat het in de longen 
wordt opgenomen) via CAR-Avidin bleek de leveropname met 91.3% 
verminderd. Deze afname in leveropname ging echter niet gepaard met 
een verhoogde opname in de logen of andere organen. Het vermoeden 
bestaat dat er een competitie tussen het gewenste doelorgaan 
(bijvoorbeeld de longen) en cellen in het bloed die het virus opruimen nu 
het virus niet meer snel en efficiënt door de lever wordt opgenomen. De 
doelorganen zijn blijkbaar dus niet in staat om deze strijd te winnen.  
 De hier beschreven technologie maakt het mogelijk om 
adenovirussen onder kweek omstandigheden voor een breder spectrum 
aan cel typen toe te passen dan tot nu toe het geval was. Om deze reden 
zal het bijdragen aan het onderzoek waarin men bepaalde cellen graag 
zou willen moduleren door middel van adenovirussen maar dat tot nu toe 
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